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Sum m ary
The aims of this study fall under four broad headings. The 
first was to follow up previous work in this laboratory 
which had indicated that local disease status is related to 
levels of specific immunoglobulin. A previous study had 
shown that gingivitis and periodontitis sites can be 
distinguished in that the latter have lower antibody levels 
to P. gingivalis in the GCF than the former, perhaps 
indicating local degradation by oral pathogens. In the 
present study, the experimental design was modified to 
allow matching of gingivitis and periodontitis sites within 
the same patient, generating the potential for a more 
powerful statistical analysis.
Reports demonstrating differences in specific humoral 
immunity with ageing prompted an experimental gingivitis 
study on periodontally healthy young and old subjects, to 
investigate possible differences in local immune and 
inflammmatory parameters. Since chronic periodontal
disease is primarily a disease of ageing, any immune 
deficiencies contributing to periodontal disease may be 
related to the ageing process itself.
A previous report from this laboratory had suggested 
that there may be differences in immune and inflammatory
xvii
processes at matched oral implant and natural tooth sites 
in the same patient. Part of this study, therefore, was to 
follow up these investigations.
The second aim was to investigate local production of 
immunoglobulins by plasma cells in the gingiva. Therefore,
separate investigations quantified the proportions of k  and
X light-chain producing plasma cells and also IgG and IgA 
subclass-producing plasma cells in the gingiva and related 
these to levels of the immunoglobulins in the GCF.
Previous work in this laboratory has demonstrated the 
significance of specific serum antibody avidity to 
periodontal diagnosis and prognosis. Therefore, the third 
aim of this study was to investigate the impact of antibody 
avidity on the outcome of periodontal treatment. A 
preliminary study was set up to assess these effects; also 
attempting to relate microbiological parameters. A larger 
study was then conducted in which patients were assigned to 
seropositivity groups at baseline. They were then followed 
longitudinally to assess differences in treatment outcome.
A fourth aim of this study was to look at the wider 
significance of immunological parameters in disease 
pathology. Both periodontal disease and pregnancy can in 
some ways be seen as a model immune-inflammatory processes.
xviii
Therefore, the relevance of serum levels of IgG subclasses 
to pregnancy outcome was assessed.
Thus the overall aim of this project was to increase 
understanding of the immunological aetiology of periodontal 
disease at local and systemic, cellular and molecular 
levels; and to put these findings into the wider context of 
immune-inflammatory processes.
Confirmation of the immunological difference between 
gingivitis and periodontitis sites was achieved. 
Similarly, local humoral immune and inflammatory reactions 
were found to differ in older and younger individuals in 
that the former had lower IgGl, IgG4 and lactoferrin levels 
than the latter. Rates of local antibody production for 
matched teeth and implants were found not to correlate 
suggesting differences in the plasma cell infiltrate.
A predominance of k  light chain positive cells was 
found among plasma cells in inflamed gingival tissues. The
k /A, ratio of inflamed sites could be a useful method of 
distinguishing the stage or activity of periodontitis 
lesions and may differ between different forms of 
periodontitis. The levels of IgG subclasses in the 
gingival crevicular fluid were found to correlate with 
levels of production by local plasma cells. However, 
levels of local IgAl were much lower than plasma cell
numbers would indicate, suggesting degradation by bacterial 
proteases. This was further indicated by high levels of 
IgAl fragments.
The studies of periodontal treatment effects indicated 
that treatment outcome was predicated on initial serostatus 
to periodontal pathogens, and that increases in antibody 
avidity only occurred in patients who were initially 
seropositive.
The studies of obstetric immunology showed that levels 
of IgG subclasses were significantly increased during the 
first trimester of normal pregnancy, but this increase did 
not occur in women who had spontaneous abortion.
In conclusion, this project has confirmed the findings 
of earlier work in this laboratory, produced new findings 
on ageing effects, treatment effects and plasma cell 
infiltration in periodontal disease, elucidated further the 
immunology of pregnancy, and established areas for further 
research.
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Chapter 1
Introduction
1. Introduction 
1.1 Periodontal disease: Prevalence, causes and host 
specificity
1.1.1 Introduction
Periodontal disease is a general term which can be used to 
refer to all diseases which could have an effect on the 
periodontium. Since the periodontium comprises tissues of 
different origin, both mesenchymal and ectodermal, a large 
range of systemic conditions with periodontal consequences 
could be included under this heading (1). However, in the 
present context, this term will only be used to denote 
gingivitis and periodontitis, i.e. dental plaque-induced 
inflammatory processes of the periodontium.
1.1.2 Gingivitis
In gingivitis, pathological changes are confined to the 
superficial gingival tissue, i.e. the gingiva. Clinical 
manifestations include redness and swelling, and an 
increased tendency to bleeding on probing, all associated 
with increased vascularity. The increased vascularity 
also leads to an increase in local temperature and
increased gingival crevicular fluid flow. Gingival 
crevicular fluid (GCF) is an inflammatory exudate or 
preinflammatory transudate present in the gingival 
crevice. Its components are derived mainly from: 1)
microbial products; 2) interstitial fluid and locally- 
produced factors of host origin; 3) plasma; and 4) tissue 
degradation/turnover products (2) . Production of GCF due 
to an inflammatory increase in the vascular permeability 
of the subendothelial vasculature was shown in early 
studies (3, 4).
1.1.3 Periodontitis
Periodontitis, however, also effects the deeper structures 
of the periodontium, i.e. cementum, periodontal ligament 
and bone attachment. This results in loss of periodontal 
support, bone loss as evidenced by radiographs and the 
development of the periodontal pocket. At least four 
different forms of periodontitis have been defined (5-7), 
and, as will be discussed later, it is thought that at 
least some of these have an aetiological basis related to 
differences in their host response.
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Early studies in this field (8-10) contributed to the 
consensus that: 1) periodontitis is a virtually universal 
phenomenon affecting a very high percentage of the
population; 2) the disease begins as gingivitis at an 
early age and if left untreated will develop into
periodontitis; and 3) most of the perceived variance in 
periodontal disease is associated with age and deficient 
oral hygiene.
1,1.4 Current Concepts in Epidemiology
However, recent studies have challenged these concepts and 
a different overall picture of the prevalence and
progression of destructive periodontal disease has
emerged.
Recent cross-sectional studies have demonstrated 
that, although a periodontium of reduced height becomes 
the norm with increasing age, relatively few subjects in 
each age group suffer from advanced periodontal 
destruction. These subjects account for most of the sites 
which are severely periodontally involved (11-13) . 
Papapanou et al reported that 75% of the total sites with
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previous attachment loss of at least 6mm occurred in 23% 
of the individuals examined (12).
Loe et al (14) reported similar findings in a 15- 
year-long study of the natural history of periodontal 
disease in Sri Lanka. These investigations identified a 
group of subjects, comprising 8% of the total sample, who 
showed rapid progression of periodontal disease, as 
defined by tooth mortality rates and interproximal 
attachment levels. In the same study, however, 11% of the 
subjects did not show progression of periodontal disease 
beyond gingivitis.
In addition, longitudinal studies have shown that 
relatively few sites undergo extensive periodontal 
destruction within a given observation period (15-17). 
Lindhe et al (16) reported that during a six year follow- 
up of 64 Swedish subjects, showing signs of previous 
periodontal destruction but not receiving active 
periodontal treatment, only 3.9% and 11.6% of their sites 
demonstrated attachment loss of greater than 2mm from 
baseline at 3 and 6 years respectively. Similar
percentages (3.2%) of sites exhibiting periodontal 
attachment loss were reported in the same study for a 
group of American subjects who were followed over a one
4
year period. Moreover, it seems that relatively few 
individuals account for the sites which show active 
periodontal destruction over an observation period. Thus, 
Lindhe et al (17) in a recent study reported that 70% of 
the sites that deteriorated by 3mm or more during a two 
year monitoring period occurred in only 12% of the 265 
Japanese subjects that were followed longitudinally.
1.1.5 Subject and Site Relatedness
Therefore, the current view is that periodontal disease is 
subject related, with a small subset of individuals within 
a given population suffering from advanced periodontal 
destruction, and with relatively few subjects and sites 
undergoing active periodontal destruction within a given 
period. In addition, in the absence of treatment, the mere 
presence of inflammatory periodontal lesions does not 
necessitate their progression (18) . Thus, it has become 
apparent that any investigation of periodontal disease 
must take account of subject-specific and site-specific 
factors, and this will become clearer in the later 
discussion of subject and site susceptibility.
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1.1.6 Recent advances in epidemiological understanding
Recent reports have added to our understanding of the 
epidemiology of periodontal disease. Kerr has shown that, 
in an archaeological study of an English population dating 
from 1645-1852 i.e. in a natural state without dental 
care, the prevalence and distribution of periodontitis 
lesions were similar to those in modern English 
populations (19) . The study confirmed the existence of 
susceptible and resistant subgroups of individuals and of 
teeth. However, the author concludes that the findings do 
not support the view that periodontal disease is the 
primary cause of tooth loss in the untreated population. 
It must be borne in mind that this is a controversial 
conclusion which does not seem to take account of rapidly 
progressive and site-specific forms of periodontal 
disease, susceptible individuals and sites, and the 
apparently higher rates of periodontal destruction among 
the much older groups surviving in modern populations.
For example, Fox et al (20) conducted a study of over 
500 people in New England between the ages of 70 and 96.
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This New England Elders Dental Study (NEEDS) revealed 
substantially higher estimates of periodontal destruction 
among older adults than previous U.S. studies seemed to 
suggest. They conclude that the increasingly ageing 
population presents a challenge for periodontal treatment 
provision.
Bagramian et al (21) studied a large number of Amish 
and non-Amish people in Michigan. The Amish reject many 
elements of modern lifestyle and their rate of daily 
toothbrushing is much lower (37%) than in non-Amish 
individuals (85%). Most periodontal measurements seemed 
to be poorer in the Amish individuals, but these 
differences were not significant. However, this report is 
complicated by the inter-relatedness of lifestyle factors 
and genetic similarity in the Amish group, which is 
genetically more homogeneous than the general population.
Genco (22) has assessed risk factors for periodontal 
disease, and has found smoking and diabetes to be 
important systemic risk factors. Important local
periodontal pathogens were found to be Porphyromonas 
gingivalis and Bacteroides forsythus. Watson et al (23) 
used the ability of Porphyromonas gingivalis, Treponema 
denticola and Bacteroides forsythus to hydrolyse the
synthetic trypsin substrate benzoyl-DC-arginine
napthylamide (BANA) to demonstrate that children whose 
parents were colonised by these BANA-positive bacteria 
were 10 times more likely to be infected themselves than 
children whose parents were not. They conclude that their 
data are compatible with the hypothesis that children may 
acquire these species from their parents, especially if 
the parents have periodontitis. Therefore, transmission 
of pathogenic organisms within the family group may be an 
important factor.
The microbiology of periodontal disease is discussed 
further in section 1 .2 ., and other factors and diseases
relevant to periodontal disease are discussed further in 
section 1.4.
Grossi et al (24,25) have confirmed the importance of 
age, smoking, diabetes mellitus and subgingival 
colonisation by Porphyromonas gingivalis and Bacteroides 
forsythus as risk factors for attachment loss. The
occurrence of low levels of periodontal disease in
untreated people in underdeveloped countries has been 
confirmed in West Bengal by Maity et al (26) . Moreover, 
Diamanti-Kipioti et al (27) have recently confirmed the
existence of a skewed distribution of advanced disease in
the population. Their study on a Greek population showed 
that 25% of the rural sample and 12% of the urban sample 
accounted for 75% of the total number of tooth sites with 
pronounced bone loss. Loesche has demonstrated that 
periodontal disease is a risk factor for heart disease 
(28) and it has previously been shown that there is a link 
between periodontal disease, heart disease, smoking and 
socio-economic group (29). This will be further discussed 
in section 1.4.
1.1.7 The Classical Model
Page and Schroeder (30) proposed five distinct states in 
the pathogenesis of periodontitis, ranging from health to 
advanced disease. The stages within this classical 
picture are health, the initial lesion, the early lesion, 
the established lesion and the advanced lesion. The 
initial PMN infiltrate was postulated to be rapidly 
replaced within 48 hours by a lymphocytic lesion. This 
lesion could then stabilise as the early lesion unless
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further challenged by plaque. With further plaque 
challenge, however, the cellular infiltrate was then 
thought to transform into a plasma cell dominated lesion. 
At this stage tissue destruction including bone resorption 
was thought to occur.
However, three factors have brought Page and 
Schroeder's model into serious question: l)the inability
to test the validity of the model with true longitudinal 
studies; 2)recent changes in ideas on periodontal disease 
activity; and 3) the fact that not all postulated stages 
have been observed histologically (31-35).
1.1.8 Three Models of Pathogenesis
Three models have been described to explain destruction of 
the periodontal supporting tissues: the continuous
paradigm, the random burst theory and the asynchronous 
multiple burst hypothesis. The continuous paradigm 
postulates slow, constant and progressive destruction, and 
is supported by cross-sectional studies (36,37), and
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longitudinal monitoring of sites not responsive to 
treatment (38) . However, as the study of Loe et al (37) 
shows, pooling data from groups, individuals and sites in 
cross-sectional studies can give the impression that 
destruction was slow and continuous.
The random burst theory proposes short periods of 
destruction punctuated by periods of resolution occurring 
randomly in time and at random sites within the subject 
(39). By contrast, the asynchronous multiple burst 
hypothesis proposes that destruction occurs within a 
defined time frame and then resolution or remission 
follows. This hypothesis suggests that many sites would 
show bursts of activity over a limited period of time and 
then these sites would become inactive indefinitely. None 
of these proposed mechanisms can be established or refuted 
by presently available data (40) . However, a matter of 
some concern must be that methods of assessing parameters, 
such as attachment loss, generally provide poor 
resolution. This means that such parameters will, almost 
by definition, lend themselves to the detection of 
"bursts" during longitudinal trials.
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1.1.9 Stages in Pathogenesis
The Page and Schroeder model will be used as a framework 
for the following discussion of each stage in the 
pathogenesis of periodontal disease, but conflicting views 
will also be presented where appropriate.
Under experimental conditions, clinically "healthy" 
gingiva can be established. The tissues are characterised 
by gingival index (GI) scores of 0 and a mere trace of 
gingival exudate (41, 42) , but this is not identical with 
histologically "normal" gingiva (43) . This normal
condition only exists in gingiva adjacent to plaque-free 
teeth and is, therefore, rarely encountered in humans. It 
has been described in animals whose gingivae have been 
kept meticulously clean (44) and also in germ-free animals 
(45) . It must be stressed that even biopsies of clinically 
normal human gingiva demonstrate infiltration of 
inflammatory cells. This infiltrate comprises 3-5% of the 
connective tissue volume contiguous with the junctional 
epithelium, and contains PMNs, monocytes, macrophages and 
lymphocytes, primarily T-cells with very few B-cells or 
plasma cells (30,34,46). This infiltrated area suffers 
from collagen depletion and its vascularity is increased.
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Fluid and plasma proteins leak from the microvasculature, 
percolating through the connective tissue and junctional 
epithelium into the gingival sulcus, giving rise to the 
GCF (47).
This stage contributes one of the main problems in 
elucidating the pathogenesis of periodontitis. 
Investigators have been unable to make a clear distinction 
between normal and pathologically altered tissue. The 
crucial point at which disease commences has not been 
determined. Since definitive evidence on this point is 
lacking so far, two hypotheses have been adduced. The 
first states that the features of the initial lesion 
merely reflect enhanced levels of the host defences 
occurring within the gingiva as part of normal
surveillance procedures (30,32,48,49). The second states
that the "initial" stage may be a quiescent phase 
following destructive disease. As such it may constitute
a later or indefinitely recurring stage in disease
progression (50).
The acute, exudative, inflammatory response to plaque 
accumulation is known as the initial lesion (32,49), 
according to the Page and Schroeder classification. The 
initial lesion usually manifests after 2-4 days, although
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vascular changes beneath the junctional epithelium can be 
seen within 24 hours of plaque accumulation; it is 
localised around the gingival sulcus. More blood is 
brought to the area by dilation of the arterioles, venules 
and capillaries of the dentogingival plexus. At the same 
time, intercellular spaces between capillary or venular 
endothelial cells appear because of the elevation of 
hydrostatic pressure. This causes increased permeability 
of the microvasculature resulting in leakage of fluids and 
proteins into the tissues. The result is the GCF flow 
which may act as a defence mechanism by flushing out 
bacterial products while, at the same time, delivering 
bactericidal host products, e.g. antibodies and 
complement.
Listgarten and Ellegaard (51) have shown that plasma 
cells predominate apically to the gingival sulcus in the 
initial lesion in animal models. However, in human 
models, the initial lesion contains no plasma cells in the 
connective tissue area subjacent to the junctional 
epithelium (32,52). It has been suggested that host 
defence mechanisms may not always have a beneficial role, 
and that they may also be destructive. Although 
neutrophils and macrophages are recruited to the area to
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defend the host against bacterial attack, their 
accumulation in the coronal part of the connective tissue 
and junctional epithelium probably accounts for much of 
the damage seen in this portion of the gingiva (53-56) .
The initial lesion transforms into the early lesion 
within about one week of plaque accumulation (32,57). The 
vessels of the coronal portion of the dentogingival plexus 
remain dilated (44,47), and the additional plaque 
accumulation results in more pronounced infiltration of 
the dentogingival epithelium by PMNs and macrophages. The 
inflammatory cell infiltrate now occupies 10-15% of the 
connective tissue volume of the free gingiva (57) and 
contains T-cells and some B-cells (34). Lymphocytes 
predominate in the early lesion but few plasma cells have 
been demonstrated (32,34,35,51).
The basal cells of the junctional/sulcus epithelium 
proliferate at this stage, and rete pegs have been 
demonstrated invading the coronal portion of the 
infiltrate (58,59). The character of the cellular 
infiltrate and the nature of the pathological alterations 
observed have led to the concept that cellular 
hypersensitivity may be an important aspect of the early 
lesion. Wilde, Cooper and Page (60) demonstrated that
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typical early lesions could be created in the gingival 
tissue of rats and monkeys sensitised to skin contact 
antigens followed by challenge at the gingival margin with 
the same antigen. They suggested a specific T-cell- 
mediated mechanism, since sensitisation can only be 
transferred to unsensitised animals by means of 
lymphocytes, but not serum.
The duration of the early lesion has not been 
determined. Recently, a six-month experimental gingivitis 
study by Brecx et al (52) has demonstrated that more than 
six months of oral hygiene abstention is required before 
plasma cells dominate the lesion. Therefore, the early 
lesion may continue for a much longer period than 
previously thought.
The established lesion, as defined by Page and 
Schroeder, is one dominated by plasma cells. Many 
investigators have stated that only 3-4 weeks of plaque 
accumulation are required for the formation of a plasma 
cell dominated lesion (32,61). However, this assumption 
has been challenged by Brecx et al (52) .
The established lesion continues to exhibit the 
features of the preceding stages, but to a more marked 
degree (59,62). Large numbers of plasma cells are seen
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(59,63), which are primarily located in the coronal 
connective tissue and around vessels in more distal 
gingival connective tissue. Collagen loss continues in 
both apical and lateral directions as the inflammatory 
cell infiltrate expands, resulting in collagen-depleted 
areas radiating deeper into the tissues (54).
Two types of established lesion appear to exist, some 
remaining stable and not progressing for months or years 
(64-67), while others become more active and convert to 
progressive destructive lesions. Controversy surrounds 
the nature of this conversion. Seymour, Powell and Davis
(68) hypothesised that a change from T-cell to B-cell 
dominance presages the conversion from stability to 
activity involving aggressive destruction. However, Page
(69) has disagreed with this view; a recent study has 
shown B-cell infiltrate mainly associated with stable, 
non-progressive lesions in childhood gingivitis (70).
The final stage in this process is known as the 
advanced lesion. The advanced lesion has characteristic 
features including alveolar bone loss and fibrosis of the 
gingiva with widespread manifestations of inflammatory and 
immunopathological tissue damage (71,72). The lesion is 
no longer localised and the inflammatory cell infiltrate
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extends laterally and apically into the connective tissue. 
It is now generally accepted that plasma cells are the 
dominant cell type in the advanced lesion (71,72).
1.1.10 Recent advances in the understanding of 
pathogenesis
The role of host factors in determining an individual's 
susceptibility to periodontal disease has been elucidated 
by Shapira et al (73) in a fascinating case study. This 
reported the case of an otherwise healthy female who 
exhibited prepubertal periodontitis at age 10, juvenile 
periodontitis at 13, and rapidly progressive periodontitis 
at 29. Therefore, although these are considered distinct 
disease entities, which, as in this case, may manifest 
sequentially in the same individual, the pathology and 
pathogenesis of the disease appears to be similar.
The host response to oral micro-organisms and, in 
particular, to bacterial enzymes which are suspected as 
important virulence factors, appears to be relevant to the 
pathogenesis of periodontal disease. For example,
argingipain, an arginine-specific cysteine protease of
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Porphyromonas gingivalis, plays a key role as a virulence 
factor of this organism in the pathogenesis of periodontal 
disease via the direct destruction of periodontal tissue 
components and the disruption of normal host defence
mechanisms (74). Targets for this enzyme include
collagens I and IV and immunoglobulin G (IgG) . Variations 
in host immune competence to eliminate or contain this 
organism are, therefore, crucial to perceived differences 
in subject susceptibility to periodontal disease. This 
issue will be discussed further in section 1.6.8.
The significance of various host factors in 
periodontal disease has recently been investigated.
Platelet activating factor (PAF) which is a potent
phospholipid mediator of inflammation has been shown to 
have saliva levels which correlate with the severity of 
periodontal inflammation (75) . Prostaglandin E2 (PGE2) 
exerts a biphasic effect on IgG production in that high 
levels such as are found in inflammation attenuate the 
local IgG response, but reduced levels allow the local 
humoral immune response to recover (76) . It was further 
reported that low dose PGE2 and interleukin-4 (IL-4) have 
a synergistic effect in raising local IgG production. The 
authors concluded that local PGE2 levels can regulate
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immunoglobulin production and potentiate cytokine-induced 
class switching within gingival tissue. Takahashi et al 
(77) have studied the role of a number of cytokines in the 
induction of adhesion molecules on cultured human gingival 
fibroblasts, and have produced data supporting an 
interactive role for inflammatory cytokines and the
expression of adhesion molecules on gingival fibroblasts 
in the pathogenesis of gingival inflammation in 
periodontal disease. The role of interleukins and 
adhesion molecules are discussed further in section 1.3.
1.1.11 Putative Immunological Mechanisms of Tissue 
Damage
Until fairly recently (78), discussions of the
immunological mechanisms of tissue damage in periodontal 
diseases have referred to the four types of
hypersensitivity reaction as classified by Coombs and Gell 
(79). However, the characteristics of these do not accord 
well with the clinical and histopathological signs.
Type I (anaphylactic) , type II (cytotoxic) and type 
III (immune complex) reactions are all antibody-mediated
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whereas type IV (delayed hypersensitivity) is cell- 
mediated. However, since B-cells and plasma cells 
predominate in the later stages of periodontitis, this 
cannot represent a pure type IV reaction.
Type I hypersensitivity reactions rely on IgE 
antibody bound to the surface of mast cells. Upon 
reaction with specific antigen, these cells release 
histamine and other inflammatory mediators. Mast cells 
have been demonstrated in the gingiva (80,81), as has IgE 
(82) , but type I reactions are probably not important 
elements in the immunopathogenesis of periodontal disease, 
as reflected in the scarcity of mast cells and IgE 
antibody in the periodontal tissues.
Type II reactions rely on complement-fixing IgG and 
IgM antibody. Damaged and lysing cells have been 
demonstrated in periodontitis (83,84). This type of 
reaction is probably essentially protective. However, a 
recent study by Reinhardt et al (85) has shown a 
predominance of total IgGl and IgG4 in active as opposed 
to stable periodontitis sites. Since IgG4 is relatively 
inefficient in fixing complement, two mechanisms suggest 
themselves here: 1) IgGl is basically protective and a
preponderance of IgG4 may promote disease progression by
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failure of antibody/complement mediated bacterial 
destruction; and 2) a shift to IgG4 production locally may 
constitute an attempt to limit the potentially damaging 
effects of complement-mediated activity. Care should be 
taken in this interpretation, however, since 
immunoglobulin synthesised by gingival plasma cells has 
been shown to have specificity for non-oral bacteria (86) 
or non-bacterial antigens (87).
Type III reactions involve complement fixation by 
antibody-antigen complexes. However, since studies of 
complement in periodontal disease have demonstrated that 
these components are easily washed out, suggesting soluble 
proteins rather than fixed immune complexes occur (88) , 
and attempts to extract insoluble immune complexes from 
periodontal tissue have not been successful (89), this 
type of reaction is unlikely to be important in 
periodontal destruction.
Another possible mechanism in the immunopathogenesis 
of periodontal disease is that of autoimmunity. Serum 
antibodies against type I collagen have been found in 
higher levels in periodontitis than in control subjects 
(90) . A model has been presented whereby polyclonal 
activators initiate clonal expansion of autoreactive B-
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cells, followed by a specific response to stimulation by 
autoantigens produced by the initial response (91) . 
However, there is a general dearth of evidence implicating 
autoimmune mechanisms in the pathogenesis of periodontal 
disease.
1.1.12 Neutrophil dysfunction in the pathogenesis of 
periodontal disease
When an inflammatory process is initiated, the 
polymorphonuclear neutrophil (PMN) adheres to vascular 
endothelium via complementary receptors on the PMN and 
endothelial cell. Secondly, the PMN moves towards the 
cause of inflammation, e.g. invading bacteria, by 
chemotaxis i.e. directed movement along a concentration 
gradient generated by a chemoattractant. The opsonisation 
of the invading organism with immunoglobulin and 
complement components (e.g. IgG and C3b) stimulates 
phagocytosis (engulfment) by the PMN. The final stage of 
this process is microbial killing by discharge of the PMN 
granule contents either intracellularly (primary granules) 
or extracellularly (secondary and secretory granules).
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The above processes are described in more detail in 
section 1.3.
Although the enzymes involved in oxidative killing 
are not released extracellularly, activated PMNs can 
produce superoxide anions on their surface which are then 
converted to hydrogen peroxide by peroxide dismutase. 
Combination of this with PMN myeloperoxidase and halide 
ions results in the formation of hypochlorous acid which 
is a potent oxidant capable of lysing gingival epithelial 
cells (92) and damaging periodontal ligament fibroblasts.
The presence of PMNs in the crevicular epithelium may 
protect the periodontal tissues against microbial attack 
by phagocytosing and ultimately killing the bacteria which 
can release lysosomal enzymes into the crevicular 
microenvironment (93) . It is suggested that the
neutrophils form a leucocyte wall interposed between the 
periodontal plaque mass and the junctional and crevicular 
epithelium. The leucocyte wall forms a digestive and 
secretory organ capable of protecting the delicate 
crevicular lining against bacterial injury (94).
Some studies have connected neutrophil dysfunction, 
e.g. defective chemotaxis, with the pathogenesis of early- 
onset forms of periodontitis (95-97) . However, other
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studies have found these parameters to be normal (98-100).
Van Dyke reported in his review of 1991 (101) that local
juvenile periodontitis (LJP) manifests with depressed 
neutrophil chemotaxis, bactericidal activity and
leukotriene B4 production. Phagocytosis of Staphylococcus 
aureus was also depressed, but, strangely, that of 
Actinobacillus actinomycetemcomitans, an organism
associated with LJP, was not.
Therefore, it would appear that there is as yet no 
definitive evidence, with the exception of documented 
genetic disorders discussed in 1.1.13., linking neutrophil 
dysfunction with periodontal disease, although the normal 
functioning of these cells may, under certain 
circumstances, contribute to tissue damage.
1.1.13 Genetic factors in periodontal disease 
susceptibility
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A significant association has been shown between a number 
of disorders with a genetic basis and periodontitis, e.g 
cyclic neutropenia (102), chronic idiopathic neutropenia 
(103), Papillon-Lefevre syndrome (104), trisomy 21 (105)
and Chediak-Higashi syndrome (106).
Cyclic neutropenia is an autosomal dominant trait 
thought to be caused by a haemopoietic progenitor cell 
defect leading to episodic fluctuations in neutrophil 
numbers. The occurrence of severe generalised prepubertal 
periodontitis with rapid alveolar bone loss (107) 
highlights the importance of neutrophils as a major 
cellular defence against bacterial infections. Intrinsic 
abnormalities in lysosomal granule formation and 
mobilisation have been associated with defective 
intracellular bactericidal activity in neutrophils from 
patients with Chediak-Higashi syndrome (108). These 
neutrophil defects may predispose patients with this 
syndrome to severe periodontitis (109,110).
There are other genetically-linked disorders such as 
Ehlers-Danlos syndromes (111) which involve defects of 
collagen synthesis and cross-linking, or Papillon-Lefevre 
syndrome which seems to be caused by aberrant epithelial
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development (112). All of the above disorders, however, 
involve systemic as well as periodontal manifestations.
In early-onset forms of periodontitis (EOP), however, 
only local disease occurs. Segregation analysis is a 
method of studying family trees (pedigrees) to formulate 
hypotheses concerning the mode of inheritance of a trait.
By this method it has been established that there is a 
significant genetic component to some forms of EOP 
displaying autosomal dominant transmission (113). 
However, this is still problematic since other modes of 
inheritance cannot be excluded given the probable 
heterogeneity of EOP, and the difficulty of adducing 
mechanisms explaining the purely local disease 
manifestations.
Although there is no clear evidence linking adult 
periodontitis to genetic factors, there are data 
suggesting fundamental differences in individual responses 
to the same bacterial stimulus reflecting underlying 
genetic differences. For example, Garrison and Nichols
(114) demonstrated that endotoxin-stimulated monocytes 
from periodontal disease-susceptible patients secreted 
more PGE2 than did endotoxin-stimulated monocytes from 
periodontal disease-resistant patients. Offenbacher et al
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(115) describe a PGE2 host response model as an 
alternative paradigm of periodontal disease that places 
the emphasis on host response rather than bacterial 
aetiology. This is not to say that bacterial virulence 
properties are not important, but that host response may 
be the key factor in susceptibility.
1.1.14 Role of Antibodv-mediated Mechanisms
The role of antibody-mediated mechanisms will be discussed 
at greater length in a later section. At this stage, it 
seems reasonable to state that the role of antibody in 
periodontal disease is primarily protective, but that 
deficiencies or functional failure of local and/or 
systemic antibody may lead to subject and/or site 
susceptibility. The pathogenesis of periodontal
destruction is probably determined to a large extent by 
the pro-inflammatory and tissue-degrading effects of 
cytokines released in response to bacterial products. 
Much evidence has been adduced demonstrating the ability 
of oral bacteria to directly stimulate cytokine production 
by macrophages (116-119) . LPS from oral Gram-negative
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bacteria can markedly augment release of PGE2 from cells 
activated by IFN-a (120), and polyclonal activators when 
present in optimal proportion to antigen can considerably 
amplify the secondary response to antigen (121). When one 
comes to consider the effects of these cytokines on 
metalloproteinase synthesis, prostaglandin release and 
bone resorption for example, the potential for pro- 
inflammatory and tissue-destructive events mediated by 
cytokines becomes obvious. The humoral immune response, 
insofar as it can bring about a reduction in bacterial 
antigen load, can be seen as acting against the promotion 
of tissue-destructive events.
1.1.15 Host Responses in Periodontal Diseases
It was demonstrated long ago that the gingiva adjacent to 
periodontal lesions is heavily infiltrated with 
mononuclear leucocytes. Models used in the earlier years 
of these studies suggested that the initial lesion is 
composed mainly of T-lymphocytes, with B-cells and plasma 
cells predominating at a later stage (34,122,123). 
However, this concept has recently been contested
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(124,125). These studies found that both T-cells and B- 
cells may predominate in lesions, but that there was
considerable variability in proportions of plasma cells. 
T4/T8 cell ratios are decreased in periodontal lesions
compared with those seen in peripheral blood of 
periodontitis patients or in healthy gingiva (126,127). A 
recent study has demonstrated that many of the CD4+ cells 
in periodontal lesions are in fact memory cells, and that 
CD8 + cells suppress and macrophages promote immunoglobulin 
production by plasma cells in the gingiva (128) . By these 
mechanisms, regulation of local immune responses by 
gingival cells is made possible.
Responsiveness of leucocytes to various stimuli has 
also been extensively studied in periodontal disease.
Polyclonal B-cell activation, which involves hyper­
reactivity of B-cells to bacterial products as indicated 
by their blastogenesis leading to massive production of 
lymphokines and immunoglobulin, has been shown to be 
increased in most periodontitis patients (91, 129) .
However, since this phenomenon cannot be demonstrated in 
about 30% of periodontitis patients, it may be that
polyclonal B-cell activation offers another criterion by 
which these patients can be dichotomised into more
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susceptible and less susceptible groups. This concept 
will be dealt with further in the discussion of antibody 
avidity.
Elevated monocyte response to LPS has also been
demonstrated (114,130). These workers showed that
periodontitis patients exhibit hyper-reactivity to LPS, 
presenting as increased monocyte PGE2 and IL-lfi production, 
and suggested that these patients may be susceptible to 
disease progression because of this state of hyper­
reactivity .
Degradation of soft tissue in periodontal disease can
be effected by both bacterial and host enzymes, including
the matrix metalloproteinases. These include collagenase 
which can be produced by both fibroblasts and PMNs. The 
fibroblast type degrades collagen type III, whereas the 
PMN type degrades collagen type I. The stromelysins have 
multiple specificity and can also superactivate the 
collagenases. Gelatinase can degrade collagen types IV 
and V and also breaks down denatured collagen. Birkedal- 
Hansen et al have shown that at least three suspected 
periodontopathogens, i.e. Porphyromonas gingivalis,
Actinobacillus actinomycetemcomitans and Fusobacterium 
nucleatum, produce factors that stimulate epithelial
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cells to degrade collagen fibrils (131). The most likely 
mediator, in the case of P. gingivalis, is a thiol-
dependent proteinase which activates mammalian 
procollagenase. In addition, the cytokines, IL-1L, TGF-a 
and EGF, can stimulate keratinocytes to produce type I and 
type IV/V specific collagenase (132). The potent ability 
of certain bacteria to precipitate tissue degradation, not 
only indirectly via cytokines, but also directly, further 
emphasises the crucial role of the host response in 
eliminating or limiting these pathogens.
From the above discussion it is clear that there is a 
relationship between immune function and the pathogenesis 
of periodontal disease. It has also been shown that 
different forms of periodontal disease show differences in 
the i r immunopathogene sis.
1,2 Microbiology of Periodontal Disease
1.2.1 Historical Perspective
Although references to periodontal diseases can be traced 
back to Roman physicians, oral microbiology can be said to 
date back to van Leeuwenhoek in 1772 (133) . Later W.D.
Miller, whose work was reprinted in 1973 (134), proposed
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his acidogenic theory of dental caries and, in addition, 
proposed that "pyorrhoea alveolaris" is not caused by a 
specific bacterium occurring in every case (as in
classical single-pathogen infections e.g. tuberculosis), 
but that various bacteria may be responsible.
As such this was one of the earliest expressions of 
what is now known as the non-specific plaque hypothesis. 
This postulates that dental plaque can be considered a 
homogeneous mass which causes periodontal disease once it 
has accreted to a point where it can overwhelm host 
defence mechanisms. Similarly, one of the first
suggestions of the specific plaque hypothesis was that of 
Bass who suggested a specific micro-organism, "Endoameba
buccalis" as the cause of periodontal disease, even going 
so far as to suggest a vaccine to this organism as a form 
of therapy (135) .
1.2.2 Infectious Nature of Periodontal Disease
Since the periodontal diseases, comprising gingivitis and 
periodontitis, are caused by bacterial plaque, they are, 
therefore infectious diseases as borne out by much 
evidence summarised by Socransky (136). Notably, the
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classic experimental gingivitis study of Loe et al (137) 
demonstrated a correlation between the build up of plaque 
and the development of clinically demonstrable gingivitis.
Secondly, periodontal treatment which reduces plaque 
mass and removes some key species altogether can be 
correlated with clinical improvement.
Thirdly, in vivo and in vitro studies of plaque 
micro-organisms provide further evidence of the infectious 
nature of periodontal disease, especially with regard to 
the specific plaque hypothesis. A number of case reports 
have demonstrated various infections caused by oral micro­
organisms in extra-oral sites (138,139). Oral
implantation into animals has been shown to cause 
periodontal disease with similar histopathology to that 
seen in humans (140,141). Mixed infections have also been 
shown to have synergistic effects (142).
In vitro studies of pathogenicity have investigated 
the ability of plaque bacteria to produce virulence 
factors. Since Gram-negative bacteria tend to predominate 
in periodontal pockets, high concentrations of 
lipopolysaccharide (LPS) endotoxin tend to build up. This 
causes a cytotoxic effect on host cells, promotes
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osteoclastic bone resorption and results in a localised 
Schwartzman reaction with tissue necrosis.
Additionally, toxic metabolic end products are 
released and there are indirect effects such as activation 
of the alternative complement pathway (143).
Certain bacteria, notably Porphyromonas gingivalis, 
also produce enzymes capable of destroying host proteins 
(144) . P. gingivalis and Actinobacillus actinomycetem- 
comitans both produce collagenase which is capable of 
degrading host collagen. P. gingivalis also produces 
enzymes capable of degrading host immunoglobulins (145) 
and this organism, along with Prevotella ssp., has been 
shown to be able to coat itself with Fab fragments of 
degraded IgAl thus evading host defences (146). Another 
example of this sort of strategy is the bacterial capsule 
which can inhibit phagocytosis by polymorphonuclear 
leucocytes (PMNs) and macrophages.
By the production of enzymes such as collagenase, 
hyaluronidase, gelatinase, aminopeptidase, proteinase 
etc., plaque bacteria can increase the permeability of the 
epithelium lining the gingival sulcus, destroy connective 
tissue and thereby cause proliferation of the junctional 
epithelium apically along the root surfaces.
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1.2.3 Microbial risk factors
There have been a number of studies which have set out to 
relate the bacterial composition of subgingival plaque 
samples with periodontal disease status. In a cross- 
sectional study of over 600 rural-dwelling blacks and 
whites older than 65 years of age, Beck et al (147,148) 
found that increased levels of periodontal disease were 
associated with several risk factors including increased 
counts of Porphyromonas gingivalis and Prevotella
intermedia in black subjects and Porphyromonas gingivalis 
in white subjects. Grossi et al (149) discovered that
Bacteroides forsythus and Porphyromonas gingivalis were
positively associated with attachment loss in 1426 
subjects who were older than 24 years of age. These 
cross-sectional studies support the idea of an important 
role for Prevotella intermedia, Bacteroides forsythus and 
especially Porphyromonas gingivalis in destructive
periodontal diseases.
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The above studies used immunofluorescent antibody 
techniques. However, a longitudinal study using the 
colony lift procedure and DNA probes (150) has 
demonstrated a relationship between ongoing attachment 
loss and sites with high levels (>105) of Prevotella 
intermedia and Porphyromonas gingivalis. The relative 
risk for Porphyromonas gingivalis was 2.8, compared with 
1.6 for Prevotella intermedia. When the differences 
between mean bacterial counts at active and inactive sites 
were compared, marked differences spanning an order of 
magnitude were seen for a number of species including 
Porphyromonas gingivalis, Prevotella intermedia and 
Actinobacillus actinomycetemcomitans serotype b.
Now that further new technology is available e.g. 
polymerase chain reaction (PCR) and checkerboard blotting, 
further light can be shed on the relationship between site 
disease status and microbiology.
1.2.4 Transmission of periodontal pathogens
The general impression given by much of the literature on 
periodontal microbiology is that each individual has his 
or her unique, endogenous microflora. However, these
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organisms must come from somewhere. Vertical, i.e. parent 
to offspring, and horizontal transmission, i.e. between 
other individuals, have both been demonstrated by 
molecular epidemiology techniques. These involve
fingerprinting DNA from strains recovered from different 
individuals. Actinobacillus actinomycetemcomitans and 
Porphyromonas gingivalis isolated from parents and 
children have been shown to be identical to one another, 
but different from other families (151-154) . On the other 
hand, transmission within married couples has also been 
demonstrated (155,156). Transmission between other
species and humans is also possible (157).
The most dramatic evidence of transmission of these 
pathogens was the epidemic of acute necrotising ulcerative 
gingivitis, caused by fusiform and spirochaete infection, 
which occurred between 1915 and 1930 (158,159) .
The emerging perspective is that person to person 
transmission may occur readily leading to new infections 
and recurrent infections throughout life.
1.2.5 Specific Micro-organisms
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The infectious nature of periodontal diseases having been 
clearly established, a number of studies have implicated 
specific micro-organisms in the aetiology of these
diseases (160-164). Classically, a pathogen has been
defined by Koch's postulates (165). Briefly, these three 
requirements demand that 1) the agent must be isolated 
from every case of the disease, 2) the agent must not be 
isolated from cases of other disease states or from non- 
pathogenic (healthy) states and 3) after isolation and 
repeated growth in pure culture the agent must induce 
disease in experimental animals. However, Koch was
required to abandon the third requirement in 1884 when he 
failed to induce cholera in animals, and in 1890 the
second criterion was relaxed when the possibility of the 
carrier state was recognised.
Recent workers in periodontal microbiology have 
modified and extended Koch's postulates (164). The 
relevant criteria can be discussed under five headings. 
First, the criterion of association requires that the 
suspected pathogen be detected more frequently and at 
higher levels in disease cases than in controls. This 
would mean that the organism should be present in higher
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levels in actively progressing sites than in non­
progressing sites, healthy sites or sites showing 
improvement. It might also be expected that a system of 
longitudinal monitoring would show an increase in the 
pathogen prior to or concomitant with clinically assessed 
disease progression.
Secondly, the criterion of elimination is based on
the premise that periodontal treatment should influence 
not only the clinical course of the disease but also the 
associated micro-flora. A corollary of this view is that 
failure to eliminate or at least reduce the level of the 
pathogen would eventually lead to further progression at 
that site.
Thirdly, the animal pathogenicity criterion continues 
to be used in the elucidation of possible pathogens, 
despite concerns about the use of animal models. They 
have been shown to produce valuable supportive evidence 
concerning the roles of certain micro-organisms in 
periodontal disease (166-168).
Fourthly, the response of the host to potential
pathogens has been applied in attempts to differentiate
the importance of various species in different forms of
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periodontal disease. This will be discussed in greater 
detail at a later stage.
Finally, some suspected organisms have the capability 
to produce virulence factors and these may not only be 
important in disease initiation and progression, but may 
also be useful as indicators of the pathogenic potential 
of the organism (169).
1.2.6 Two prime candidates
Two organisms that have been particularly implicated in 
periodontal disease using these criteria are P. gingivalis 
and A. actinomycetemcomi tans. Both of these organisms 
have been found in elevated numbers in periodontitis 
sites. However, A. actinomycetemcomitans has been 
associated particularly with the early-onset forms of 
periodontitis, localised juvenile periodontitis (LJP) and 
rapidly progressive periodontitis (RPP). It has also been 
detected in prospective studies of disease progression. 
Further evidence of association is that P. gingivalis has 
been shown to bind to epithelial cells (164).
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Elimination of both organisms results in successful 
therapy and recurrent lesions were found to harbour these 
species. Both species have been shown to induce 
periodontal disease in animal studies (164) . The host 
response in terms of specific antibody production, both 
local and systemic, has been shown to be elevated with 
both organisms in different types of periodontal disease, 
a high titre to A. actinomycetemcomitans being associated 
with LJP. Both organisms also produce a number of 
virulence factors including enzymes such as collagenase, 
numerous proteases in the case of P. gingivalis capable 
of destroying most host proteins, endotoxin, leucotoxin 
and epitheliotoxin in the case of A. actinomycetem- 
comitans, and also factors inducing bone resorption and 
inhibiting PMN function (164).
1.2.7 Other possible suspects
A number of other micro-organisms have also been 
implicated in periodontal disease. However, of these only 
spirochaetes, Prevotella intermedia and Fusobacterium 
nucleatum have been suggested as satisfying all of the
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extended postulates (164). Spirochaetes are found in 
"superficial layers" of plaque near host tissues, as 
evidenced by electron microscopy, where they are actively 
motile, suggesting that they have a strong affinity for
host tissue. Indeed, they have been shown to invade 
gingiva in acute ulcerative gingivitis (AUG) (170). 
However, since spirochaetes do not form colonies on agar 
media but instead form "spirochaetal haze" as they move 
through the agar when cultured by membrane-filter and
agar-well techniques, and are also sensitive to mechanical 
forces during sample dispersion or dilution and
particularly to atmospheric oxygen, the laboratory culture 
of spirochaetes has been fraught with problems.
F. nucleatum is a Gram-negative obligate anaerobe 
which is frequently isolated from subgingival dental 
plaque in patients with adult periodontitis. Indeed, high 
numbers are often detected in sites undergoing active 
periodontal destruction. However, high numbers of
F.nucleatum can also be isolated in inactive sites and,
therefore, the role of this organism in periodontitis is 
equivocal (164).
Prevotella intermedia, like P. gingivalis, is 
frequently isolated from periodontitis sites. A recent
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study has demonstrated Prevotella intermedia in 88% of 
periodontitis subjects and P. gingivalis in 94% of these 
subjects. However, Prevotella intermedia was also
detected in 42% of gingivitis subjects (i.e. no probing 
attachment loss > 2mm over one year of observation) , 
whereas P. gingivalis was not detected in any of these 
subjects (171). Therefore, the association of Prevotella 
intermedia with periodontitis as opposed to gingivitis is 
also equivocal.
Since P. gingivalis and A. actinomycetemcomitans 
appear to be most strongly and unambiguously associated 
with periodontitis (172-175), the immune responses to 
these two organisms in particular were chosen for
intensive study.
1.2.8 Specific antibiotic therapies for periodontal 
infections
Recently, some studies have attempted to relate specific 
antibiotic therapies to the presence of specific
subgingival microflora. Slots et al (176) found that they 
had a small group of patients who had high counts of gram-
negative enteric rods in their subgingival plaque. These 
were successfully treated with systemic ciprofloxacin, 
which is effective against enteric bacteria. van 
Winkelhoff et al (177) suggested that amoxicillin plus 
metronidazole may be useful in controlling periodontal 
infections when A. act inomycetemcomi tans is a major
constituent of the subgingival plaque. Tetracycline was 
found by Haffajee et al (178) to be a useful adjunctive 
therapy when combinations of P. gingivalis, Prevotella 
intermedia and B. forsythus were predominant. However, 
augmentin seemed to be a better choice when these species 
were present in low numbers.
These examples illustrate the need for diagnostic 
tests which elucidate the nature of the microbiota in 
order to target antimicrobial therapy for periodontal 
infections more effectively.
1.2.9 Current Concepts of Aetiology
In 1992 Socransky and Haffajee summarised current concepts 
of the aetiology of destructive periodontal disease in 
their review (179). Pathogenic species have been
discussed above, and host susceptibility will be dealt
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with in the next section. However, the effect of 
beneficial species in the disease process is less clear, 
but it would seem reasonable to assume that non-pathogenic 
species could have a role in preventing disease initiation 
and progression by displacing pathogenic species.
Socransky and Haffajee conclude that the presence of 
a pathogenic species is necessary but not sufficient for 
disease to occur. In order that disease results from this 
pathogen 1) it must be of a virulent clonal type; 2) it 
must possess the chromosomal and extra-chromosomal genetic 
factors to initiate disease; 3) the host must be 
susceptible to this pathogen; 4) the pathogen must be in 
numbers sufficient to exceed the threshold for that host; 
5) it must be at the right site; 6) other bacterial 
species must foster, or at least not inhibit, the process 
and 7) the local environment must be one which is 
conducive to the expression of the species' virulence 
properties.
It would seem to the cynical observer that the use of 
such extended requirements is an attempt to draw up a list 
of postulates which accord with what is already known 
about suspected periodontopathogens. However, their value 
can only be judged in truly prospective studies. In
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addition, the demonstration that virulence factors can be 
transmitted between different strains and even between 
different species, as evidenced by the transfer of 
antibiotic resistance between P. denticola and P. 
intermedia (180), may have enormous implications. The 
importance of bacteria in periodontal aetiology may in 
future be ascribed to genes coding for specific virulence 
factors rather than to particular micro-organisms.
Socransky and Haffajee (179) conclude that diagnostic 
tests for bacteria should probably not exist in isolation 
but in combination with other diagnostic tests of host 
susceptibility. It is to this latter aspect in terms of 
humoral immune response that this study is applied.
1.3 Some aspects of basic immunology relevant to 
periodontal disease
4 7
1.3.1 Introduction
Immunology has advanced at a rapid pace in recent years 
and many of these developments have impacted 
significantly on research into chronic immune and 
inflammatory diseases such as periodontal disease.
These developments have been synthesised in a number of 
recent textbooks (181-185) and only a summary of the 
relevant points is presented here.
1.3.2 Innate immunity
Immunity to infection falls into two main categories, 
innate or non-specific immunity and acquired or specific 
immunity.
Mechanisms of innate immunity operate regardless of 
any prior contact with the invading organism. The 
simplest and most basic of these mechanisms are physical 
barriers preventing access to the body. These include 
skin which is impermeable, when intact, to most micro­
organisms. In addition, mucus is secreted by membranes 
lining the inner surfaces of the body and this not only
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prevents adherence of micro-organisms to epithelial 
cells but also traps them allowing them to be eliminated 
mechanically by e.g. movement of cilia within the lungs.
The washing action of fluids such as tears, saliva 
and urine also help keep epithelial surfaces clear of 
invading organisms and many of the secreted body fluids 
contain bactericidal agents e.g. lysozyme in tears, 
saliva and nasal mucus, lactoferrin and lactoperoxidase 
in milk, and hydrochloric acid secreted by the stomach,
A similar beneficial washing function might be 
attributed to gingival crevicular fluid (GCF) also.
This will be discussed at a later stage.
The normal bacterial flora of the body can also act 
as an effective buffer against infection by both passive 
and active mechanisms. They can inhibit the growth of 
pathogenic organisms by competition for nutrients or 
production of inhibitors. Commensal organisms in the 
gut can produce colicins. These bactericidins bind to 
the negatively-charged surface of susceptible bacteria 
and insert a hydrophobic, helical molecule into the 
membrane. This molecule then becomes completely 
hydrophobic and forms a voltage-dependent channel in the
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membrane, destroying the cell's electrical energy 
potential and leading to cell death.
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1.3.3 Molecular Factors
If this first cohort of defence strategies is 
circumvented, the two main remaining innate mechanisms are 
those dependent on molecular factors and those dependent 
on cells.
Lysozyme is probably the most ubiquitous and abundant 
of secreted anti-bacterials, a muraminidase which can 
split the peptidoglycan cell wall of susceptible bacteria.
Endotoxins produced by micro-organisms during 
infection stimulate the production of the cytokines, 
interleukin-l (IL-1) and IL-6. IL-1 is an endogenous 
pyrogen (a general increase in body temperature being 
another innate defence mechanism), and can also, along 
with IL-6, stimulate the liver and other organs to produce 
molecules such as al-antitrypsin (al-AT), a2-macroglobulin 
(a2-M), both potent inhibitors of human proteases, and C- 
reactive protein (CRP); proteins produced in this way as a 
response to infection are known as acute-phase proteins.
CRP binds in a Ca-dependent way to micro-organisms 
which contain membrane phosphorylcholine. Once complexed,
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the CRP-bound particle activates complement through the 
classical pathway resulting in binding of complement C3b 
to the membrane. This process, called opsonisation 
(literally "making ready for the table"), renders the cell 
susceptible to adherence of phagocytes. Both phagocytic 
cells and complement will be discussed later. 
Interestingly, molecules such as CRP appear to be highly 
conserved in evolutionary terms, since the horseshoe 
crab's haemolymph contains a very similar analogue, 
1imulin.
Finally, interferons are a group of broad-spectrum 
anti-viral agents. They are so named because they were 
first recognised by the phenomenon of viral interference. 
This is the mechanism by which an animal infected with one 
virus is rendered capable of resisting superinfection by 
another virus.
Cells produce interferon when infected by a virus and 
secrete it into the extracellular fluid. The interferon 
then binds to uninfected cells. This promotes
derepression of two genes in the target cell, permitting 
the synthesis of two enzymes. One of these is a protein 
kinase which catalyses the phosphorylation of a ribosomal 
protein and an initiation factor necessary for protein
synthesis, thereby preventing mRNA translation to a large 
extent. The other catalyses the formation of a short 
adenylic acid polymer which activates a latent 
endonuclease. The latter has the ability to degrade both 
viral and host mRNA. The overall effect of this mechanism 
is to create a "cordon sanitaire" of uninfected and
uninfectable cells around the locus of infection, thus
ensuring containment.
However, as this mechanism can also inhibit host cell 
division as effectively as viral replication, it could 
have implications also in immune surveillance of 
neoplastic cells. By the same token, interferons could 
conceivably have a role in the healing phase of
periodontal disease by "damping down" the immune and 
inflammatory reactions to bacterial products once the
challenge has been removed.
1.3.4 Cellular factors
Interferons may also modulate the activity of natural 
killer (NK) cells, which brings us to a discussion of the 
cellular components of innate immunity.
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NK cells are large granular lymphocytes which have 
membrane receptors thought to be capable of recognising 
structures on high molecular weight glycoproteins 
expressed on the surface of virally infected cells. Via 
these receptors, the NK cell is brought close to the 
target cell and becomes activated leading to polarisation 
of granules between nucleus and target, and extracellular 
release of their contents into the intercellular space. 
Among the proteins released is perforin or cytolysin which 
bears some structural homology to complement C9. It can 
bind to the target cell membrane and form a transmembrane 
pore effecting apoptosis (programmed cell death) via a Ca- 
dependent endonuclease.
Another cell which effects extracellular killing is 
the eosinophil, a polymorphonuclear leucocyte which can 
bind to large parasites, e.g. helminths, coated with C3b. 
Most of these parasites are resistant to C9. The 
eosinophil granules contain a cationic protein and a major 
basic protein, both capable of damaging the parasite 
membrane, and also a protein capable of forming a 
transmembrane pore similarly to C9 or perforin.
The two main cells involved in killing of micro­
organisms by phagocytosis, a form of total encirclement by
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the cell followed by intracellular destruction and 
digestion, are macrophages and neutrophils, the so-called 
"professional phagocytes".
Promonocytes in the bone marrow differentiate into 
mature monocytes which disseminate through the bloodstream 
to locate in a number of tissues as mature macrophages. 
These macrophage populations make up the mononuclear 
phagocyte system, which comprises alveolar macrophages in 
the lung, cells in the lining of spleen sinusoids and 
lymph node medullary sinuses, Kupffer cells in the liver, 
and also macrophages throughout the connective tissue and 
around the basement membrane of capillaries. They also 
exist as osteoclasts in bone, mesangial cells in the 
kidney glomerulus and microglia in the brain. Macrophages 
are long-lived cells which can phagocytose invading 
bacteria directly. However, their particular specialism 
is their ability to phagocytose host cells infected with 
bacteria, protozoa or viruses.
The polymorphonuclear neutrophil (PMN) is a 
polymorphonuclear cell similar to the eosinophil but 
considerably more abundant, constituting about 70% of the 
leucocytes in the peripheral blood. These are short-lived 
cells produced in vast numbers in the bone marrow and
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spending about 36 hours in the bloodstream upon maturation 
before migrating into the tissues. PMNs contain three 
types of granules. The primary azurophilic granules 
contain myeloperoxidase, a group of cationic proteins and 
also some lysozyme. The secondary, so-called "specific", 
granules contain lactoferrin and large amounts of 
lysozyme. Acid hydrolases are contained in the tertiary 
granules. Since PMNs contain large glycogen stores which 
can be metabolised by glycolysis, these cells are ideally 
suited to operate under anaerobic conditions; a factor of 
crucial importance in periodontal disease.
However, these cells do not operate in isolation. 
For example, activation and emigration of PMNs into a site 
of infection, e.g. a periodontal pocket, involves 
interaction between PMNs, macrophages and the complement 
system.
1.3.5 Complement
Complement comprises a complex series of 20 plasma 
proteins which constitute a triggered enzyme system 
similar in mechanism to the blood clotting, fibrinolytic
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and kinin-forming systems. Like these, it operates as a 
cascade where the product of one reaction then acts as an 
enzyme in the next. The net effect of this is to produce 
a rapid and highly amplified response to an initial 
trigger stimulus.
1.3.6 Regulatory Cell Surface Receptors
As previously discussed, the interactions between immune 
cells are not only influenced and controlled by soluble 
agents, e.g. cytokines, complement and immunoglobulins, 
but also by regulatory cell surface molecules. These fall 
into four categories on immune cells: 1) MHC receptors; 2) 
cell surface receptors; 3) cluster of differentiation (CD) 
antigens; and 4) adhesins.
MHC receptors are transmembrane heterodimers. MHC 
class I molecules consist of a 43kDa peptide heavy chain
non-covalently linked to a smaller llkDa peptide called p- 
microglobulin. Most of the heavy chain is organised into 
three globular domains which protrude from the cell 
surface. A hydrophobic domain anchors the molecule in the 
membrane and a short hydrophilic sequence carries the C- 
terminus into the cytoplasm. Class II MHC receptors are
5 7
also transmembrane glycoproteins, consisting of an a-chain 
of 34kDa and a (3-chain of 28kDa. Class I receptors are 
found on virtually all cells, whereas class II receptors 
are found in B-cells and macrophages, and can be induced 
by y-interferon on capillary endothelial and epithelial 
cells. In addition, a number of other genes within the 
MHC chromosome 6 region are known as MHC class III. These 
include genes coding for complement factors C2, C4 and 
factor B, and also TNF-a and -13. The MHC system has 
evolved as a highly polymorphic system based on multiple 
alleles (i.e. alternative genes at each locus). These 
multiple allelic forms are produced by various means 
including recombination, homologous but unequal cross­
over, point mutation and gene conversion. This latter 
mechanism involves transfer of short nucleotide sequences 
from apparently non-functional genes, e.g Qa, into 
functional ones.
The importance of MHC receptors in immunological 
phenomena has already been discussed, but they also have 
influence in developmental and hormonal events.
The T-cell receptor (TCR) merits further discussion. 
Like the MHC receptor it is also a heterodimer, comprising
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two chains of 40-50kDa each. Unlike B-cell receptors 
which exist as membrane-bound immunoglobulin monomer, the 
TCR is obviously not synthesised by immunoglobulin genes. 
Functional T-cells display the TCR on their surface non- 
covalently bound to CD3 (one of the cluster of
differentiation antigens). The seven-peptide chain CD3 
transduces the antigen recognition signal into the cell.
Although the a and ft chains of the TCR are not
related to immunoglobulin, they share the same function. 
Each chain folds into two domains, one having a relatively 
invariant structure, the other displaying great 
variability akin to that of the immunoglobulin Fab 
f ragment.
The CD antigens were discovered by immunising animals 
with human lymphocytes. The antibodies produced recognise 
particular lymphocyte sub-populations. For example, CD3 
is present on all T-cells but not on B-cells. CD4 is
expressed on T-helper cells and CD8 on cytotoxic T-cells. 
These latter CD antigens act as co-receptors for class II 
MHC-antigen complex and class I MHC-antigen complex 
respectively, and are part of the TCR complex. CD4 is
also a receptor for the human immunodeficiency virus.
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The adhesins fall into four main groups: 1)
integrins; 2) adhesion molecules of the immunoglobulin 
supergene family; 3) lectin-like adhesion molecules, the 
select ins; and 4) the CD44, or Hermes group, which 
interact with ligands called addressins on vascular 
endothelium.
Important integrins include CR3 and CR4 which bind to 
complement C3b and LFA which binds to ICAM-1 and ICAM-2. 
I CAM-1 and ICAM-2 are both found on capillary endothelium, 
and ICAM-1 is also expressed on B-cells and T-cells, and 
is probably involved in the interaction between antigen- 
presenting cells and lymphocytes. ICAM-1 is also probably 
important in transendothelial migration of PMNs.
Selectins include endothelial/leucocyte adhesion 
molecule (ELAM). Binding of neutrophils to ELAM is 
thought to be a crucial first step in neutrophil 
emigration across the capillary endothelium.
The CD44 homing receptors expressed on lymphocytes 
appear to be important in the binding of these cells to 
the high endothelial venules (HEV) of peripheral lymph 
nodes. The ligands for the CD44 antigen found on 
lymphocytes have been called vascular addressins. It is 
thought that there are other homing receptors selective
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for other lymphoid tissues, e.g. Peyer's Patch HEV, and, 
therefore, these receptors may be crucial in communicating 
lymphocytes to specific sites.
1.3.7 Initiation, maintenance and resolution of 
inflammation
The original inflammatory stimulus typically results in 
the release of thrombin or histamine which upregulate the 
surface expression of P-selectin and platelet activating 
factor (PAF) on the endothelial cells lining the venules. 
The polymorphonuclear neutrophil (PMN) surface mucins 
contain sialyl Lewis x carbohydrate ligands which engage 
with the lectin-like domain at the terminus of P-selectin. 
This causes the neutrophil to roll along the endothelial 
wall and helps PAF to bind with its corresponding PAF-R 
receptor on the PMN, increasing the efficiency of PMN 
activation.
This makes the PMN more susceptible to chemotactic 
agents and, once adhesion has been stabilised by binding 
of PMN LFA-1 to endothelial ICAM-1, C5a and leukotriene B- 
4, stimulate the exit of the PMN from the circulation by 
movement across the basement membrane between endothelial
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cells and along the chemotactic gradient to the 
inflammation site. This is known as diapedesis.
Other stimuli such as damage to the basement membrane 
of the vascular endothelium and bacterially-derived toxins 
e.g. lipopolysaccharide (LPS) cause activation of 
endothelium and increased vascular permeability via
plasmin, thrombin, bradykinin and C3a. Thus bacterial 
toxins act at a later, ongoing or maintenance phase, of 
the inflammatory process by stimulating macrophages to 
produce interleukin-1 (IL-1) and tumour necrosis factor a
(TNF-a). Clearly this bacterial ability to maintain 
inflammation if not removed by immunological or other
processes is of particular relevance to the micro­
environment of the periodontal pocket.
Lipopolysaccharides (LPS) and carbohydrates produced 
by bacteria react with receptors on the membranes of
macrophages, e.g. the mannose/fucose receptor and the
complement receptor. The mannose/fucose receptor binds 
surface carbohydrates of the bacterium whereas the CR3 
complement receptor binds bacteria which have been 
opsonised with C3b via the alternative pathway. 
Macrophages so stimulated release IL-1 and tumour necrosis
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factor (TNF), and synthesise and release neutrophil 
chemotactic factor (NCF; also designated IL-8).
These factors diffuse into the local vasculature and 
stimulate vascular endothelial cells to express the 
endothelial leucocyte adhesion molecule, ELAM-1, and up- 
regulate the concentrations of the adhesion molecules, 
ICAM-1 and ICAM-2. PMNs in the adjacent circulation are 
then bound by these adhesion molecules via their own 
adhesin, LFA-1. Movement of the PMN through the vascular 
endothelium and the basement membrane is modulated by IL-1 
and TNF, this action being independent of any existing 
chemotactic gradient. However, the neutrophil's further 
journey through the subendothelial extracellular matrix 
occurs by chemotaxis through a chemotactic gradient, a 
form of directed migration. Chemotaxins involved here 
include IL-8, C5a, bacterially-derived formyl peptides, 
e.g. formyl-methionyl-leucyl-phenylalanine, and the 
leukotriene, B4.
These chemotaxins also activate the PMNs which can 
then destroy opsonised bacteria (i.e. with bound 
antibody/complement or complement only) by a number of 
oxygen-dependent mechanisms involving lipid peroxidation 
and the peroxide-myeloperoxidase system. As previously
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mentioned, PMNs can also kill using oxygen-independent 
mechanisms, e.g. neutral serine proteases (proteinases, 
elastase, cathepsin G), lactoferrin, lysozyme and 
defensins. These latter mechanisms are probably of much 
greater relative importance in the anaerobic micro­
environment of the periodontal pocket.
Normally, inflammation can be resolved. This
involves:-
1) acute-phase proteins acting as protease inhibitors;
2) agents active at the cellular level e.g. a) 
prostaglandin E2 inhibits cytokine production by T-cells 
and macrophages, b) T-cell growth factor B (TGF-B) 
deactivates macrophages by inhibiting the production of 
reactive oxygen intermediates and downregulating major 
histocompatibility complex class II expression and natural 
killer (NK) cell cytotoxicity, c) IL-10 inhibits antigen 
presentation, cytokine production and nitric oxide (NO) 
killing by macrophages, d) binding to the surface proteins 
on monocytes and neutrophils by lipocortin-1 controlled by 
endogenous glucocorticoids produced via the hypothalamic- 
pituitary-adrenal axis.
When the inflammatory agent has been cleared from the 
tissue, the above regulatory processes will normalise the
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site. If the inflammation has traumatised the tissue 
through its intensity and extent, TGF-ft plays a major role 
in the subsequent wound healing by stimulating fibroblast 
division and the laying down of new extracellular matrix 
elements via e.g. increased tissue inhibitor of 
metalloproteinases (TIMP) production.
However, chronic inflammation can develop if the 
cause of the inflammation, e.g. an invading organism, 
cannot be eliminated by the immune system. The site 
becomes dominated by macrophages, often activated. Some 
form arrays of epithelioid cells and others fuse to form 
giant cells. Lymphocytes also infiltrate and a granuloma 
is formed. The specifics of chronic inflammation in 
periodontal disease are dealt with in section 1.1.
1.3.8 Role of B-lymphocytes in acquired immunity
The cells mainly involved in specific or acquired immunity 
are antigen-presenting cells and lymphocytes. The former 
include macrophages, dendritic cells in the follicles of 
the lymph nodes, Langerhan's cells of the skin and mucous 
membranes, and B-lymphocytes themselves. These cells 
present antigen to B-lymphocytes and T-helper lymphocytes.
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The activated T-helper cells then produce cytokines which 
stimulate B-cells to differentiate into antibody-producing 
plasma cells.
Early workers in the field of antibody production 
postulated that antibody was produced as a malleable, 
uniform molecule which could be moulded to a specific 
structure by using the antigen as a template. However, 
Ehrlich (186), even a century ago, anticipated the 
mechanism which is accepted today, that of clonal 
selection by antigen. B-cells differentiate in the bone- 
marrow and are programmed to produce only one antibody. 
They display this on their surface as a receptor (about 105 
molecules) but produce no further antibody (i.e. they are 
quiescent). When these antibody receptors are bound by 
antigen a triggering signal causes the B-cell to develop 
into an antibody-producing plasma cell.
The second step in this process is that the activated 
B-cell proliferates to produce a clone i.e. a large number 
of identical cells producing identical antibody. This is 
known as clonal expansion and allows a high level of serum 
antibody to be produced within a few days.
A third feature of this process is that clonal 
expansion not only produces antibody-producing plasma
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cells but also a proportion of quiescent cells expressing 
antibody on their surface. These memory cells provide a 
relatively large pool ready to produce a much more rapid 
and intense antibody response on further antigen 
challenge.
1.3.9 Role of T-lymphocytes in acquired immunity
T-cells act by another mechanism to destroy invading 
viruses, mycobacteria and protozoa which attempt to evade 
host defences by proliferating inside host cells. T-cells 
differentiate within the thymus and will only recognise 
foreign antigen when it is on the surface of a host cell 
in association with cell surface markers of the major 
histocompatibility complex (MHC). These regulatory cell 
surface molecules will be discussed in depth later.
Killing of virally-infected cells can be achieved by 
two mechanisms, one involving NK cells and the other 
cytotoxic T-cells. Apart from their direct effect on 
virally-infected cells, as already discussed, NK cells can 
also kill these cells by the process of antibody-dependent 
cell-mediated cytotoxicity (ADCC). NK cells have a
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receptor for the Fc portion of antibody and can thus bind 
to antibodies directed against virally-coded surface 
antigens. The ADCC mechanism works well in vitro, but its 
relevance in vivo is difficult to assess.
However, a subpopulation of cytotoxic T-cells 
produces a wide range of surface receptors similar to the 
surface antigen receptors on B-cells. Similarly, these T- 
cells are programmed to recognise only one antigen when it 
is found in association with a class I MHC receptor. The 
cytotoxic T-cell can thus bind to the infected cell and 
destroy it.
T-helper cells will bind to an antigen for which they 
are programmed when it is found in association with a 
class II MHC receptor on the surface of an infected
macrophage. They then produce lymphokines, including y- 
interferon and other macrophage activating factors, re­
triggering the microbiocidal mechanisms of the macrophage 
which had been repressed by the intracellular pathogen. 
Cytotoxic T-cells are also capable of acting in this way 
by producing y-interferon. These actions of T-lymphocytes 
are referred to as cell-mediated immunity. In a similar 
fashion to that which pertains for B-cells, T-cells are 
selected and activated by antigen and expanded by clonal
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proliferation to produce a large clone of activated T- 
cells and also a pool of quiescent memory cells.
1.3.10 Immunoglobulins
An antibody, or immunoglobulin, molecule is made up of 
four peptide chains, two identical heavy chains and two 
identical light chains linked by interchain disulphide 
bonds. Immunoglobulin G (IgG) can be split by proteolytic 
enzymes to produce fragments giving clues to their 
function. The Fab fragment is now recognised as the 
antigen-binding fragment and the Fc as having other 
functions, e.g. complement binding. The Fab fragment 
contains considerable variability whereas the Fc fragment 
is relatively constant, and analysis of amino-acid 
variability has identified three hypervariable sequences 
on the heavy chain and three on the light chain in the Fab 
fragment.
Five different types of heavy chain exist in humans 
and these define the immunoglobulin classes, IgG, igA, 
IgM, IgD and IgE. These are termed the immunoglobulin
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classes. IgG is the principal immunoglobulin produced in 
the secondary immune response. IgG diffuses more easily 
than the other immunoglobulins into the extracellular 
spaces where it has the predominant role in neutralising 
bacterial toxins and binding to micro-organisms to promote 
complement fixation followed by phagocytosis.
The unique biological function of different 
immunoglobulin classes is mediated by the Fc portion. In 
the case of IgG, monocytes and macrophages contain 
receptors for Fey (FcyRI) . FcyRII is found on monocytes, 
neutrophils, eosinophils, platelets and B-cells. IgG 
complexes can bind to platelets causing thrombosis. 
Stimulation of B-cell Fc receptor leads to downregulation 
of IgG production, a possible mechanism whereby IgG and 
IgG immune complexes exert a negative feedback effect on 
antibody production.
The Fey region of IgG is responsible for complement 
activation via the classical pathway, binding to Clq and 
causing its activation.
Another low-affinity Fc receptor, FcyRIII, which is 
found on NK cells, macrophages, PMNs and eosinophils, is
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thought to be responsible for mediating ADCC by NK cells 
and immune complex clearance by macrophages.
IgG possesses the unique property among 
immunoglobulin classes of being able to cross the placenta 
providing considerable protection to the newborn in the 
first weeks of life, further supplemented by IgG in milk.
The transport processes required here involve 
translocation of IgG across the cell barrier by complexing
with another Fey receptor. A recent study has shown that
the FcyRn receptor in the gut cells of the newborn rat 
complexes with IgG at relatively low pH in the gut lumen. 
This complex dissociates at the higher pH of the basal 
layer once the IgG has been transported across the 
intestinal cell (187) . However, this mechanism has been 
only been demonstrated in rodents.
IgA is adapted to defend the exposed external and 
internal surfaces of the body against micro-organisms. It 
is found predominantly in sero-mucous secretions, e.g. 
lung secretions, saliva and secretions of the
gastrointestinal and genito-urinary tracts. In these 
fluids it is present as a dimer which is stabilised
against proteolysis by combination with the secretory 
component, which is synthesised by local epithelial cells.
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Dimerisation occurs intracellularly via a joining sequence 
(J-chain), to prevent association of monomers with 
differing specificity. Essentially, IgA antibodies coat 
micro-organisms and thereby inhibit their adherence to 
mucosal cells. Aggregated IgA can also bind PMNs and can 
activate the alternative complement pathway. Monomeric 
IgA is also found in relatively high levels in the 
circulation indicating an additional systemic role for 
IgA.
IgM exists as a pentamer joined by a J-chain. IgM 
antibodies, although of low affinity as measured against 
single determinants, can demonstrate relatively high 
avidity, i.e. overall binding strength with molecules
containing multiple epitopes. This is because the 
multivalency of IgM confers a synergistic effect whereby 
the binding of the molecule to two epitopes is of many 
times greater strength than the sum of the two
interactions. In fact, the avidity is determined by a 
multiplication of the two binding strengths. This bonus 
effect of multivalency can be thought of as a vast 
reduction in the probability of simultaneous dissociation 
of several interactions as opposed to a single
interaction.
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IgM appears in the primary immune response and is 
extremely efficient in agglutination and cytolysis of 
invading cells. As such it is thought to play a vital 
role in control of bacteraemia.
Immunoglobulins are further grouped into subclasses. 
IgG, for example, exists as IgGl, IgG2, IgG3 and IgG4, the 
difference being in the heavy chains which exist as y 1,2,3 
and 4 respectively. These heavy chain differences give 
rise to differences in biological properties. IgG2, for 
example, is relatively inefficient in placental transfer, 
whereas IgG3 is a very avid binder of complement, and IgG4 
is a poor fixer of complement. IgGl and IgG3 both 
promote strong binding of monocytes. Some of these 
differences between different IgG subclasses may have an 
impact on the course of periodontal disease, and this will 
be discussed later.
The hypervariable regions on the immunoglobulin 
molecules which form the antigen-binding site are 
themselves unique antigens which can be recognised by 
antibodies raised against them. In this context, these 
regions are referred to as idiotypic determinants; these 
compare with the isotypic determinants which define the
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various class and subclass variants and allotypes which 
define genetic variants of various regions.
Jerne's network hypothesis (188) states that because 
lymphocytes can recognise a vast array of foreign 
antigens, they should also be able to recognise the 
idiotypes of other lymphocytes. It is thought that a 
network may be formed which relies on idiotype-anti­
idiotype recognition between lymphocytes of different 
subsets. The response to foreign antigen would then 
affect the equilibrium of this network and provoke an 
appropriate response.
Interestingly, it has been shown that if hybridomas 
are formed by fusing myeloma cells with spleen cells from 
foetal mice which are just beginning to secrete 
immunoglobulins, then an unusually high proportion are 
selected as idiotype-anti-idiotype pairs. This high level 
of idiotype connectivity involving CD5 B-cells is echoed 
in the so-called "natural antibodies" which appear 
spontaneously in germ-free animals not exposed to 
exogenous antigens. In both cases the antibodies produced 
have specificity for autoantigens such as heat-shock 
protein hsp65 and also highly-conserved microbial antigens
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such as hsp65 which have several potential epitopes 
identified with the self homologue.
These findings have given rise to the concept of a 
CD5 B-cell population forming an inward-looking world in 
which the component cells recognise and stimulate one 
another constantly through their idiotypic receptor 
interactions to produce a range of IgM antibodies which 
provide an early general, or "broad-brush", defence 
against infection. Indeed Cohen and Young (189) have 
expounded the idea of an immunological homunculus in which 
a functional picture of the body is encoded within the 
immune system by regulatory committees of B- and T-cells 
which recognise certain dominant self-antigens
representing the major organs of the body. This is 
analogous with the neurological homunculus which is a 
functional picture of the body mapped onto the cerebral 
cortex in which the space occupied by a given neural 
network is directly related to the neurological importance 
of the organ it encodes, e.g. human visual and speech 
organs and canine olfactory organs are prominently 
represented.
An illustration of how this mechanism might work 
would be CD5 B-cells bearing surface receptors for self-
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hsp65 will, in an infection, selectively focus the 
bacterial hsp65 onto their surface receptors, making it 
dominant over other bacterial antigens, and process it. 
The self-epitopes will be recognised by autoreactive T- 
cells which are highly regulated within the homunculus; 
whereas T-cells specific for the non-self hsp65 epitopes 
are not so constrained and will generate an effective 
immune response.
This idiotype connectivity between self and highly- 
conserved bacterial antigens may thus be regarded as a 
means of downregulating self-reactivity whilst providing 
an enhanced general response to bacterial antigens upon 
initial exposure. However, in the context of
susceptibility to periodontal disease, it is fascinating 
to speculate on foetal exposure to bacterial antigen, as 
has been postulated by Lopatin et al (190) , especially if 
this involves non-conserved (i.e. species-specific) 
antigen exposure prior to commencement of immunoglobulin 
production. This will be discussed further in section 
1.4.
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1.3.11 Antigen-antibodv binding
There are four main intermolecular forces involved in 
antigen-antibody interactions:-
1) Electrostatic forces caused by the attraction between 
ionic groups with opposite charge on the two molecules. 
Typically between proteins, this could be an amino group, 
NH3+ on e.g. lysine, and a carboxyl group, C02" on e.g. 
glutamine. The force of attraction is expressed a s  F  oc 
l/kDd2. Therefore, the attractive force increases by a 
factor of four as the separation is halved. Water has a 
very high dielectric constant (kD) , so the elimination of 
water molecules as the interacting groups are forced 
together further increases F. Moreover, electrostatic 
forces can be generated by electron transfer reactions 
between antigen and antibody.
2) Hydrogen bonding occurs via the innate polarity (not 
charge) of groups such as hydroxyl (OH) and amino (NH2) 
causing mutual attraction. It may be mediated via water 
molecules. whose hydrogen bonding leads to the innate 
viscosity of water. However, since this is essentially an 
electrostatic interaction, the elimination of water
increases the binding energy by reduction in dielectric 
constant.
3) Similarly, hydrophobic bonding between antigen and 
antibody is mediated by hydrogen bonding between water 
molecules. Thermodynamically, a higher entropy, lower 
energy state is produced in the surrounding aqueous 
environment if hydrophobic groups on adjacent molecules 
come together to exclude water molecules. It has been 
estimated that hydrophobic forces may contribute up to 50% 
of the total strength of the antigen-antibody bond.
4) Van der Waals forces result from a temporary 
perturbation of electrons in one molecule effectively 
forming a dipole which induces a dipolar perturbation in 
the other molecule. The two dipoles then have a force of 
attraction between them generated by the dipolar 
oscillation as the displaced electrons swing back through 
the equilibrium point and beyond. The force produced here
is expressed as F oc l/d7 and depends on the interaction 
between the external electron clouds on atoms of adjacent 
molecules.
In general, the complementary electron cloud shapes 
on the combining site of the antibody and the surface 
determinant of the antigen enable the two molecules to fit
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snugly together so that the intermolecular distance 
becomes very small and the nonspecific protein interaction 
forces (given above as 1-4) are considerably increased.
The affinity of a monovalent antigen-antibody bond 
can be expressed as a dissociation constant for the 
interaction. However, in the natural situation where an 
individual has been immunised with a multivalent antigen, 
a bonus effect occurs in which the dissociation constants 
are multiplied together to derive the overall dissociation 
constant known as functional affinity or avidity. This is 
because antibodies which bind more than one antigenic site 
(epitope) can only be dissociated by the simultaneous 
breaking of two or more bonds. The probability of two 
simultaneous events is equivalent to the product of the 
probabilities of the two independent events.
The role of antibody avidity in periodontal disease 
will be discussed further in section 1.6.
1.3.12 Generation of Diversity of Antibodies
Since the immune system must be capable of producing 
millions of different antibodies, the dedication of a
7 9
single gene to programme for each antibody is clearly not 
an option as the mechanism producing such diversity.
To illustrate how such diversity is generated from a 
limited gene pool, the genes coding for heavy chains will 
be discussed here. The first element is that there are 
several genes coding for these; a single cluster is 
formed by the subclass constant region genes, and there is 
also a group of twelve highly variable D segments inserted 
between the V segment coding for the hypervariable regions 
and the J segment coding for a joining sequence to the 
constant region.
The diversity latent in this pool is considerably 
amplified by various mechanisms. The first of these 
involves rearrangement of these genes as the precursor 
cell differentiates into a mature B-lymphocyte. For 
example, there are 500 different V segments, 15 different 
D segments and 4 different J segments coding for heavy 
chain hypervariable region. Possible VxDxJ combinations 
generate thirty thousand rearrangements.
A second mechanism involves splicing out of base 
triplets upon recombination of V, D and J genes resulting 
in removal of one amino-acid from the protein sequence. 
Splicing out of single base pairs and doublets can also
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occur resulting in a frame shift which thereafter codes 
for a completely different protein sequence.
A third mechanism involves random association between 
heavy chains and light chains, both of which have 
hypervariable regions. Since possible light chain
combinations are of the order of 103, total heavy/light
V 8chain combinations are on the order of 10-10 .
Other mechanisms amplify this diversity yet further, 
e.g. V gene swapping and reading of D genes in three 
different reading frames.
A final mechanism which deserves specific attention 
is that of somatic mutation. The V region rate of somatic 
mutation as a result of single base substitutions has been 
assessed at 2-4%, with mutations being more prevalent in 
IgG and IgA than in IgM. It is thought that somatic 
mutation is more involved in class switching and affinity 
maturation in association with immunological memory 
generation than simply in the generation of greater 
antibody diversity.
These and other mechanisms which tune the humoral 
immune response to pathogens in terms of avidity, subclass 
etc. during the course of periodontal disease will be 
discussed in more depth later.
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1.4 Other factors relevant to the aetiology of
periodontal disease 
1.4.1 Introduction
A number of other factors are worthy of consideration as 
potentially relevant to the development of periodontal 
disease. Here, smoking behaviour, ageing and the
induction of oral tolerance are chosen for further 
discussion, both because of their intrinsic value in the 
elucidation of this disease process and for their 
relevance to the present study.
1.4.2 Smoking and periodontal disease
MacGregor has extensively reviewed the effects of smoking 
on plaque formation, the oral microflora, the host 
response and periodontal wound healing (191).
It has been established that there is no significant 
difference in the rate of plaque growth between smokers 
and non-smokers (192-194). However, a number of
epidemiological studies have shown that smokers have 
poorer oral hygiene and thus greater accumulation of
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plaque than non-smokers. Ainamo (195) conducted a study 
of 167 male individuals aged 18-26 and found mean plaque 
index (PI) (196) to be lower in non-smokers, increasing 
linearly with increasing cigarette consumption. An 
identical twin study by Bergstrom and Flolerus-Myrhed 
demonstrated higher levels of plaque in smokers than in 
non-smokers, and also higher levels with increasing 
smoking exposure (197) . This is particularly significant 
because endogenous factors were taken into account by 
pairing genetically identical individuals.
It has been established that smokers and non-smokers 
differ in personality traits in that smokers tend to be 
more extrovert, exhibiting more developed grooming 
behaviour but, at the same time, less well developed 
health-related behaviour (198). This bears out previous 
studies showing that smokers spent less time toothbrushing 
and brushed less adequately than non-smokers (192,199). 
Therefore, the increased rates of plaque accumulation in 
smokers, which clearly have a bearing on the development 
of periodontal disease, seem to be attributable to 
differences in toothbrushing behaviour.
Oral bacteria have been shown to be susceptible to 
the effects of tobacco smoke in vitro, with some species
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being differentially affected. Neisseriae, Streptococci 
and Staphylococci have been shown to be particularly 
vulnerable to the effects of smoke (200) . On the other 
hand, tobacco smoke has a strong reducing effect in the 
mouth (201), which might promote the growth of anaerobic 
bacteria by the elimination of oxygen. This might explain 
the marked association between smoking and acute 
necrotising ulcerative gingivitis (ANUG) (202), which is 
caused by obligate anaerobic spirochaetes and fusiforms.
Smoking has been shown to cause vasoconstriction and 
a decrease in blood flow in the oral mucosa (203) . This 
may confound the assessment of periodontal status when 
bleeding on probing is used as a parameter. Moreover, if 
host defences are reliant on systemic input of cells and 
serum components, the supply of these may be reduced in 
smokers.
Holt et al (204) found that cells of the immune 
system were highly susceptible in vitro to tobacco smoke 
exposure compared with epithelioid and fibroblastic cells. 
Noble and Penny (205) noted that circulating PMNs from 
habitual smokers had a reduced rate of chemotactic 
migration compared with non-smokers. Therefore, immune 
and inflammatory reactions may be impaired in smokers.
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Smoking has also been shown to have a deleterious 
effect on periodontal wound healing. Preber and Bergstrom 
demonstrated that there was less reduction in periodontal 
probing depths in 40 heavy smokers after non-surgical 
periodontal therapy than in 35 non-smokers (206) . It was 
also found that abstention from smoking allowed healing to 
return to normal levels.
1.4.3 Ageing and periodontal disease
Seymour and Heasman have extensively reviewed the effects 
of ageing on periodontal disease (207). Life expectancy 
has increased substantially during the course of the
twentieth century, and it has been estimated that 45% of 
the overall aged population will be 75 years and over by
the year 2000 (208) . Five million of these in the U.K.
will be 85 or over. This tendency towards increases in 
older and older cohorts has substantial impact on rates of 
periodontal destruction and treatment needs. For example, 
Fox et al (20) studied 554 people aged 70 to 96 and
discovered substantially higher estimates of periodontal 
destruction among older age groups than previous studies 
have suggested. Their results suggest that, as older and
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older age groups survive, rates of recorded periodontal 
disease increase as does demand for periodontal services.
There are changes in plaque composition with age. 
Spirochaete levels increase with age (209), but numbers of 
Streptococci decrease (210), suggesting increasing 
anaerobiasis with ageing. There are also changes in the 
periodontal structures. Alveolar bone shows marked 
changes with age. These include a decrease in the 
osteogenic layer of the cribriform plate. Moreover, the 
periodontal surfaces of the alveolar bone become jagged 
and collagen fibres show a less regular insertion into 
bone (211).
Thus, physiological and microbiological changes 
having a bearing on periodontal disease occur with ageing. 
Recently, defects in the specific humoral immune response 
with ageing have also been demonstrated (212,213). Part 
of this study, therefore, investigates differences between 
young and old individuals in terms of immune and 
inflammatory responses.
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1.4.4 Potential relevance of oral tolerance to
periodontal disease
The following discussion of the phenomenon of oral 
tolerance springs from the hypothesis that the immune 
system may be confused in its recognition of periodontal 
antigens because of their continual presentation to the 
gastrointestinal tract in a manner similar to that of food 
antigens. Lopatin et al (190) have speculated that in 
utero exposure to periodontal antigens may occur because 
of pregnancy gingivitis, which is often severe leading to 
bacteraemia (214-216), followed by placental transfer. 
Clearly, if this occurs early during immune maturation, 
there is the real possibility that these antigens will be 
recognised as auto- rather than allo-antigens. These two 
mechanisms of in utero exposure and oral tolerance may, 
indeed, account for the fact that the avidity of 
antibodies to periodontal antigens is generally very low 
compared with human responses to standard antigens, e.g. 
tetanus toxoid, or responses in animals vaccinated with 
periodontal bacteria (190). Therefore, an investigation 
was carried out within this study to establish whether or
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not bacterial DNA could be detected by polymerase chain 
reaction (PCR) in the human bloodstream.
Oral tolerance refers to the observation that if one 
feeds a protein and then immunises with the fed protein, a 
state of hyporesponsiveness to the fed protein exists. It 
was first described by Wells in 1911 (217) . Guinea pigs
were fed hen's egg proteins, and were subsequently found 
to be resistant to anaphylaxis when challenged with the 
same proteins. The phenomenon has recently been confirmed 
in humans fed, and later immunised with keyhole limpet 
haemocyanin (218).
Immunological tolerance is a basic property of the 
immune system that provides for self/non-self 
discrimination so that the immune system can protect the 
host from external pathogens without reacting against 
self. When the immune system reacts against host 
antigens, autoimmune disease results. For a time it was 
thought that self/non-self discrimination was a simple 
matter of deleting autoreactive clones in the thymus, but 
it is now clear that the maintenance of immunological 
tolerance is a much more complicated process. 
Autoreactive cells, such as those reacting with brain, are 
not deleted and can be found in normal individuals
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(219,220). Why these cells become activated and cause
disease in some individuals, whereas in others they remain 
harmless is a major question in basic immunology.
However, the mechanism of oral tolerance has been 
recognised as being so important that human trials
involving oral administration of myelin basic protein
(MBP) are now under way in patients with multiple
sclerosis (221), who have auto-antibodies to MBP.
There are two primary mechanisms by which oral
tolerance is induced, active cellular suppression or 
clonal anergy. Low doses favour active suppression,
whereas high doses produce anergy (222-224) . Active 
suppression is mediated by the induction of regulatory T- 
cells in the gut-associated lymphoid tissue (GALT), such 
as Peyer's patches. This mechanism would appear to be 
more relevant in periodontal disease, when low but 
constant doses are being experienced. There have been no 
studies of the relevance of oral tolerance to periodontal 
disease, but an interesting observation is that 
lipopolysaccharide (LPS) enhances oral tolerance to MBP 
(225) .
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1.5 Other clinical correlates which mav have relevance
to periodontal disease 
1.5.1 Introduction
In this section other clinical correlates which may have 
relevance are discussed. Periodontal disease may also be 
a model system of immune-inflammatory disorders at the 
local level.
1.5.2 Rheumatoid arthritis
Mechanisms of bone resorption have been shown to be 
similar in periodontitis, rheumatoid arthritis and 
osteomyelitis (226). Lerner showed that haptoglobin, an 
acute-phase protein, can stimulate bone resorption in 
vitro, indicating the possibility of generalised bone loss 
in chronic inflammatory diseases. The fact that bone loss 
in periodontal disease is limited to the locus of 
inflammation may have implications for other disease 
processes which have systemic consequences. Inflammation- 
induced localised bone resoption in these immune-
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inflammatory disorders is due to activation and 
recruitment of osteoclasts by locally produced cytokines 
and inflammatory mediators. Inflammatory bone resorption, 
which is a feature of both rheumatoid arthritis and 
periodontal disease, appears to be mediated by
interleukin-lp (IL-lp) (227) . This appears to happen via 
the induction of plasminogen activator activity converting 
plasminogen to plasmin, which in turn can activate 
precursor procollagenase to collagenase. B1 and B2 kinin 
receptors are also involved in inflammation, by e.g.
causing release of prostaglandins, histamine and IL-lp.
This has led to speculation that B1 and B2 receptor 
antagonists allied with y-interferon might serve as a 
pharmacological basis for more effective treatment of 
joint inflammatory and related diseases such as 
periodontal disease (228). Most interestingly, Jeffcoat 
et al have indicated that non-steroidal anti-inflammatory 
drugs (NSAIDs) may slow alveolar bone loss in periodontal 
disease, and they conclude that further studies of such 
methodologies are required to more fully investigate the 
effects of NSAIDs in rheumatoid arthritis (229) . For 
these reasons, more consideration of the pathogenesis of
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rheumatoid arthritis may be useful to our understanding of 
periodontal disease, which may be viewed as a model
immune-inflammatory process at the local level.
Rheumatoid arthritis, like periodontal disease, seems 
to have a genetic basis. Stastny demonstrated that HLA-
DR4 (one of the antigens of the major histocompatibility
complex (MHC)) was associated with an approximately
fourfold relative risk of rheumatoid arthritis in North 
American populations (230). However, in certain sub-
populations, rheumatoid arthritis is more often associated 
with DR1 than DR4 (231) . Using molecular biological 
techniques, McDaniel et al were able to detect one
fragment of (3-chain DNA produced by one endonuclease that 
appears to carry with it a 50-fold increased
susceptibility for rheumatoid arthritis (232) .
Aetiological factors which have been suggested 
include Epstein-Barr virus (233) and parvoviruses (234) . 
However, the discovery that Helicobacter pylori is
involved in gastrointestinal ulceration suggests that a 
bacterial aetiology cannot be ruled out for diseases like 
rheumatoid arthritis. Moreover, Girouard et al have shown 
that there is an association between the presence of 
autoreactive antibodies against the recombinant human heat
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shock protein, huHsp60, and infection with the 
spirochaete, Borrelia burgdorferi (235) . Heat shock 
proteins are highly conserved, and it is suggested that 
exposure to microbial Hsp60 stimulates the production of 
auto-antibodies to huHsp60. The potential importance of 
spirochaetes in periodontal disease will be discussed in 
section 1.6., but difficulties in culturing these 
organisms has restricted data in both disease processes. 
However, the ability of these organisms to invade tissue 
may have implications for the humoral immune response.
In a comparative study of patients with rheumatoid 
arthritis and periodontal disease, Macey et al found 
generalised expression of adhesion molecules on peripheral 
blood leucocytes from rheumatoid arthritis patients but 
not periodontitis patients, suggesting that localisation 
of inflammatory activation occurs in periodontal disease 
(236) . Zheng et al demonstrated that platelet activating 
factor (PAF) may mediate osteoclastic resorption in bone 
and mineralised cartilage in both rheumatoid arthritis and 
periodontal disease (237) .
Recent work on anti-TNF-a monoclonal antibody as a 
therapy for rheumatoid arthritis may have considerable 
implications for periodontal disease treatment (238) .
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Over-production of TNF-ot has been shown to promote 
inflammation by stimulating the further over-production of 
IL-l(3, IL-6, IL-8 and granulocyte /macrophage-colony
stimulating factor.
1.5.3 Pregnancy
Normal pregnancy involves immunological mechanisms 
allowing tolerance of paternal antigens by the mother. 
Rocklin et al showed that maternal lymphocytes can produce 
an immigration inhibitory factor in normal pregnancy 
(239). Their studies on the nature of the blocking factor 
indicated that this factor was an IgG antibody and it was 
directed against paternal antigens. Moreover, women who 
abort lack this antibody in their sera (240-242). It has 
been suggested that recurrent miscarriage is in many cases 
related to immunological factors (243). Previous studies 
have shown that IgG and IgM production are significantly 
raised in the first trimester of normal pregnancy (244- 
246) . In addition, miscarriage has been shown to be 
associated with increased incidence of thyroid auto­
antibodies (247-249) .
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These findings suggest that normal pregnancy involves 
the production of an IgG inhibitory antibody, and 
miscarriage involves production of auto-antibodies and 
anti-paternal-antigen antibodies. These possibilities 
were thought worthy of further investigation within this 
study. Moreover, by PCR analysis detection of bacterial 
DNA could be attempted in the bloodstream to establish if 
bacterial antigens can cross the placenta thus inducing 
tolerance of oral bacteria, as discussed in section 1.6.
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1.6 Specific Humoral Immune Response in Periodontal
Disease
1.6.1 Introduction
When we come to consider the specific humoral immune 
response in periodontal disease, i.e. antibodies directed 
against particular oral micro-organisms, there are a 
number of issues which must be addressed. First, the 
organisms to which a response is being detected must be 
considered. At this point microbial aetiology and 
pathogenesis must be taken into account since, as has 
previously been discussed, organisms may provoke an immune 
response but not fulfil other aspects of the extended 
postulates (179). In addition, antibodies may be detected 
to non-oral bacteria and non-bacterial antigens (86,87). 
Some investigators have used a battery of micro-organisms, 
including many of doubtful relevance, and this has led to 
an apparent lack of focus. In this study P. gingivalis 
and A. actinomycetemcomitans were chosen for particular 
attention because of their strong association with
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periodontal disease using all of the criteria previously 
mentioned.
Secondly, there has been controversy over whether 
whole bacterial cells should be used in assays of specific 
antibody, or particular antigens isolated from these cells 
(250). However, in this study, it was decided to 
generally employ whole cells because of the importance 
attached to another aspect of the antibody response, that 
of antibody avidity. This can be seen as a global factor 
made up of the strength of interactions between numerous 
bacterial antigens and numerous host antibodies produced 
in response to these. Therefore, the overall response to a 
particular bacterium may yield information that would be 
lost by strict concentration on specific antigens, which 
may, in fact, not be virulence factors.
Thirdly, and related to the last point, there is the 
matter of antibody function. Clearly, demonstrations of 
an association between host antibody response and 
periodontal disease may be only academic unless it can be 
related to the biological function of this antibody. 
These functions, which include the ability to opsonise 
bacteria and the ability to bind strongly to fimbriae,
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which may prevent bacterial colonisation, may relate to 
antibody avidity.
Fourthly, we must consider whether local antibody 
levels in the GCF or systemic levels or both are of
importance; and whether local levels are merely a
reflection of serum levels, or whether significant 
antibody production by gingival plasma cells is taking
place. This is important in the consideration of subject
and site susceptibility to disease onset and progression.
Fifthly, assessments of the titre and avidity of 
patient's antibody to suspected periodontopathogens may be 
useful in the differential diagnosis and classification of 
periodontal diseases.
Sixthly, the assay of these antibodies in
longitudinal studies may provide information on the
relationship between antibody titre and avidity and
disease progression at both subject and site levels, which 
may prove to be a marker of disease activity.
Finally, there is evidence that the subclass of 
immunoglobulin produced has a bearing on aspects of its 
function such as complement fixation and opsonisation.
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1.6.2 Response to Gram-positive Organisms
Most studies concerned with the humoral immune response to 
oral micro-organisms have tended to concentrate on Gram- 
negative organisms, but there have been some which have 
focused on Gram-positive organisms; however few of these 
have been in recent years.
An earlier study by Ebersole's group assayed IgG and 
igM antibody directed against Actinomyces naeslundii,
Actinomyces viscosus, Eubacterium brachy, Streptococcus 
mutans and Streptococcus sanguis in localised juvenile 
periodontitis (LJP), generalised juvenile periodontitis 
(GJP), adult periodontitis (AP), acute ulcerative 
gingivitis (AUG), and edentulous patients and normal
subjects. For all of these bacteria and all of these 
disease states there was no difference from the normal 
subject population (251). Similarly, this group went on 
to examine antibody titres to some of these organisms in
Papillon-Lefevre syndrome, a type of neutrophil
dysfunction manifesting with severe periodontal disease 
(252) . In this study no significant response to these 
organisms was detected. This does not suggest an
important role for such organisms in this disease
aetiology, since it might be expected that if Gram- 
positive antigens were penetrating the gingival tissues 
they would provoke a humoral immune response.
Page and Ebersole's groups also collaborated in a 
study which assayed levels of antibody to Actinomyces 
naeslundii in a family with a high prevalence of juvenile 
periodontitis (JP) (253). Elevated IgG levels to this 
organism were not detected although both patients and 
controls showed high levels of Actinomyces species in the 
subgingival microflora.
Ebersole's group have concluded that relatively 
abundant constituents of the Gram-positive flora in 
subgingival plaque, e.g. Actinomyces species, 
Streptococcus mutans and Streptococcus sanguis, do not 
provoke a significant humoral response even in patients 
whose microflora contain a large proportion of these 
organisms (254) . They have also shown that these bacteria 
do not contain antigens that cross-react with Gram- 
negative constituents of the plaque (251,255).
Studies of these organisms by other groups have also 
failed to demonstrate increased titres in periodontal 
disease (256-258) . These have generally shown wide 
variation, lack of discrimination between diseased and
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healthy groups, and, in one study (256), higher levels of 
IgG and IgA antibody to Streptococcus sanguis in healthy 
controls than in periodontitis sera. The only exception 
seems to be a study in 1970 by Nisengard and Beutner (259) 
showing higher levels of IgG antibody to Actinomyces 
species with increasing periodontal inflammation. 
However, the antibody assays in this study were by 
immunofluorescence and, therefore, the facility for 
quantification was probably inferior to that achieved in 
later ELISA-based studies.
Generally, differences in the humoral immune response 
to Gram-positive bacteria do not appear to occur between 
periodontitis patients and healthy controls. However, a 
notable exception may be the study of Tew et al (260) 
which examined antibody levels to Eubacterium species, 
Lactobacillus minutus and Peptostreptococcus micros; this 
being based on their previous study (261) in which they 
showed these organisms to be predominant members of the 
cultivable subgingival microflora in a cohort of patients 
with severe periodontitis. Their findings were that IgG 
antibody to Eubacterium brachy and Peptostreptococcus 
micros was raised in those patients but not in JP patients 
or healthy controls. However, it must be borne in mind
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that this study employed radioimmunoassay (RIA), rather 
than ELISA, which is known to be more sensitive, and 
refers to dichotomous measures of
seropositivity/seronegativity rather than quantitative 
differences.
Therefore, it seems fair to conclude that there are 
no abnormal changes in the humoral immune response to the 
Gram-positive flora in periodontal disease; but that 
constituents of this flora, e.g. Eubacterium species, 
although probably not aetiologic, may assume a more 
predominant role during the change to a pathogenic flora. 
There may concomitantly be an antibody response which 
could be a useful marker of this process.
1.6.3 Response to Gram-negative Organisms
Studies of the humoral immune response to Gram-negative 
organisms have tended to target organisms such as P. 
gingivalis and A. actinomycetemcomitans because of their 
marked association with periodontal disease (164). An 
earlier study of particular relevance is that of Mouton et 
al in which serum IgG, IgM and IgA antibody to P.
1 0 2
gingivalis was assayed in various patient groups, 
including AP, LJP and GJP (or RPP) , and also in healthy 
controls (262). This report established that detectable 
levels of antibody to P. gingivalis are found in a 
significant proportion of healthy adults and also that 
there is a positive correlation between antibody levels 
and age. 80% of the healthy individuals studied had IgG 
antibody to this organism, 55% had IgM and 34% had IgA. 
Moreover, IgG and IgM serum antibodies were detectable in 
children as young as six months, and children aged 6-12 
demonstrated significantly higher antibody levels than in 
younger children. The authors concluded that this 
organism probably has an aetiologic role in the disease 
process, and that the antibody response is essentially 
protective.
In addition, mean levels of IgG antibody were found 
to be five times higher in AP patients and eight times 
higher in RPP patients than in controls. Higher IgM 
levels were seen in JP patients and higher IgA levels in 
RPP. Therefore, this paper was important in establishing a 
number of points:-
1. Based upon the humoral immune response, P. gingivalis 
is probably aetiologic in periodontal disease.
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2. This response is probably protective.
3. Diseased and healthy individuals can be distinguished 
in terms of their antibody response to this organism.
4. There are indications of differences in the response in 
different periodontal disease states.
These findings were confirmed and extended by this 
and other research groups. Ebersole et al (263) studied 
85 AP patients, 67 JP patients, 62 RPP patients and 82 
controls, and found that 95% of JP patients had elevated 
antibody levels to at least one organism, predominantly A. 
act inomycetemcomi tans. 48% of AP patients, and 37% of RPP
patients had elevated serum antibody levels to P. 
gingivalis, whereas 85% of control subjects showed no 
elevations in antibody to any of the organisms in their 
battery.
Naito et al (264) assayed IgG antibodies to P. 
gingivalis in 42 AP patients and 17 controls. They graded 
the AP patients according to disease severity and found a 
positive correlation of antibody level and disease 
severity. Although antibodies to A. actinomycetem- 
comitans were also elevated in this study, this was not 
significant, and, therefore, this was perhaps an
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indication of the differing relevance of these two 
organisms in AP.
1.6.4 Response to Porphvromonas gingivalis
Two studies by Ebersole et al (255) and Tew et al (260) 
examined antibody responses to various members of the 
Bacteroides genus as it was then classified. These 
included Bacteroides gingivalis, now Porphyromonas 
gingivalis, and Bacteroides intermedius, now Prevotella 
intermedia. Although elevated responses to other
Bacteroides species were detected in some periodontitis 
patients, especially to Prevotella intermedia, P. 
gingivalis was found to be the most consistent example of 
a Bacteroides species eliciting an antibody response 
during periodontal disease; these responses being most 
frequent and of greatest magnitude.
Moreover, an investigation by Gmur et al (265) 
reported that IgG antibody levels to P. gingivalis were 
highly correlated with the extent of periodontal 
destruction, whereas anti-Prevotella intermedia
reactivities were not. Similarly, studies by other groups
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have confirmed that antibody levels to P. gingivalis are 
higher in AP patients than in controls (266,267) .
Although these studies have tended to concur that an 
increased antibody response to P. gingivalis is
associated with periodontal disease and may serve as an 
indicator, the protective nature of this antibody has been 
questioned. For example, Tollefsen et al (268) reported 
that immunoglobulin levels to P. gingivalis were lower in 
immunosuppressed transplant patients than in periodontitis 
patients, although the immunosuppressed patients also had 
a lower frequency of bleeding on probing and lower mean 
pocket depth than the periodontitis patients. They 
concluded that a reduced immune reactivity to plaque 
bacterial antigens leads to a milder and less destructive 
form of periodontitis. However, since both patient groups 
were not shown to be comparable in terms of previous 
periodontal disease experience, and the effects of 
immunosuppression on inflammation and vascularity could 
not be ruled out, it is difficult to see how such a 
conclusion can be drawn.
Generally, reports in this area have agreed that 
there is a positive relationship between serum antibody to 
P. gingivalis and other suspected periodontopathogens and
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periodontitis. However, there have been a significant 
number of studies reporting no difference between patients 
and controls or even lower antibody levels in patients 
(256,260,269-273). Although some of these studies are not 
particularly recent, and, therefore, may be seen as less 
accurate in their antibody assays, others, such as that of 
Chen et al (273) present a more significant counterpoint 
to this argument. These workers studied RPP in particular 
and found that some patients mounted a humoral immune 
response to P. gingivalis, whereas others did not. In 
addition, these antibodies were of low avidity, but 
periodontal therapy could induce the production of higher 
avidity, and presumably more biologically effective 
antibodies. Thus, Chen et al, in their discussion, 
crystallise many of the issues which will be dealt with in 
this study in relation to the humoral immune response to 
P. gingivalis, e.g. patient susceptibility, diagnostic 
categories, treatment effects, and the importance of 
antibody avidity.
Recently, Gemmell et al have demonstrated that 
gingivitis and periodontitis subjects with P. gingivalis 
infection may recognise different antigens. More
specifically, periodontitis patients' sera reacted against
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five lower molecular weight antigens falling within the 
range of lipopolysaccharide (LPS) antigens, whereas 
gingivitis patients' sera reacted against four higher 
molecular weight antigens. There was a significantly 
higher recognition of the 91.4kDa band in gingivitis than 
in periodontitis sera (274).
Wheeler et al have demonstrated that serum IgG levels 
to P. gingivalis were positively correlated with loss of 
alveolar bone in an elderly population, whereas antibody 
levels to F, nucleatum and P. intermedia were negatively 
correlated (275). Nakagawa et al found a positive 
correlation between serum IgG levels to P. gingivalis and 
homologous infection (276).
1.6.5 Response to Actinobacillus actinomvcetemcomitans
An early study of the antibody response to A. actino- 
mycetemcomitans linked this response specifically to LJP 
by demonstrating the presence of these antibodies in these 
patients but not in normal subjects (277). Ebersole et al 
also showed an association between increased levels of,
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and increased frequency of, antibody to A. actinomycetem- 
comitans and LJP (278) . These authors elaborated on this 
in a later study (279) in which they showed a 
significantly increased level of IgG antibody to A. 
actinomycetemcomitans serotype b in 90% of LJP patients, 
but only 40% of RPP and 25% of AP patients. Listgarten et 
al (280) had previously made similar findings by 
immunofluorescent techniques. Several other reports have 
shown a strong association between antibody to A . actino- 
mycetemcomitans (especially serotype b) and LJP (271,281, 
282) .
Zambon, in his review of 1985, stated that A. actino- 
mycetemcomitans was an important organism in the aetiology 
of JP because of its increased prevalence in LJP patients 
and their families, and increased antibody responses to 
this organism (139).
Eisenmann et al (283) reported similar results with a 
Central African population and suggested that 
susceptibility to JP may have a genetic component related 
to a gene pool originally derived from Africa. This 
hypothesis was tested by a study examining the effect of 
race and periodontal status on antibody to A. actino- 
mycetemcomitans (284). This showed a relationship between
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high levels of antibody to A. actinomycetemcomitans Y4 
and both diagnosis of JP and black race.
Other studies in other ethnic groups have confirmed 
that A . act inomycetemcomi tans is frequently associated 
with, and probably an aetiologic agent of JP, and may also 
be implicated in certain cases of RPP (285,286). In 
addition, an investigation of anti-A. actinomycetem- 
comitans antibodies in individuals with AP showed no 
correlation between antibody levels and disease (265).
Recently, Wilson et al have shown that patients with 
localised juvenile periodontitis (LJP) produce IgG2 
antibodies directed against the outer membrane proteins of 
A. actinomycetemcomitans which promote opsonophagocytosis 
of A. actinomycetemcomitans (287,288). O'Dell and 
Ebersole hypothesised that antibody avidity to A. actino- 
mycetemcomitans could help to explain the relationship 
between the active host response and chronic infection 
with this pathogen. Their data suggested that both 
antibody levels and avidity may contribute to the 
variation in host resistance to infection and disease 
associated with A. actinomycetemcomitans (289).
Underwood et al have demonstrated that anti- A. actino- 
mycetemcomitans antibodies are important in promoting
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phagocytosis and killing of A. actinomycetemcomitans. 
They suggest that subjects who develop high levels of 
highly avid antibodies against A. actinomycetemcomitans 
may have greater resistance to continued and repeated 
infection by this pathogen (290).
1.6.6 Response to other Gram-negative Organisms
Antibody responses to other Gram-negative organisms have 
generally failed to demonstrate any consistent and 
convincing association between these responses and the 
occurrence and extent of periodontal disease. For 
example, Ebersole et al could not demonstrate any
association between antibody levels to the Capnocytophaga 
species, gingivalis, ochracea and sputigena, and 
particular disease classifications (291,292). Levels of 
antibody to Fusobacterium nucleatum have been shown to
decrease after the age of twelve years in children with
insulin-dependent diabetes (293), in contrast to the
previously reported positively age-related antibody levels 
to P. gingivalis. Eikonella corrodens has been shown to 
provoke an antibody response during mono-infection
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induced periodontitis in gnotobiotic rats (294,295). 
However, such studies are of doubtful relevance to human 
periodontal disease, not only because of the animal model 
employed but also because human periodontal disease 
involves mixed plaques rather than single organisms. It 
may be that some organisms, although capable of provoking 
periodontal destruction under artificial conditions, are 
normally limited in their effects by other plaque flora.
1.6.7 Response to Spirochaetes
There have also been some studies of antibodies directed 
against spirochaetes. Generally, these have not shown 
significant differences in antibody responses to organisms 
such as Treponema denticola between patients with 
periodontal disease and healthy controls (260,296-298). 
Four explanations have been advanced to account for these 
findings:-
1. Spirochaetes lack antigenicity.
2. Immunosuppression by spirochaete products.
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3. Spirochaetal colonisation is limited to subgingival 
plaque. Organisms and their products do not pass into 
host tissues.
4. The quality of culture techniques for spirochaetes is 
insufficient to inspire confidence in derived ELISA 
systems.
However, spirochaetes have been shown to be antigenic 
in animals, and variable responses in the above studies 
demonstrate their antigenicity in humans. Also,
immunosuppressive agents produced by spirochaetes have 
been shown to be generally suppressive in vitro. 
Therefore, the most probable explanation is that 
spirochaetes are limited to the subgingival plaque. The 
implication that spirochaete products cannot invade host 
tissues, although whole spirochaetes have been shown to 
invade the gingiva to a limited extent in AUG (170) , does 
not suggest an aetiologic role. Spirochaetes have, 
however, been shown to be particularly associated with 
AUG. Even in this condition, however, no significant 
difference was seen in antibody levels to Borrelia 
vincentii between patients and controls (299).
1 1 3
1.6.8 Response to Particular Antigens
Some studies have investigated the humoral antibody 
response to particular antigens of bacteria rather than 
whole bacterial cells. However, intensive research into 
the fimbriae of Gram-positive organisms such as 
Actinomyces viscosus (300-304) , on the premise that anti- 
fimbriae antibodies could block adherence and thus 
colonisation, do not appear to have taken into account the 
extensive literature showing that no significant response 
to these organisms occurs in periodontal disease. 
Similarly, a study showing differences in the ability of 
antibodies of various inbred strains of mice to bind to 
fimbriae of Actinomyces viscosus (305) is of doubtful 
relevance for the same reason, and also because of the 
equivocal contribution of such animal models to our 
understanding of the aetiology and pathogenesis of 
periodontal disease in humans.
Increased levels of IgG antibody to LPS of P. 
gingivalis have been demonstrated in periodontitis 
patients (251,306). Another study demonstrated increased 
antibody levels to trypsin-like protein produced by P. 
gingivalis in periodontitis patients compared with control
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subjects (307). However, the ability of this antibody to 
inhibit this enzyme has not been shown.
There have also been investigations of the antibody 
response directed against fimbriae of P. gingivalis. 
Mouse monoclonal IgGl antibody developed against P.
gingivalis strain 381 inhibited adherence of P. 
gingivalis to buccal epithelial cells (308). Further work 
has shown that 67% of AP patients had antibody reactive 
with fimbriae, and that antibody activity could be 
detected to the 43kDa fimbrillin monomer and also to
dimers, trimers and oligomers (309).
Ebersole et al have demonstrated differences in the 
antibody responses to particular membrane antigens of P. 
gingivalis (310) . However, it should be noted that these 
antigens have not been identified as virulence factors,
and patients with strong responses to these antigens often 
tended to be those who had a strong response to whole 
cells. Although these studies will undoubtedly help to
elucidate the immune response to P. gingivalis, their use 
in clinical studies can be criticised on three points
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1. Until particular antigens are identified as virulence 
factors, the demonstration of antibodies against these may 
be of doubtful relevance.
2. The results of some of these studies, e.g. that of 
Watanabe et al (311), have suggested that antibody 
reactivity to particular groups of antigens may be no more 
useful than to whole cells.
3. Focusing too narrowly on particular antigens may result 
in other valuable information being lost.
A study of antibody directed against LPS of A. 
act inomycetemcomi tans found no increase in AP or JP 
patients over controls (312) . By contrast, an
investigation of the ability of antibody to neutralise A. 
actinomycetemcomitans leucotoxin found that 95% of JP 
patients demonstrated these antibodies as compared with 
much lower frequencies in other patient groups and control 
subjects (313).
Other studies have also dealt with antibodies 
directed against leucotoxin (314,315). However, the 
association between these antibodies and JP can also be 
shown in studies of antibodies to whole A. actinomycetem- 
comitans cells (285,286), and the relevance of leucotoxin
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as a virulence factor has not yet been demonstrated in
vivo.
Recently, Aduse-Opoku et al have characterised a cell 
surface or extracellular arginine-specific protease 
antigen which has previously been shown to have 
significant reactivity with IgG antibody of periodontal 
disease patients (316). Since these proteases have 
previously been shown to give P. gingivalis the ability 
to degrade human proteins (145) , a study of the serum 
antibody avidity was included as part of this 
investigation. The aim of this was to determine if this 
protease is a virulence factor, and to further elucidate 
the relationship between the systemic response to this 
antigen and disease progression. It has also been 
suggested recently that it may be possible to distinguish 
gingivitis from periodontitis patients in terms of 
patterns of response to outer membrane antigens of P. 
gingivalis. Gemmell et al found that gingivitis patients 
had significantly more antibody to a 91.4kDa antigen and 
significantly less antibody to LPS than periodontitis 
patients (274) .
1 1 7
1.6.9 Antibody Avidity
Antibody avidity, that is a measure of the net binding 
strength between antibodies and antigens, has been 
extensively studied in a number of fields, both in 
relation to antibody titre and in isolation, in terms of 
disease susceptibility and progression. For example, 
Morikawa et al (317) found that the titre of IgA to 
soybean antigen in the breast milk of Indian mothers was 
significantly higher than in Japanese mothers, although 
the avidity was significantly lower. Udhayakumar et al 
(318) have shown that monoclonal antibodies of higher 
avidity have much greater effectiveness in activating 13- 
cells and presumably enhancing an immune response. 
Interestingly, Charoenvit et al (319) found that a 
monoclonal antibody to Plasmodium yoelii, a malarial 
parasite, had lower avidity for the antigen than vaccine- 
induced polyclonal antibodies in mice.
Doi et al (320) suggested that low avidity may be a 
pathogenic characteristic of IgG circulating immune
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complexes in membraneous nephropathy. Significantly, 
Joynson et al (321) found that toxoplasmosis patients with 
acute infection had low avidity IgG to this organism 
whereas those with chronic infection had high avidity. 
This may have application in investigations of the phasic 
destructive episodes of chronic periodontitis, with the 
possibility that acute exacerbations and quiescent periods 
could be differentiated.
The secondary immune response classically generates 
antibodies of higher avidity. Francus et al (322) have 
demonstrated that a possible mechanism may be carrier 
primed T-cells which selectively activate virgin B-cells, 
which are then committed to the production of high avidity 
antibodies. A study with particular relevance to the 
suggested autoimmune aspects of periodontal disease is 
that of Panoskaltsis and Sinclair (323), who showed that 
autoimmune mice have lower avidity anti-single strand DNA 
than non-autoimmune mice.
There have, however, been very few reports dealing 
with antibody avidity in relation to periodontal disease. 
Ebersole et al (324) studied the increase in avidity in 
the non-human primate, Macaca fascicularis, following 
immunisation with tetanus toxoid, which they used as a
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prototype bacterial exotoxin. They found that IgG avidity 
increased from 0.9M to 1.72M following primary
immunisation, and 2.56M after secondary immunisation. 
Lopatin et al (190) demonstrated that avidity of antibody 
rose to a similarly high level in rabbits post-
immunisation with P. gingivalis, but that human
antibodies to this organism appear to be of generally low 
avidity. They also discovered that IgG antibodies to P. 
gingivalis were of significantly higher avidity in 
periodontitis patients than in control subjects (0.96M 
compared with 0.71M). They suggested that the presence of 
low-avidity antibodies contributes to the pathology
associated with periodontal disease.
Chen et al (273) demonstrated that IgG avidities to 
P. gingivalis were lower in RPP patients than in control 
subjects. However, after treatment, the avidities
increased significantly to levels higher than in controls. 
They concluded that many RPP patients do not produce 
protective levels of biologically functional antibody as a 
result of natural infection, but that treatment may induce 
the production of such antibodies. Another recent study 
of titre and avidity of IgG antibodies to P. gingivalis in 
RPP patients by Whitney et al (325) also shows lower
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avidities in RPP patients than in controls. A recent 
study by Sjostrom et al (326) showed that IgG antibodies 
in low-titre sera from control subjects were significantly 
more effective in opsonising A. actinomycetemcomitans than 
IgG antibodies in low-titre sera from RPP patients. This 
study suggests a crucial link between antibody avidity and 
function. Further support for this is derived from two 
recent reports demonstrating that effective binding of IgG 
to virulent P. gingivalis has a crucial role in 
complement activation and also in the opsonisation and 
phagocytosis of this organism (327,328).
A recent study by Ebersole and Kornman (329) 
demonstrated that P. gingivalis emerges as an organism in 
the subgingival plaque during the conversion from 
gingivitis to progressing periodontitis in a non-human 
primate model, and that this elicits a systemic antibody 
response specific for this organism. Similarly, a study 
by Dahlen and Slots (142) in rabbits showed that animals 
co-inoculated with P. gingivalis and A. actinomycetern -
comitans showed significantly more severe disease than 
animals which were monoinfected. They concluded that the 
immune system acting through systemic antibodies and/or 
cellular mechanisms may modulate the pathogenic potential
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of infecting periodontal pathogens. It may be that 
antibody avidity has a crucial role in this modulation.
A recent study in this laboratory showed that chronic 
periodontitis patients who went on to develop further 
attachment loss, in a longitudinal study, had lower 
systemic antibody levels to P. gingivalis than those who 
did not (330). This was statistically significant. This 
finding was confirmed by O'Dell and Ebersole in terms of 
the avidity response to A. actinomycetemcomitans (289) . 
Their study also suggested a potential prognostic value 
for avidity measurement in destructive periodontal 
infection. They found that, in patients who were positive 
for A. actinomycetemcomitans infection, avidity values 
tended to decrease as clinical parameters worsened and 
infection increased.
1.6.10 The Local Response
Most studies investigating the humoral immune response 
have concentrated on systemic antibody levels. Much less 
work has been done on the relationship between local 
antibody levels and local disease status. Baranowska et
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al (331) found no significant difference in the level of 
specific IgG to P. gingivalis in GCF between healthy and 
diseased sites within the same individual. Tew et al 
(332) found no obvious differences in the clinical 
parameters of probeable depth and attachment level between 
sites with elevated antibody to P. gingivalis and/or A. 
actinomycetemcomitans, and those with normal or low 
levels, and concluded that elevated antibody in GCF may 
relate to changes in disease activity that are not 
detectable by normal clinical assessments.
However, Suzuki et al (267) demonstrated that local 
production of IgG to P. gingivalis was markedly increased 
in AP as compared with RPP patients, suggesting that 
disease progression is influenced by local antibody 
production. Challacombe et al (333) showed that levels of 
IgG antibody to P. gingivalis were lower in crevicular 
fluid washings (CFW) of patients with high periodontal 
disease index (PDI) as compared with those with low PDI, 
although this was not found to be statistically 
significant. Opsonic activity against P. gingivalis was, 
however, found to be significantly depressed in high PDI 
as compared with low PDI patients.
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Lamster et al (334) reported a significant 
correlation between total IgG in GCF and specific serum 
antibody to Prevotella intermedia but not P. gingivalis. 
They concluded that the development of a serum 
immunoglobulin response to suspected periodontopathogens 
is consistent with a protective host response. A 
corollary of this view is that a local deficiency of IgG 
to these pathogens may lead to local disease progression. 
Alternatively, Kilian (145) has demonstrated that P. 
gingivalis can degrade human IgG and IgA, suggesting that 
low GCF levels of IgG may be caused by degradation by this 
organism, or that locally available antibodies are 
adsorbed by the greater mass of subgingival plaque 
present.
An earlier study by Schenck (335) showed an inverse 
relationship between the number of deep pockets (>4mm) and 
serum antibody level to P. gingivalis LPS in chronic 
periodontitis patients. Similarly, Mouton et al (336) 
demonstrated a dichotomy in serological responses to P. 
gingivalis among chronic periodontitis patients, with one 
subgroup exhibiting high serum antibody levels and another 
having levels similar to those of healthy individuals.
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Jansen et al have recently adduced further evidence 
suggesting that the ability of P. gingivalis and other 
oral bacteria to degrade host IgG may be important in the 
causation of polymicrobial infections (337).
It has been previously demonstrated in this 
laboratory that lower GCF antibody levels to P. gingivalis 
were found in deeper pockets and in more inflamed sites 
(338) . Recently, OuYang has corroborated this by showing 
that periodontitis patients had lower GCF levels of 
antibody to P. gingivalis, when related to serum levels, 
than gingivitis patients (339). OuYang had previously 
demonstrated that elevations in the GCF/serum ratio of 
antibody to P. gingivalis occurred one month after 
periodontal treatment (340) . This suggested that local 
antibody consumption may be reduced after removal of the 
organism and that the GCF/serum ratio of antibody level 
might be used as a significant indicator in evaluation of 
treatment effectiveness. Moreover, it has also been 
established in this laboratory that IgG levels were lower 
in inflamed tooth and implant sites than in healthy 
matched sites (341).
Moreover, the finding of Haffajee et al that patterns 
of response are important in disease differentiation in
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periodontitis, suggests that local patterns of response in 
the GCF may also be of interest. Therefore, a feasibility 
study was carried out using GCF from patients with early- 
onset periodontitis using checkerboard immunoblotting. 
This allows patterns of response to a number of species 
and strains, particularly serotypes of A. actinomycetem- 
comitans, to be assessed qualitatively.
1.6.11 The Host Response in Differentiation of Disease 
States
The humoral immune response has been suggested as a means 
of differentiating between distinct periodontal disease 
states. A strong local and systemic antibody response to 
A. actinomycetemcomitans has been adduced as an indicator 
of JP (342-344) . An association between the most severe 
and extensive cases of RPP and relative lack of antibodies 
to P. gingivalis and/or A. actinomycetemcomitans has 
also been reported (271,345). This, coupled with the 
previously quoted findings that humoral responsiveness in 
RPP in terms of antibody avidity is depressed compared
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with that found in AP patients and healthy individuals, 
suggests possible disease mechanisms. When localised and 
generalised early-onset periodontitis (EOP) cases (i.e. JP 
and RPP) are grouped together and the extent and severity 
of disease is related to age and plaque index, there is a 
positive correlation for the RPP group for both factors. 
This contrasts with the JP group for which the correlation 
is significant for plaque only (346). This would be 
consistent with an interdiction of disease progression in 
JP by an effective immune response, while those with an 
ineffective response would go on to develop generalised 
disease (RPP). Previous hypotheses have connected JP with 
PMN abnormalities (95-97), but these findings have been 
challenged recently (98-100). Thus this area would appear 
to be one in which fruitful progress may be made in 
enhanced differential diagnosis by objective tests of the 
humoral immune response.
It has recently been shown in this laboratory that 
adult periodontitis (AP) and rapidly progressive 
periodontitis (RPP) patients can be distinguished in terms 
of their avidity responses to P. gingivalis. RPP patients 
were found to have significantly lower avidities than AP 
patients (347) . Haffajee et al have also been able to
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show differences in patterns of antibody response in 
differing periodontal disease groups (348).
The most striking feature of early-onset 
periodontitis patients in this study was elevated serum 
antibody levels to A. actinomycetemcomitans serotype b. 
By contrast, adult periodontitis patients in this study 
were characterised by high levels of antibody serotype a. 
By methods based on those of bacterial taxonomy, the 
authors employed cluster analysis to assign patients to 
disease groups on the basis of patterns of antibody 
response. They found only responses to P. gingivalis, B. 
forsythus and A. act inomycetemcomi tans serotypes a and b 
were useful for this purpose.
1.6.12 Longitudinal Monitoring
In the most definitive study to date of longitudinal 
monitoring of humoral immunity in patients with 
destructive periodontal disease, Ebersole's group (349) 
studied 51 subjects bi-monthly for a period of up to five 
years. These comprised four subject groups which they
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defined as AP, LJP, GJP and RPP. They found that, in 
general, most serum antibody levels to subgingival species 
remained relatively constant for periods of up to five 
years. However, major increases and decreases in antibody 
to specific species could be detected in certain subjects. 
They concluded that major changes occurring in serum 
antibody may reflect fluctuations in the nature of the 
infection. In addition, they stated that their data 
suggest that serum antibody levels to certain species over 
certain thresholds indicate an increased likelihood of 
disease activity taking place at some site in the oral 
cavity, and that it would be desirable to measure antibody 
to that species at the local sites in order to detect 
areas of active disease.
They further note differences between diagnostic 
categories and observe that the pattern of antibody 
fluctuation detected does not indicate a primary response, 
and that original antigen exposure probably occurred a 
long time in the past. This accords with the view of 
Lopatin et al (190) that immunologic tolerance may be 
induced by asymptomatic bacteraemia associated with often 
severe pregnancy gingivitis (214-216), resulting in in 
utero exposure, and leading to depletion of high-affinity
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antibody-producing clones, leaving only low-avidity 
capability (350).
Horibe et al have recently demonstrated that mean 
antibody titres to P. gingivalis and P. intermedia 
decreased significantly after treatment (351). Their 
results suggest that the changes in serum IgG titres to 
these organisms are related to the suppression of these 
organisms in the subgingival plaque.
A longitudinal study of periodontal treatment effects 
is included as part of this study in order to elucidate 
the role of the humoral immune response in disease 
resolution.
1.6.13 Immunoglobulin Subclass
A small number of studies have focused on the subclass of 
IgG which is produced against suspected
periodontopathogens. Reinhardt et al studied total IgG 
subclass levels without investigating the specificity of 
these antibodies (85). IgGl and IgG4 levels were found to 
be higher in active as compared with stable periodontitis 
sites with similar clinical characteristics. A more recent
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study investigated total IgG subclass levels in 
periodontitis patients and matched controls (352) . This 
found that IgG2 levels were significantly higher in 
patients than in controls, and these data suggested that 
the predominant antibody response to periodontal pathogens 
is directed against carbohydrate or glycolipid antigens.
Whitney et al (325) investigated the titre, avidity 
and subclass distribution of serum IgG antibodies to P. 
gingivalis. They found the subclass order in both 
patients and controls to be IgG2>IgG3>IgGl>IgG4. They 
concluded that their findings were consistent with the 
hypothesis that both carbohydrate and protein antigens are 
important in the IgG response to P. gingivalis. However, 
the relative predominance of IgG2, a subclass which lacks 
strong complement fixation and opsonic properties, and the 
low avidity of patient anti-P. gingivalis antibodies 
suggested that the humoral response to infection may be 
ineffective in clearing this organism.
Lopatin and Blackburn (353) have recently reported 
that adult periodontitis patients produced IgG antibodies 
to streptokinase (SK) and tetanus toxoid (TT) with much 
higher avidity than to P. gingivalis. However, when the 
IgG subclasses were examined, the IgGl antibodies to this
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organism were found to be of similarly high avidity to 
those against SK and TT. Since IgG antibodies to P. 
gingivalis tended to be of the IgG2 subclass, which were 
of significantly lower avidity, the net effect of this 
predominating subclass was to lower the avidity of the 
overall IgG response to this organism.
Wilson and Hamilton have recently established that 
the concentration of IgG2 antibody to a major outer 
membrane protein of A. actinomycetemcomitans was higher 
than that of IgGl antibody directed against this protein 
in seven out of fourteen LJP patients' sera. This 
response could be attributed to the presence of IgG2 
antibodies to LPS or to glycoprotein. Therefore, these 
authors have shown that the IgG2 response to oral bacteria 
is not necessarily directed against carbohydrate or 
glycoprotein antigens (354) . Wilson et al have also shown 
that these IgG2 subclass antibodies are opsonic for A. 
actinomycetemcomitans (355) . Polak et al studied IgG 
subclass responses to outer membrane antigens (OMA) of P. 
gingivalis and discovered that IgG2 was the predominant 
subclass in terms of the number of OMA recognised, 
followed by IgG3, IgGl and IgG4 respectively (356).
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1.6.14 Vaccine development
The idea of a vaccine to control oral bacterial infections 
was developed in the early part of this century. 
Autogenous vaccines (357), pure cultures (358-359) and 
mixed stock vaccines (360-362) were all employed at 
various times. However, these approaches also had their 
critics (363-364). Recently, possible means of vaccine 
development have again been explored. Bird et al (365) 
used the mouse abscess model to show that protective 
immunity to P. gingivalis promoting resolution of lesions 
could be produced by immunisation with an outer membrane 
preparation of P. gingivalis. The depletion of CD4 T- 
cells prior to immunisation resulted in depressed serum 
levels of anti- P. gingivalis antibody and increased 
physical signs of disease. These findings suggested the 
protective role of serum antibody and a potential role for 
T-cell mechanisms in the control of the lesion locally. 
Page has recently reviewed the literature pertaining to 
the humoral response and its relevance to treatment 
response and vaccine development. The fact that the 
normal humoral immune response which occurs in patients 
with infectious disease, and that eventually arrests the
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process of the infection, does not appear to happen in 
periodontal disease raises the question anew of human 
vaccine development as a means of addressing this problem 
(366) .
1.6.15 Local plasma cell involvement
Seymour et al have proposed a model of the 
immunopathogenesis of chronic inflammatory periodontal 
disease. This suggests that susceptible subjects may have 
an increase in type 2 IL-4 producing T-cells selectively 
homing to the gingiva and leading to B-cell expansion. 
This may trigger periodontal destruction via IL-1 or 
protection via production of specific antibody by antigen- 
specific B-cells. Resistant subjects may have an increase 
in type 1 IL-2/IFN-a producing T-cells selectively homing 
to the gingiva resulting in B-cell suppression and a T- 
cell stable lesion with slow tissue destruction (367) . 
Kinane et al used PCR amplification of the V-J junctions
of T-cell receptor y (TCRy) gene rearrangements to 
establish that T-cells localising in gingiva differ from 
those in skin and peripheral blood. They conclude that
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their findings are consistent with the existence of local 
immune systems composed of skin-homing and gingiva-homing 
memory T-cells (368) . Shimauchi et al, in an adoptive 
transfer experiment, demonstrated that accumulation of a 
Th2 type A. actinomycetemcomitans specific CD4+ clone 
would only accumulate in the gingival tissue of rats which 
had been infected with this organism (369) . Thus, a 
system for the potential kinetics of T-cell entry into 
gingival tissues and their retention has been described 
for the first time.
Since the indications are that the periodontitis 
lesion in the susceptible subject is B-cell dominated, the 
immunoglobulins being produced by plasma cells at the 
site, their subclass distribution and relationship to 
immunoglobulins detected in the GCF are of relevance to 
local and systemic immunity. In the present study, 
therefore, an investigation was carried out into the
distribution of IgGl-4, IgAl-2 and light chain k and X 
producing plasma cells in the gingivae of periodontitis 
subjects, and their relationship to actual levels of 
immunoglobulin detected in the GCF.
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1.7 Overall aims of the study
The aims of this study fall under five broad headings. 
The first was to follow up previous work in this 
laboratory which had indicated that local disease status 
is related to levels of specific immunoglobulin. A 
previous study had shown that gingivitis and periodontitis 
sites can be distinguished in that the latter have lower 
antibody levels to P. gingivalis in the GCF than the 
former (338); perhaps indicating local degradation by oral 
pathogens (145) . In the present study, the experimental 
design was modified to allow matching of gingivitis and 
periodontitis sites within the same patient, generating 
the potential for a more powerful statistical analysis.
Reports demonstrating differences in specific humoral 
immunity with ageing (212-213) prompted an experimental 
gingivitis study on periodontally healthy young and old 
subjects, to investigate possible differences in local 
immune and inflammatory parameters. Since chronic
periodontal disease is primarily a disease of ageing, any 
immune deficiencies contributing to periodontal disease 
may be related to the ageing process itself.
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A previous report from this laboratory had suggested 
that there may be differences in immune and inflammatory 
processes at matched oral implant and natural tooth sites 
in the same patient (341). Part of this study, therefore, 
was to follow up these investigations.
Checkerboard immunoblotting may have the potential to 
allow multiple assessments of local antibody responses to 
oral pathogens from a GCF sample (370) . Therefore, a 
pilot study of the feasibility of this technique was
included as part of this study.
The second aim was to investigate local production of 
immunoglobulins by plasma cells in the gingiva. 
Therefore, an investigation was conducted into the ratios
of k  and X light-chain producing plasma cells and their 
possible relevance to periodontal disease. Another study 
dealt with production of IgG and IgA subclasses by plasma 
cells in the gingiva and related these to levels of the
immunoglobulins in the GCF. Degradation of IgAl was also 
assessed, to determine the significance of bacterial 
digestion of host immunoglobulin in the periodontal 
pocket.
Previous work in this laboratory has demonstrated the
significance of specific serum antibody avidity to
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periodontal diagnosis and prognosis (330,347). Therefore, 
the third aim of this study was to investigate the impact
of antibody avidity on the outcome of periodontal
treatment. A preliminary study was set up to assess these 
effects; also attempting to relate microbiological 
parameters. A larger study was then conducted in which 
patients were assigned to seropositivity groups according 
to the definition of Chen et al (273) at baseline. They 
were then followed longitudinally to assess differences in 
treatment outcome. Since earlier studies had suggested 
the particular relevance of P. gingivalis antigens such as 
the ARG-1 protease, a separate study was carried out into 
the prognostic relevance of antibody avidity to this 
antigen.
A fourth aim of this study was to look at the wider
significance of immunological parameters in disease
pathology. Periodontal disease can in some ways be seen 
as a model immune-inflammatory process. By the same 
token, the immunology of pregnancy has some unique 
characteristics making it worthy of study. The relevance 
of serum levels of IgG subclasses to pregnancy outcome was 
assessed. In addition, levels of an auto-antibody were 
assessed as a possible outcome marker.
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The fifth aim of the study, related to the above, was 
to determine if bacterial fragments can enter the human 
bloodstream. If so, and these fragments can then enter 
the foetal circulation via the placenta, then this in 
utero exposure may explain the very weak antibody avidity 
response to oral pathogens in humans (190). Tolerisation 
may occur, either by a mechanism akin to oral tolerance or 
the action of an IgG blocking factor as seems to occur 
with paternal antigens in pregnancy.
Thus the overall aim of this project is to increase 
understanding of the immunological aetiology of 
periodontal disease at local and systemic, cellular and 
molecular levels; and to put these findings into the wider 
context of immune-inflammatory processes.
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Chapter 2
Materials and Methods
2. Methods
2.1 Local antibody studies
2.1.1 Specific antibody levels in GCF at healthy, 
gingivitis and periodontitis sites within the same 
patient 
Clinical Criteria
Forty patients, (26 F; 14 M; mean age 43.1 (SD=10.9))
attending the Periodontal Clinic of Glasgow Dental 
Hospital participated in this study. These individuals 
had no history of systemic disease and had not received 
antibiotics for the past three months. Three sites 
(healthy, gingivitis and periodontitis) from each patient 
comprised the study sites. Using the modified gingival 
index (MGI) (371) and a pressure sensitive probe with a 
constant force of 25g, sites with gingival scoring of 0 or
1 and pocket depth (PD) less than 2mm were categorised as 
healthy. MGI between 2 and 4 and PD<3mm were the criteria 
for gingivitis sites, and sites with MGI of between 0 and
2 and PD>4mm comprised the periodontitis sites (Table 1.).
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Although difficulties were experienced in finding the 
three types of sites (healthy, gingivitis and 
periodontitis) within the same patient, there were 
considerable advantages with this protocol since the 
subject variability could be excluded by pairing three 
sites to be compared in the statistical analysis. The 
following criteria for site selection were adopted: 
mesial sites were preferred to distal sites since they 
were more accessible; upper molar palatal sites were 
preferred to buccal sites; and on the lower teeth 
buccal/labial sites were preferred to lingual sites, since 
these sites were less prone to any possibility of saliva 
contamination of the GCF sample.
Gingival Crevicular Fluid (GCF) Sampling and Processing
GCF samples were collected using Whatman grade 4 paper 
strips (2x13 mm) (372). The site being sampled was gently 
air-dried and any supragingival plaque was removed. The 
area was carefully isolated to prevent samples being 
contaminated by saliva. The paper strip was inserted into
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the crevice until mild resistance was felt, and left for 
30 seconds. Care was exercised in order to avoid 
mechanical injury of the tissues. After GCF collection, 
the paper strip was transferred to the chairside-located 
Periotron 6000 (Harco Electronics, Winnipeg, Canada) for 
the quantification of the fluid volume. The jaws of the 
Periotron were wiped with pure methanol between each 
reading. The strips were then placed in individual
sterile tubes and stored at -30°C until further processing.
Subsequently, the strips were eluted into 500(0,1 of 
phosphate-buffered saline containing 0.05% Tween 20 (PBST) 
at room temperature using a rotary mixer. After removal 
of a small volume (20(111) for albumin analysis, the 
remainder was diluted with an equal volume of PBST 
containing 0.2% bovine serum albumin (BSA), giving a final 
concentration of 0.1% BSA. This procedure allowed the 
albumin samples to be eluted into an albumin-free buffer, 
while also allowing the antibody samples to be eluted into 
the assay buffer with the appropriate blocking agents 
(0.05% Tween 20 and 0.1% BSA) . The strips were discarded 
and the eluate aliquoted and stored at -30°C.
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Calibration of the Periotron 6000
In order to transform the Periotron digital readings 
for each paper strip into volumes and also assess the 
accuracy of the instrument, known volumes of distilled 
water were delivered to Whatman grade 4 paper strips with 
a Hamilton microsyringe in a range of volumes (0.05-l|il).
Each measurement was performed 3 times and the mean value 
for each volume was used in a linear regression analysis 
from which the slope and intercept were used to determine 
the volumes of GCF collected.
Anti-bacterial antibody ELISA
Specific antibody titres were measured by ELISA based on 
the method of Ebersole et al (373,374), using formalinised 
whole cells at an absorbance (OD600) which had previously 
been determined as optimum to coat microtitre plates. The 
bacterial strains used was P. gingivalis NCTC 11834. P. 
gingivalis was grown under anaerobic conditions (85% N2, 
10% H2, 5% C02) . P. gingivalis was harvested after 5 days 
into phosphate-buffered saline (pH 7.4), with lmM Na2EDTA,
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washed by centrifugation, and fixed for 1 hour in 10% 
formal saline. The cells were then washed twice in PBS 
and once in 0.1M Na carbonate-bicarbonate buffer 
containing 0.02% NaN3 at pH 9.6 (coating buffer). Fixed 
cells were stored in coating buffer at 4°C until use. 
Immulon 1 plates (Dynatech) were employed because of their 
low protein-binding characteristics. After coating, the 
plates were treated with PBS containing 0.1% bovine serum 
albumin (BSA), 0.05% Tween 20 and 5% skimmed milk to 
remove background binding. GCF diluted in this buffer, to 
a concentration within the range of the calibration graph, 
were then added for 2 hours at 37°C, and the plates were 
subsequently incubated with biotin-anti-human IgG 
(150ng/ml) , igA (220ng/ml) or IgM (170ng/ml) (Sigma) and 
thereafter with lmg/ml extravidin-peroxidase (Sigma). 
Reaction was visualised using o-phenylenediamine substrate 
and stopped with 1M H2S04. Optical densities were read at 
490nm. Samples were assayed in triplicate, correction was 
made for non-specific binding and results were read from a 
reference line derived from serial dilutions of a 
reference positive control serum. Results were expressed 
as ELISA units (EU) (375).
Quantification of albumin
Albumin was assayed in GCF by sandwich ELISA based on the 
technique described by Hetherington et al. (376) and 
modified by Adonogianaki et al. (377). In brief, the 96-
well polystyrene microplate (Immulon 4, Dynatech 
Laboratories, Billingshurst, Sussex) was coated with the 
first antibody, a goat antiserum specific for albumin 
(1/6000 dilution in carbonate/bi-carbonate pH 9.6 coating 
buffer) . The eluate of the sample was then added and any 
antigen present was captured by the immobilised antibody.
This was followed by incubation with the second specific 
antiserum, developed in rabbit at 1:4000 dilution in 
incubation buffer (PBS containing 0.05% Tween 20). Both 
of these antisera were obtained from Sigma. Finally, the 
horseradish peroxidase (HRP) conjugated anti-rabbit IgG 
(goat) (Jackson Laboratories) was added (1:4000 dilution 
in incubation buffer). Visualisation was achieved by 
incubation with the substrate and stopping the reaction 
with H2S04. The plate was read at 490nm. Plates included 
serial two-fold dilutions of purified antigen for the 
construction of a standard curve. The working range for 
the albumin ELISA was 1.95-125 ng/ml.
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ELISA buffers
The buffers employed in ELISA assays throughout this 
entire study were as follows except where specifically 
mentioned in later sections:-
1. Coating buffer: 1.59g Na2C03/ 2.93g NaHC03 in 800ml
distilled H20, dissolve, pH to 9.6 at just under 1L, add 
0.2g NaN3, make up to 1L in volumetric flask. Store in 
sterilised bottles at 4C for 1 week.
2. Wash buffer (xlO cone.) : 80g NaCl, 14.4g Na2HP04. 2H20, 
2g KH2P04, 2g KC1, 5g Tween 20. Dissolve in 800 ml of 
distilled H20, make up to 1L and store at RT diluting 1/10 
immediately pre-use.
3. Incubation buffer: 1/10 of the quantities added to 
above (2) made up to 1L with the addition of lg of BSA. 
This should be layered on the surface without mixing.
Store at 4°C for maximum of 1 week.
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4. Substrate buffer: 0.35g Na2HP04/ 0.2375g citric acid.
Dissolve, make up to 25ml in measuring cylinder and add 1
tablet (lOmg) of oPD and 10|Al 30% hydrogen peroxide,
mixing well, immediately before use.
Statistical analysis
The non-parametric Wilcoxon signed rank test was used to 
perform paired comparisons of the non-normally distributed 
titre data for healthy, gingivitis and periodontitis sites 
within the same individual.
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2.1.2 Effects of ageing on local humoral immunity and
inflammatory responses in an experimental gingivitis 
study 
Subjects and study design
Five young individuals, 20-25 years of age and 5 older 
individuals, 65-80 years of age volunteered to 
participate in the study. The subjects in the 20-25 year 
age category were all dental students, while the 
subjects in the 65-80 year age group were patients of 
the Comprehensive Dental Care Unit, Community Dental 
Clinic, Goteborg, Sweden. The study protocol was 
approved by the Human Subjects Review Committee of 
Goteborg University.
All subjects received professional tooth cleaning 
during 4 weeks and had at the end of this preparatory 
period excellent oral hygiene, clinically healthy 
gingivae and no deepened periodontal pockets. A baseline 
examination which included assessment of plaque and 
gingivitis was performed on Day 0. The examination was 
restricted to the experimental sites, namely the mesio-
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palatal, palatal, and disto-palatal surfaces of the 
teeth present in the 15....25 tooth region. 4 sites were 
selected for gingival fluid assessment (fluid sites); in 
addition, as part of a larger study in Goteborg, 3 sites 
were selected for biopsy (biopsy sites) , and a further 3 
sites for microbial sampling (microbial sites) within 
the experimental sites. The biopsy and microbial 
samples were taken as part of a larger study and, 
therefore, no data on these aspects appears here.
Gingival crevicular fluid sampling
As in section 2.1.1.
Quantification of a2-M and LF
a2-M, and LF in eluates of GCF were assessed using 
sandwich enzyme linked immunosorbent assays (ELISA).
These are based on the technique described by 
Hetherington et al. (376) and modified by Adonogianaki et
al (377). In brief, the 96-well polystyrene microplate 
(Immulon 4, Dynatech Laboratories, Billinghurst, Sussex)
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was coated with the first antibody, a goat antiserum 
specific to the antigen to be quantified (1:6000 dilution 
in carbonate/bi-carbonate buffer). The eluate of the 
sample was then added and any antigen present was captured 
by the immobilised antibody. This was followed by 
incubation with the second specific antiserum, developed 
in rabbit (1:4000 dilution in incubation buffer). 
Finally, the horseradish peroxidase (HRP) conjugated anti­
rabbit IgG (goat) was added (1:4000 dilution in incubation 
buffer). Visualisation was achieved by incubation with 
the substrate and stopping the reaction with H2S04. The
plate was read at 490nm, and optical densities (ODs) 
obtained using the Dynatech Minireader II (Dynatech 
Laboratories, Alexandria, VA) . Plates included serial 
two-fold dilutions of purified antigen for the 
construction of a standard curve. Only the central wells
were used when running standards or samples (in
triplicate). The peripheral wells were used for assaying
the controls. All controls were run in duplicate except 
for the zero-antigen control which was run in 
quadruplicate. The working range of the standard for each 
of the above assays was determined prior to assaying and 
GCF sample eluates were diluted further in IB in order to
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achieve an optimal final dilution for each assay.
Purified a2-M was obtained from SIGMA (SIGMA Chemical 
Company Ltd., Poole, Dorset) whereas LF was purchased 
from Calbiochem (Novabiochem Ltd. , Nottingham) . Goat and
rabbit anti-a2-M were also obtained from SIGMA. Goat 
anti-LF as well as rabbit anti-LF were obtained from
Nordic Immunological Laboratories (Maidenhead, Berkshire). 
The horseradish peroxidase (HRP) conjugated anti-rabbit 
(goat) was purchased from ICN Immunobiologicals 
(Lisle, IL, USA) . Of the above antisera the rabbit
antiserum to a2-M and the HRP conjugate were fractionated.
Quantification of albumin
This was in section 2.1.1.
ELISA assays for total IgGl, IgG2, IgG3 and IgG4 
subclass levels in GCF.
These assays were broadly based on the sandwich 
ELISA system previously developed (85). However, these 
were substantially modified to increase sensitivity and 
thus detectability in GCF.
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Microtitre plates (Immulon 4, Dynatech 
Laboratories, Billingshurst, UK) were coated with 
monoclonal anti-human IgGl, IgG2, IgG3 or IgG4 (Sigma, 
Poole, Dorset, UK). These monoclonal antibodies have 
been shown to be completely specific for their 
respective subclasses (378). This was followed by 
incubation with a standard human serum, the IgGl-4 
subclass concentration of which had been determined by 
nephelometry (Department of Clinical Immunology, Western 
Infirmary, Glasgow). This allowed reference lines for 
IgGl-4 concentrations to be constructed.
The plate was then incubated with biotin-anti-human 
IgG (Sigma) followed by an incubation with Extravidin- 
peroxidase (Sigma - TM) thus achieving amplification of 
signal strength. Reaction was visualised with 
tetramethylbenzidine (TMB) substrate (KPL, Gaitersburg, 
Maryland, USA), stopped with 2.5% sodium fluoride and 
plates were read at 630nm with 490nm reference on a 
MR5000 Multiskan (Dynatech Laboratories). GCF levels 
were calculated by reference to linear regression 
analysis of the standard serum line.
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Statistical analysis
Protein levels were not normally-distributed. and 
therefore comparisons between the young and old groups 
was conducted using the Mann-Whitney test.
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2.1.3 Comparison of the local immune response in
osseointecrrated implants and natural teeth. 
Patients and sites
Twenty partially edentulous subjects (8 males, 12 
females; age range:42 to 86 years) at Bern Dental 
School, Switzerland who had no history of systemic 
conditions which could influence the course of 
periodontal disease and had not been on antibiotics for 
the previous two months, were selected to participate in 
this study. The participants had at least one 
osseointegrated implant, which had been in function for 
a minimum of six months (average: 9 months; range: 6 
months to 12 months). The sites had to conform to the 
following criteria:-
1. No bleeding on probing.
2. probing pocket depths < 4mm.
3. absence of visible plaque (PI = 0).
4. Clinical and radiographic signs of osseointegration 
at implant sites.
Processing of gingival crevicular fluid (GCF)
As in section 2.1.1.
GCF and PISF sampling
As in section 2.1.1.
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Anti-bacterial antibody ELISA
This was as in section 2.1.1.
Quantification of albumin
This was as in section 2.1.1.
Relative coefficient of excretion (RCE) calculation
Total IgG, IgM, IgA and albumin was assayed in GCF or 
PISF and serum from the same patient and the RCE value as 
used by Out et al (379) was calculated. The formula 
applied was as follows
Icr (GCF or PISF)
Ig (serum)
RCE = --------------------------
albumin (GCF or PISF) 
albumin (serum)
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Since albumin is only systemically derived, RCE values >1 
indicate a preponderance of locally produced 
immunoglobulin and thus this ratio gives a value directly 
proportional to the extent of local immunoglobulin 
production.
Statistical Analysis
Since values for titres and RCE ratios were non-normally 
distributed, the Wilcoxon signed rank test was used to 
determine whether or not the matched paired values were 
significantly different between natural teeth and 
implants. Multiple regression analysis was used for 
correlations.
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2.1.4 Checkerboard immunoblotting of gingival crevicular
fluid 
Clinical criteria
Between four and six sites were sampled in each of 43 
RPP patients. A range of pocket depths was sampled in 
each patient i.e. <4mm and ^4mm.
Collection of GCF
As in section 2.1.1.
Immunoblotting technique
This was based on the method of Kazemi and Finkelstein 
(370). The immunoslotting and immunoblotting equipment 
was purchased from Immunetics (Cambridge, MA, USA). 
Sonicated bacterial antigen was applied to 
nitrocellulose C-extra membranes (Amersham 
International, Little Chalfont, Bucks.) under vacuum in 
horizontal slots. The membranes were then blocked
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overnight in PBS containing 0.2% Tween 20 and 2.5% non­
fat dried milk (Marvel). GCF was diluted in the 
blocking buffer and blotted onto the membrane 
vertically. After washing with PBS-Tween, the vertical 
channels were further incubated with a monoclonal 
antibody to human IgG conjugated to alkaline phosphatase 
(Sigma). The development substrate was NBT/BCIP (see 
methodology in section 2.2.).
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2.2 In situ hybridisation studies on plasma cells
2.2.1 Study of k /A, expressing plasma cells
Seventeen gingival tissue samples were obtained during 
periodontal surgery under local anaesthesia following the 
initial hygiene phase treatment of these sites, from 8 
patients with adult periodontitis attending the 
Periodontology Unit, Glasgow Dental Hospital & School. In 
all cases pocket depth were >5 mm with radiographic 
evidence of bone loss. Tissues were immediately immersed 
in 10% neutral buffered formalin at room temperature. The 
tissues were blocked in a plane parallel to the long axis 
of the teeth and oriented so that pocket epithelium, oral 
epithelium and connective tissue were present in the same 
section. They were embedded in paraffin wax and 5 [xm 
sections were made onto silane (Sigma Chemical Co., St. 
Louis, MO) coated glass slides.
Immunoglobulin light chain mRNA-expressing cells were 
detected by in situ hybridisation as described in the 
protocol of DAKO k/A, mRNA ISH kit (Code No. K045) and ISH 
Detection Kit (Code No. K046) with minor modifications.
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The buffers used in the in situ hybridisation procedure 
were as detailed in section 2.2.2. All solutions were 
prepared with 0.1% diethyl pyrocarbonate (Sigma) treated 
distilled water. Briefly, three distinct areas of each 
biopsy were studied and consecutive serial sections from 
each area were deparaffinised in xylene, hydrated through 
descending ethanol, and washed in distilled water, then 
immersed in 0.2 M HC1 at room temperature for 20 minutes 
to remove basic proteins. Then the sections were digested 
with proteinase K (0-50 fig/ml, Sigma) in 0.1 M Tris-HCl, 
pH 8.0, containing 50 mM EDTA for 30 minutes at 37°C. 
After immersing in 0.2% glycine/distilled water for 30 
seconds, they were washed twice for 5 minutes in distilled 
water. Post-fixation was performed by incubation in 0.4% 
paraformaldehyde for 20 minutes at 4°C, and then washed 
twice for 5 minutes in distilled water. After drying with
ethanol, the sections were hybridised with 20|il volumes of 
the mixtures containing fluorescein isothiocyanate (FITC)-
conjugated k  or X oligonucleotide probes and hybridisation 
buffer (1:1) . They were then covered with
dimethyldichlorosilane-(BDH, UK)-coated coverslips, and 
incubated overnight at 37 °C in a humid chamber. The 
slides were rinsed in x2 standard sodium citrate for 5
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minutes, sequentially, in Tris-buffered saline (TBS; 0.05M 
Tris/HCl, 0.15M NaCl, pH 7.6)/0.1% Triton X (Sigma) for 10 
minutes, and then immersed in TBS. The slides were 
incubated with diluted (1:80) rabbit F(ab) anti- 
FITC/alkaline phosphatase conjugated secondary antibody 
for 30 minutes in room temperature. After immersing in 
TBS for 5 minutes, the slides were rinsed in detection 
buffer (1.21% Tris base, 0.58% NaCl, 1.0% MgCl2 pH 9.5 ) 
for 5 minutes and developed with enzyme substrates 
(Nitroblue tetrazolium and 5-bromo-4-chloro-3-
indolylphosphate) with levamisole for 30-45 minutes, and 
then washed in distilled water three times. Finally, the 
sections were counterstained with 1% Neutral Red and 
mounted in aqueous mounting medium (DAKO).
k  or A, positive cells were evaluated separately in 
serial sections. Five distinct microscopic fields which 
showed the strongest cell infiltration, from each serial 
section of all seventeen biopsies, were chosen for 
counting using a meshwork eyepiece (0.172 mm x 0.172 mm;
0.0296 mm2). The statistical significance between k  to X 
chain mRNA positive cells was analysed by Wilcoxon's 
matched-pairs signed-ranks test. The percentages of k  and
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X immunoglobulin light chain positive plasma cells and the 
k  to X ratio were also calculated. In addition, the mean 
percentage of patient plasma cells which were k  light chain 
positive and the patient standard deviation were also 
calculated.
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2.2.2 Study of IgGl-4 and IqAl-2 expressing plasma cells
including comparison with immunoglobulin levels in GCF 
Tissues
Twenty-four gingival tissue samples were obtained during 
periodontal surgery, after GCF sampling was performed, 
from 8 patients with adult periodontitis attending the 
Periodontology Unit, Glasgow Dental Hospital for 
periodontal therapy. The pocket depths of the sampled 
sites were greater than 5 mm with radiographic evidence of 
bone loss. The tissues were cut from buccal to lingual 
gingiva in a plane parallel to the long axis of the teeth 
and oriented so that pocket epithelium, oral epithelium 
and connective tissue were present in the same section. 
The tissue sections were transferred to 10% neutral 
buffered formalin at room temperature and subsequently
embedded in paraffin wax after which 5 |nm serial sections 
were made onto silane-coated glass slides.
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Preparation of oligonucleotide probes
Probes were normally supplied on columns by the 
Department of Veterinary Pathology, University of 
Glasgow. The probe was eluted from the column with 40 %
ammonia, incubated at 55°C overnight and then 
precipitated with 3M sodium acetate in 2% ethanol and
0.4% ammonia at -70°C for 3 0min. The solution was then 
centrifuged at 13,000 rpm for 10-15 min in a 
microcentrifuge and the supernatant removed. The pellet 
was washed with 1 ml 70 % ethanol followed by a further 
spin at 13,000 rpm for 5 min. The pellet was then air- 
dried and resuspended in TE buffer, and quantified by 
spectrophotometry (260 nm). The probe was then stored
at - 20°C until required.
Probe labelling
This essentially used the Boehringer kit method (cat. 
no. 1093088) with some reagents being obtained 
elsewhere. The first stage was the tailing reaction in
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which digoxigenin was attached to the probe, and the 
following mixture was used:-
5x stock tailing buffer (Gibco) 4 |J,1
Dig-11 dUTP (1 nmol /ml) or Bio-16dUTP 2 |nl
Probe (oligonucleotide adjusted to l-2mg/ml) 2 \il
TdT enzyme (15 U/ml) 2 \il
DEPC/dH20
This was then mixed and centrifuged briefly in a 
microcentrifuge (13 000 RPM), then incubated overnight 
at 3 7°C.
The second stage involved isolation of the probe by
separation on a Sephadex G25 N A P ™  - 5 column. The 
running buffer was xO.1 SSC + 0.1% SDS in DEPC/dist.H2O . 
10 xlml fractions were collected and the fractions 
containing labelled probe were identified by
dotblotting. 1h1 samples were dotblotted onto a 
nitrocellulose filter and baked in a UV-cross linker at 
1200W for 30s. Immunological detection was achieved as 
described below using digoxigenin-3'-labelled control 
oligonucleotide as a standard conrtol.
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Oligoprobes employed
Synthetic digoxigenin-labelled oligonucleotide anti-sense 
human IgGl, IgG2, IgG3 and IgG4 oligonucleotide probes 
were constructed (GCA CGG TGG GCA TGT GTG AGT TTT GTC ACA 
AGA TTT GGG CTC; TGG GCA CGG TGG GCA CTC GAC ACA ACA TTT 
GCG CTC AAC TGT; A AGA TTT GGG CTC TGG GCA CCG TGG GCA TGT 
GTG AGT TGT; AA CTC AGG TGC TGG GCA TGA TGG GGG ACC ATA, 
respectively) as were synthetic digoxigenin-labelled 
oligonucleotide anti-sense human IgAl and IgA2 gene (CC 
GGA TTT TGA GAG GGT GGC GGT TAG CGG GGT CTT GGA CTC GGG
GTA GGC; CC GGA TTT TGT GAT GTT GGC GGT TAG TGG GGT CTT
CAA CTC GGG GTG GGC) (380-384) . The absence of cross-
hybridization of the two probes was confirmed by Islam et
al (380). For double staining an ABC-alkaline phosphatase 
kit (Vector AK-5002) was employed to label the IgA 
probe with biotin. Subsequent reaction with avidin- 
peroxidase and a phenylenediamine peroxidase substrate 
produced a brown product. This contrasted with the 
earlier blue NBT/BCIP product produced by the alkaline- 
phosphatase antibody to digoxigenin-labelled IgG probe.
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Thus, this technique allowed sequential detection of 
different immunoglobulin mRNA in the same section. The 
anti-sense probe sequences for IgA and IgG were GTC ACA 
TCC TGG CTG GGA TTC GTG TAG TGC TTC ACG TGG CAT GTC ACG 
GAC (381) and GGC TGC CTG GTC AAG GAC TAC TTC CCC GAA 
CCG GTG ACG GTG TCG TGG AAC TCA (384) respectively.
In situ hybridization
The sections were depariffinised in descending alcohols 
then washed twice in PBS for 5 min. Proteinase K (5(ig/ml, 
Sigma) digestion was then carried out in 0. 1M Tris-HCl, pH 
8.0 containing 50mM EDTA for 30 min at 37°C. After 
immersion in 0.2% glycine distilled water for 30s, they 
were washed twice for 5 min in PBS. At this stage, pre­
treatment with RNAse A type 1A (Sigma) at 200|ig/ml in 2x
SSc/lOmM MgCl2 at 37°C for lh was used as negative control. 
Post fixation was by incubation in 4% paraformaldehyde at
4°C for 5 min, followed by two washes in PBS for 5min. The 
sections were then immersed in prehybridisation buffer (2x
standard SSC and 50% formamide) for 2h at 37°C.
After draining, the sections were hybridized with 20 
|nl volumes of the mixtures containing digoxigenin-labelled
probes at a concentration of 0.16 - 0.65 ng/nl in the
hybridization buffer. The slides were covered with
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dimethyldichlorosilane-(BDH, UK)-coated coverslips that 
were sealed with rubber cement, and incubated at 37°C 
overnight. The slides were rinsed in x4 SSC,
sequentially, in x2 SSC at room temperature twice for 20 
min, xO.l SSC at 37°C twice for 20 min, then washed in x2 
SSC for 10 min at room temperature.
Immunological detection
The sections were placed for 3 h in a PBSTM containing 
alkaline phosphatase (AP)-conjugated sheep anti- 
digoxigenin (1: 500; Boehringer Mannheim) at room
temperature. After thorough rinsing in a PBST buffer and 
5 min pre-incubation in an alkaline buffer solution, the 
AP complex was revealed with a freshly prepared solution 
of nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3- 
indolylphosphate (Sigma) containing levamisole (Sigma) in 
an alkaline buffer solution for 8 h to overnight in a dark 
room at room temperature, and then washed in distilled 
water 3 times. Finally, the slides were counterstained 
with 1% neutral red, washed in distilled water 3 times 
and mounted in aqueous mounting medium (Dako) . The dark 
blue/black precipitate, an indication of the presence of 
IgG and IgA subclass mRNA, was revealed with bright-field 
microscopy.
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Buffers employed
1. DEPC (Diethyl pyrocarbonate)/PBS or double dist. 
H2O:-
1 ml DEPC was added per 1 litre of PBS (or dH20) then 
mixed well and allowed to stand overnight before 
autoclaving.
2. Proteinase K (PK) solution:-
The stock solution was 500 mg/ml in DEPC/dH20 and was
stored in 100 yil aliquots at -20°C.
3. PK dilution buffer:-
0.1 M Tris/HCl, pH 8.0 with 0.05 M EDTA) filter 
sterilised with a 0.45 ym filter.
4. TE buffer:-
0.01M Tris/HCl, pH 7.5 with 0.01M EDTA filter sterilised 
with a 0.45 ym filter.
5. Standard sodium citrate (SSC):-
Sodium chloride 0.15 M, Sodium citrate 0.015 M prepared 
in DEPC/ dH20 as x20 stock solution and used at x4, x2, 
xl and xO.1 concentrations.
6. Detection buffer 1:-
0.25M Tris Hcl, 0.3M NaCl, pH 7.5.
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7. Detection buffer 3:-
0.1M Tris/HCl, 0.1M NaCl, 0.05 M MgCl2, pH9.0.
8. Nitro-blue tetrazolium/bromochloro-indolylphosphate 
(NTB/BCIP):-
Stock NBT soln: 75 mg/ml NBT in 70 % dimethylformamide. 
Stock BCIP soln: 50 mg/ml BCIP in 100 %
dimethylformamide.
Both solutions were light sensitive and were stored in
foil-wrapped glassware at 4°C.
9. Hybridisation buffer:-
This was 50% formamide, 10% dextran Sulphate, 0.5% SDS, 
0.3% Triton, in 0.01M Tris, xl2.5 Denhardts, x2 SSC, 
made up to final volume and concentration in DEPC/dH20.
10. Denhardts xlOO stock solution:-
20mg/ml BSA, 20mg/ml Ficoll, 20mg/ml in DEPC/dH20.
The specific functions of reagents
The more important specific functions of reagents are 
summarised below:-
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BSA Sc salmon sperm DNA is used to block non-specific 
binding of the probes.
DEPC Inhibits the effect of RNAses. This is an 
important aspect of inhibition of endogenous and 
exogenous RNAses allied with precautions such as 
autoclaved glassware, dust-free storage and wearing of 
gloves.
Formamide destroys hydrogen bonding, making it easier 
for probes to anneal with mRNA in tissue sections at low 
temperatures.
Proteinase K is an enzyme used to digest the tissue in 
order to allow optimum access of oligoprobe. The 
optimisation of protienase K concentration used for 
digestion is the most crucial determinant of the quality 
of staining.
Glycine is a proteinase K inhibitor used to inhibit 
further digestion.
Levamisole is an endogenous alkaline phosphatase (AP) 
inhibitor used to ensure that only exogenous antibody- 
bound AP is detected.
Paraformaldehyde is employed in post-fixation of the 
tissue.
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Prehybridisation buffer is used as a blocking agent 
before the hybridisation step.
Silane acts as a "glue" allowing sections to adhere more 
efficiently to glass slides.
SSC is used in the stringency washing of sections i.e. 
they are subjected to decreasing sodium concentration 
and increasing temperature to detach non-specific 
binding of probes.
Controls for in situ hybridization
As a negative control, sections were incubated with 
hybridization buffer only or sense probes. To determine 
the specificity of probe bound to tissues RNAs, sections 
were digested with RNAse prior to hybridization. Other 
specificity controls were carried out by hybridizing with 
the labelled probe together with the unlabelled probe 
simultaneously. The concentration of the former was as 
above, but the latter was in 10-fold excess. For example, 
labelled IgAl probe with 10-fold non-labelled IgA2 were 
used to check the specificity of the IgAl probe and vice 
versa. In addition, double-target in situ hybridization 
methodology has been developed in this laboratory using
digoxigenin- and biotin-labelled IgG and IgA subclasses 
probes and it has been confirmed here that there were no 
cross reactions between the probes (manuscript submitted).
Cell counts
As previously described, twenty-four gingival biopsy 
samples were obtained from 8 patients. Briefly, five 
distinct microscopic fields which showed the strongest 
cell infiltration, from each serial section of all 
seventeen biopsies, were chosen for counting using a 
meshwork eyepiece (0.172 mm x 0.172 mm; 0.0296 mm2). IgG 
and IgA subclass specific mRNA-expressing cells were 
enumerated in each serial section. The percentage of each 
IgG and IgA subclass as compared to the total IgG or IgA 
positive cells were also calculated (e.g. (IgGl/(IgGl + 
IgG2 + IgG3 + IgG4) ) x 100 %) . The percentage of IgAl 
subclass positive cells were also calculated (IgAl/(IgAl + 
IgA2)) x 100 %.
Gingival crevicular fluid sampling
As in section 2.1.1.
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Determination of IgG subclass proteins in GCF
As in section 2.1.2.
Determination of IgA subclass protein and IgAl fragment 
levels in GCF
In the IgAl assay, microtitre plates (Immulon 4, 
Dynatech Laboratories) were coated with anti-human IgA 
(Scottish Antibody Production Unit, Carluke, UK) . This 
was followed by incubation with a standard human serum the 
IgA concentration of which had been determined by 
nephelometry (Department of Clinical Immunology, Western 
Infirmary, Glasgow). By jacalin absorption the relative 
concentrations of IgAl and IgA2 in this serum were 
determined (385). This allowed a reference line for IgAl 
concentration to be constructed. The plate was then 
incubated with monoclonal biotinylated anti-human IgAl 
(Sigma, Poole, Dorset, UK) followed by an incubation with 
Extravidin-peroxidase (Sigma - TM) thus achieving 
amplification of signal strength. Reaction was visualized 
with tetramethylbenzidine (TMB) substrate (KPL, 
Gaitersburg, Maryland, USA), stopped with 2.5% sodium 
fluoride and plates were read at 630 nm with 490 nm
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reference on a MR5000 Multiscan (Dynatech Laboratories) . 
GCF levels were calculated by reference to linear 
regression analysis of the standard serum line. The IgA2 
assay was similar except for the coating and second 
antibodies employed. Plates were coated with monoclonal 
anti-human IgA2 (Boehringer Mannheim) . The second
antibody was biot in-anti -human IgA (Sigma) . The
methodology of the IgAl Fab fragment assay was based on 
that of Frandsen et al. (146). Briefly, plates were 
coated with a monoclonal antibody to the IgAl neo-epitope 
(kindly provided by Dr EVG Frandsen), followed by 
incubation with GCF and development with biotin-anti-human 
IgAl monoclonal antibody (Sigma).
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Statistical analysis
Wilcoxon's matched-pairs signed-ranks test was used to 
determine differences between subclass ratios of IgG and 
IgA mRNA-expressing cells and these proteins, and between 
the amount of IgAl Fab fragments and that of intact IgAl.
The correlation between the data of the amount of intact 
IgG and IgA subclass protein and the numbers of these 
subclass specific mRNA-expressing cells per section was 
estimated by Spearman's rank correlation coefficient.
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2.3 Studies of systemic antibody avidity
2.3.1 Preliminary longitudinal study in patients with 
refractory periodontitis
Patient selection and treatment regimen
Ten adult Caucasian patients (three males, seven female 
mean age 42±8 yr, range 34-57 yr) were recruited from a 
recall pool of 600 in a specialist periodontal practice 
in Northern Iceland. Eight patients were regular 
smokers. All gave informed consent to participate in the 
study and had no systemic disorders. They had not 
received antibiotics in the six months prior the 
baseline investigation. All patients had 20 or more 
teeth and .had lost more than 50 percent of supporting 
alveolar bone around at least two teeth in each 
quadrant. In addition, all patients had successfully 
completed periodontal treatment, including surgery, at 
least two years before being enrolled in the study and 
had received supportive hygiene therapy three times a 
year thereafter until the study commenced. Sites for
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inclusion in this study were selected in groups of 
three: (a) one treated by open debridement; (b) one by
root planing; and (c) the third scaled supragingivally, 
which served as a control. The selection of sites and 
protocol for the surgical and non-surgical treatment 
phase of the study has been reported elsewhere (386) .
Antibiotic regimen
Between weeks 53 and 55, all patients had were treated 
with amoxycillin and metronidazole both at doses of 250 
mg three times daily for 10 days.
Control subjects
Ten control subjects recruited from staff of the Dental 
Faculty in the University of Iceland were matched for 
age and sex with the patients. It also proved possible 
to match three controls with patients according to 
smoking pattern and a further two controls smoked 
occasionally. The two patients that did not smoke were 
matched with non-smoking controls. All gave their 
informed consent to the investigation. Samples of
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subgingival plaque were removed from four quadrants 
using paper points and sent to the laboratory for
culture. Control subjects were selected on the basis 
that they did not carry A.actinomycetemcomotans or P. 
gingivalis in these samples. One serum sample was then 
collected from each control and stored frozen as
described for the serum samples from patients.
Microbiological investigation
Microbiological sampling of the gingival pockets under 
investigation was performed at baseline (week 0) ; two 
weeks after periodontal therapy (week 4) and then at 
weeks 6, 26 and 52. The patients received antibiotics
for two weeks (weeks 53-55) and microbiological sampling 
was repeated at week 75. Subgingival paper point 
samples were collected from all lesions after the
removal of supragingival plaque with sterile curettes 
and cotton-wool pellets. Three paper points were placed 
into each pocket, removed after 10 seconds and placed 
immediately into 1 ml of VMG II transport medium (387) . 
Air in the headspace of the sample container was 
displaced with a burst of CO2 and the specimen sent to
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the laboratory for analysis. After vortexing the 
sample, 100jLtl aliquots were inoculated on to tryptic-soy 
agar containing bacitracin and vancomycin (TSBV) (388) 
and fastidious anaerobe agar (Lab M, Bury, Lancs, U.K.
) supplemented with 10 percent horse blood. TSBV plates 
were incubated in candle jars and examined after two and 
seven days for the presence of A a which was identified 
on the basis of colony morphology on this selective 
medium and a positive catalase reaction. Blood-agar 
plates were incubated anaerobically for 14 days using 
the Gas Pak system (Oxoid, Basingstoke, U.K.). Colonies 
resembling Pg in appearance were further identified by 
ultraviolet light fluorescence (389), MUG test (390) and 
haemagglutination (391).
Immunological investigations
Serum was collected from all subjects at baseline and 
again at week 75. All serum was stored frozen at -80°C 
until analysis could be carried out simultaneously on 
both test and control samples. Antibody titres and 
antibody avidities were determined in the Dental School
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of the University of Glasgow and the specimens were 
transferred frozen between laboratories.
Determination of antibody titre
As in section 2.1.1.
Dissociation Assay
The dissociation assay to determine antibody avidity was 
performed as follows:- After incubation with serum as 
described above, the wells were treated with increasing 
concentrations of ammonium thiocyanate (0.2-8.0M). The 
concentration of thiocyanate required to dissociate 50% of 
bound antibody was determined by linear regression 
analysis. This was termed the ID50 and provides a measure 
of relative avidity as previously reported (392,393) .
Statistical analysis
Wilcoxon's Signed Rank Test was employed for the non- 
parametric testing of paired data (394) (Minitab). The 
median differences in titres and in avidities of serum
antibodies IgG, IgM and IgA to Pg and Aa were 
computed: (i) for the patients' sera at baseline and
after the course of periodontal and antibiotic therapy;
(ii) for the pre-treatment patients sera group and 
controls; and (iii) for the post-treatment patients' 
sera and controls. In all statistical tests a 
probability of p<0.05 was considered statistically 
significant. Despite the high variability of the data 
observed in patients and in controls, statistics were 
computed with all the data due to the small number of 
subj ects.
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2.3.2 Study of immunological effects in the course of
periodontal treatment 
Patients
Seventeen subjects (9 males, 8 females, age range: 33-53) 
suffering from advanced periodontal disease (probing 
depths of >5.5mm in at least one site per sextant and at 
least 2 non-adjacent sites per quadrant with probing depth 
of >4mm) were recruited for this investigation. These 
subjects had no history of systemic conditions which could 
influence the course of periodontal disease and had not 
received antibiotics during the previous three months.
Two non-adjacent sites per quadrant with probing 
depth >4mm were selected in each subject and followed 
during the course of this study. Non-adjacent sites were 
used so as to reduce the possibility of contamination and 
ensure independence of the GCF and plaque samples. At the 
baseline appointment, probing depths (PD) and bleeding on 
probing (BOP) at these sites were assessed using the 
Florida Probe (395) and blood samples were taken. Blood 
was allowed to clot, centrifuged at 750g for 15 minutes,
and the sera separated, aliquoted and stored at -30°C.
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Patients were treated by an experienced periodontist (EA) 
with oral hygiene instruction and quadrant scaling and 
root planing under local anaesthesia (HPT).
Subjects were reassessed using conventional probing 
charts between six and seven weeks after HPT (post-HPT), a 
blood sample was taken and PD and BOP measurements 
recorded at the eight preselected sites using the Florida 
Probe. The duration of HPT ranged between 6 weeks and 7 
months, with a mean of 5.5 months. All of the patients 
were reassessed after three months (± 2 weeks), which was 
the first of their maintenance visits. A blood sample was 
also taken during this appointment. Only the eight study 
sites were used to assess the response to treatment in
terms of % sites that have a PD>3.5mm and BOP. It should 
be noted, however, that the initial assessment of
periodontal disease status was made on the basis of a
larger number of sites.
Control subjects
These were twenty-three periodontally healthy individuals 
(age range 20-40; 12 males, 11 females) . The
immunological data from these individuals was used to 
define the serostatus of the patients as described by Chen
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et al (273), seropositive patients are those with titres > 
2X control median.
Bacteria
P. gingival is NCTC 11834 was grown under anaerobic 
conditions (85% N2, 10% H2/ 5% C02) and A.
actinomycetemcomitans ATCC 29523 (serotype a) in C02 at 37C 
on Columbia blood agar. This medium was routinely 
supplemented in our laboratory with Vitamin K and haemin 
for the growth of black-pigmenting Gram-negative 
anaerobes. Otherwise fastidious anaerobe agar should be 
used. P. gingivalis was harvested after 5 days and A. 
actinomycetemcomitans after 24 hours into phosphate- 
buffered saline, ImM Na2 EDTA, pH 7.4 (PBSE) , washed by 
centrifugation, and fixed for 1 hour in 10% formal saline.
The cells were then washed twice in PBSE and once in 0.1M 
Na carbonate-bicarbonate buffer containing 0.02% NaN3 at 
pH 9.6 (coating buffer). Fixed cells were stored in
coating buffer at 4°C until use.
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Collection of subgingival plague samples
Subgingival plaque samples were taken with a single 
stroke using a separate sterile curette for each sample to 
prevent cross-contamination and collected in tubes 
containing 0.5 ml of Fastidious Anaerobe Broth (FAB; Lab 
M, Bury, England). Samples were immediately transported to 
the laboratory where they were vortex mixed for 30
seconds. Broths were then stored at -70°C until PCR 
analysis was performed.
Polymerase chain reaction
For PCR analysis, 90pl of vortex mixed subgingival 
plaque was added to 10pl of lOx lysis buffer (lOOmM Tris 
HC1 pH 8.0, lOmM ethyl enediamine tetraacetic acid, 10% 
Triton X-100) and boiled for 5 min. lOpl of this lysate 
was used in each PCR reaction. The primers used for PCR 
identification of A.actinomycetemcomitans targeted the 
leukotoxin A gene as previously described (396): LKT2
(5' -GGAATTCCTAGGTATTGCGAAACAATTTGATC- 3' ) and LKT3 (5' - 
GGAATTCCTGAAATTAAGCTGGTAATC-3'), which give an expected 
amplification product of 262 base pairs. For 
identification of P.gingivalis, the primers used targeted
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the fimbrillin gene as previously described (397) : FIM1
(5 7 -ATAATGGAGAACAGCAGGAA- 3 7 ) and FIM2 (5 7 -
TCTTGCCAACCAGTTCCATTGC-37), which gave an expected 
amplification product of 131 base pairs. PCR amplification 
using primers LKT2/LKT3 was carried out in reaction volume
of 100 \xl consisting of 10 (il sample lysate and 90 \.il of 
reaction mixture containing 1 x PCR buffer (10 mM Tris-HCl 
[pH 8.8], 2.5 mM MgCl2/ 50 mM KC1, 0.1% Triton X-100), 2.5 
units of DynaZyme DNA polymerase (Flowgen) , 0.2 mM dNTPs
(dATP, dCTP, dGTP, dTTP) amd 50 pmol of each primer. When 
the primer pair FIM1/FIM2 was used, PCR reaction 
conditions were as above except that the reaction mixture 
contained 1.5 mM MgCl2. Primers were separated from the 
other components of the reaction mixture by a layer of wax 
('hot start7 PCR), preventing the reaction from starting 
until the wax melted upon commencement of PCR cycling and 
thus improving the specificity and yield of reaction 
products. PCR cycling was carried out in a Hybaid OmniGene
thermal cycler. After an initial denaturation step of 95°C
for 5 min, 33 amplification cycles of denaturation at 95°C
for 1 min, annealing of primers at 55°C for 1 min and
primer extension at 72°C for 1 min were carried out,
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followed by a final primer extension step at 72°C for 10
min. Reaction products were stored at -20°C or analysed
immediately by gel electrophoresis. 20 |il of each reaction 
product was fractionated on a 2% agarose gel containing
ethidium bromide (0.5 |ig/ml) and visualised on a UV 
transilluminator.
In order to avoid contamination, strict procedures 
were employed when carrying out PCR. Separate rooms were 
used for sample preparation, setting up of PCR reactions 
and analysis of PCR reaction products. Filter tips were 
used at all stages of the process, except when adding the 
sample to the reaction mixture when a positive 
displacement pipette was used. Negative and positive PCR 
controls were included with each batch of samples being 
analysed by PCR. The negative control was a standard PCR
mixture with the sample being replaced by 10 |il of sterile 
water; the positive control used was a standard PCR 
reaction mixture containing 100 ng of genomic DNA from A. 
act inomycetemcomi tans or P. gingivalis instead of the 
sample.
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ELISA
T h i s  w a s  a s  i n  s e c t i o n  2 . 1 . 1 .
Dissociation Assay
This was in section 2.3.1.
Statistical Analysis
Mean values are given for antibody avidities throughout; 
whereas median values are given for titres because these 
were not normally distributed.
Student's paired t-tests were used to assess whether 
differences in antibody avidity were significant between 
baseline, post-HPT and the first maintenance visit. 
Because antibody titres were not normally distributed, the 
non-parametric Wilcoxon signed rank test was used to 
perform the parallel assessments. When seropositive and 
seronegative sub-groups were directly compared in terms of 
treatment outcome, two-sample t-tests were employed.
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2.3.3 Avidity of antibody to ARG-1 protease of P.
crincrivalis related to treatment effects
The patient group was as in section 2.1.4. Avidity 
analysis was as in section 2.3.2. Recombinant ARG-1 
protease was kindly provided by Aduse-Opoku et al (316).
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2.4 Studies of immunological changes during pregnancy
2.4.1 Immunoglobulin G subclasses during normal 
pregnancy and recurrent abortion
Subjects
Five groups were studied.
Group 1 comprised 10 healthy non pregnant women of mean 
age 25±3.5 years.
Group 2 comprised 8 healthy primigravidae (mean age 
23.0±5.1 years) who were sampled in the first, second 
and third trimesters of an on going pregnancy and at 6 
weeks post partum.
Group 3 comprised 7 pregnant women of mean age 26.8±3.6 
years with a previous history of recurrent miscarriage 
(RM) (3 or more consecutive miscarriages), but whose 
pregnancy on this occasion continued to term. The women 
were sampled in the first, second and third trimesters 
and at 6 weeks post partum.
Group 4 comprised 10 first trimester pregnant women(mean 
age 25.9±2.3 years) with a previous history of RM and
1 9 2
whose pregnancy on this occasion again ended in 
miscarriage later in the first trimester. At the time of 
sampling outcome was not known.
Group 5 comprised 7 first trimester pregnant women (mean 
age 24.6±2.9 years) admitted suffering spontaneous 
abortion(SA).
Blood samples were obtained and stored at -20°C till 
required.
Measurement of IgG subclasses
This was as in section 2.1.2.
Statistical analysis
Data are presented as mean ± standard deviation. 
Statistical analysis of results was performed with a 
Mann Whitney test. P < 0.05 was considered significant.
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2.4.2 Thyroid peroxidase (TPO) auto-antibodv as a
pregnancy outcome marker 
Patient group
Group 1 comprised 8 RMc subjects i.e. women who were 
recurrent aborters but on this occasion continued to 
term. Group 2 comprised 7 RMa subjects i.e. women who 
were recurrent aborters and on this occasion aborted 
again.
Method of assessing TPO auto-antibody
This was according to the ELISA kit method of RSR Ltd., 
Cardiff.
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2.5 Use of PCR analysis to detect bacterial fragments in
host bloodstream
The patient group and the method of PCR analysis was in 
section 2.3.2. A pan-specific bacterial probe was used 
in this study to determine if bacteria enter the 
bloodstream at all.
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Chapter 3
Results
3. Results
3.1 Local antibody studies
3.1.1 Study of local antibody levels at sites with 
differing clinical status
The clinical parameters from the three categories of site 
(healthy, gingivitis and periodontitis) are shown in Table 
1. These data show that periodontitis sites had lower 
levels of inflammation, deeper pockets and greater yields 
of GCF than gingivitis sites. Therefore, if levels of GCF 
antibody were simply related to volume collected, then 
higher median levels would be expected in periodontitis 
sites than in gingivitis sites. Table 2 shows the titres 
found in each disease category as EU/30s sample and EU/30s 
sample per unit albumin expressed as mg/ml. The p-values 
for the Wilcoxon signed rank tests which were used to 
perform paired comparisons between different site types 
are given in Tables 3 and 4. Figure 1 shows a typical 
ELISA assay once developed.
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3.1.2 Effects of ageing on local humoral immunity and 
inflammatory responses
The median concentrations of IgGl-4 for young and old
individuals are given in Table 5. These show tendencies 
towards IgGl and IgG4 concentrations being higher in GCF 
in young subjects and IgG3 being lower than in old
subjects. All of these differences were bordering on 
statistical significance at p<0.05. Table 6 displays 
these levels expressed as a ratio to albumin, thus 
giving a measure of local synthesis. Higher ratios 
indicate higher levels of local input. Thus there 
appears to be more local production of IgG3 and less of 
IgGl in old than in young subjects. The levels of the 
other proteins are given in Table 7, suggesting that
lactoferrin concentrations are lower in GCF in old 
individuals than in young individuals. Therefore, PMN
Infiltration may be reduced in older subjects. The
time-progression points for all of the proteins measured 
during the course of experimental gingivitis are shown 
in Table 8. Generally, these show differences in 
response between young and old individuals in that peaks
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8
in IgG levels tend to occur after seven days for young 
subjects, but later and/or to a reduced extent, 
especially in relation to the median level, for old 
subjects. LF levels also tend to increase more slowly 
and to a lesser extent in old than in young subjects. 
The more marked of these differences are illustrated in 
Figures 2-4 with statistically significant differences 
denoted by asterisks (*) (p<0.05, Mann-Whitney test).
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Figure 2: lgG2 levels
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Figure 3: lgG4 levels
lgG4 (ug/ml)
1400
1200
1000
young
old
Figure 4: LF levels
LF (ug/ml)
500 -------------------------------------------------------
400
300
200
100
10 20 
day
- s -  young 
- ■  - old
30
3.1.3 Matched comparison of humoral immune response at 
tooth and implant sites
At the outset a paired comparison between GCF and PISF 
volumes was carried out using the paired t-test assuming 
the null-hypothesis, i.e. that there is no difference 
between these volumes. This established that there was no
significant difference between GCF (0.46|il (0.28-0.66))
and PISF (0.52fil (0.36-0.60)) volumes and that, therefore,
any observed differences between GCF and PISF are not
attributable simply to differences in volume. The
comparison between matched teeth and implants in terms of 
IgG, IgM and IgA antibody titre to P. gingival is and A. 
actinomycetemcomi tans are shown in Tables 9 and 10. The 
antibody titres were non-normally distributed, therefore 
a Wilcoxon signed rank test was used to determine whether 
the matched pair values for teeth and implants were
significantly different. There is a tendency towards 
titres being lower in implant sites than in tooth sites
(p-value ranging from 0.08 to 0.14), although this failed 
to be statistically significant at p<0.05.
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Using the same analyses, Tables 11 and 12 demonstrate 
that, although RCE ratios are in all cases higher at 
implant sites than at matched natural tooth sites, 
suggesting greater local production of specific 
immunoglobulin, the paired comparisons do not yield 
statistically significant differences. Levels of local 
production of antibody to A. actinomycetemcomitans seem to 
be much higher than to P. gingivalis, perhaps reflecting 
the relative importance of A. actinomycetemcomitans as an 
opportunistic pathogen in the early stages of disease.
Table 13 shows the correlations between RCE ratios 
for different immunoglobulin class responses to P. 
gingivalis and A. actinomycetemcomitans for natural 
teeth, and Table 14 provides the same information for 
implants. An interesting finding here is that, although 
there are strong correlations between class responses in 
tooth sites, these are not found in implant sites.
Analyses were performed to examine for correlations 
between RCE ratios of the same immunoglobulin class to P. 
gingivalis and A. actinomycetemcomitans between matched 
teeth and implants (Table 15) . IgG and IgM class 
responses do not correlate between teeth and matched
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implants, but there are statistically significant 
correlations between IgA responses.
Overall, these results show that specific antibody 
titres tend to be lower in implants than in matched 
natural teeth. This trend fails to achieve statistical 
significance, but does suggest that a larger follow-up 
study would be worthwhile. The data presented in tables 
13-15 are indicative of differences in the correlations 
between rates of local production of specific 
immunoglobulins between matched teeth and implants, 
suggesting possible differences in the nature and 
proportions of the plasma cell infiltrate between implants 
and natural teeth. This finding is also deserving of 
further study.
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3.1.4 Checkerboard immunoblotting of GCF
This technique was demonstrated here to have the 
potential to screen a large number of GCF samples 
against a large number of bacterial antigens. 56 GCF x 
10 antigens were possible simultaneously. An example is 
shown in Figure 5. However, some purified antigens e.g. 
the ARG-1 protease did not coat onto the membrane even 
at relatively high concentration. Moreover, the data 
produced were qualitative making it difficult to 
correlate levels in different sites. In general, 
however, antibody levels to P. gingivalis seemed to be 
lower in deeper pockets than in shallower pockets within 
the same patient; bearing out the findings of section 
3.1.1.
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3.2 In situ hybridisation studies in plasma cells
3.2.1 Study of k/X-producing plasma cells
The connective tissue subjacent to the pocket epithelium 
and central zone of the lamina propria revealed a dense 
and diffuse infiltration of lymphocytes and dilated 
capillaries. All specimens exhibited clustering of plasma 
cells mainly in the perivascular areas deep within the 
central zone of the lamina propria and subjacent to the 
epithelium. Plasma cells and small lymphocytes
(presumably B cells) showed weak to strong cytoplasmic 
staining with either k  or X probes (Figure 6 and 7). The 
specificity of the hybridisation signals were confirmed by 
the control sections which were incubated with a
hybridisation solution lacking probe and showed a complete 
absence of signal in plasma cells (Figure 8) . In
addition, results of the hybridisation staining procedure 
following pre-treatment with RNAse were negative,
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confirming that the method specifically indicates the 
presence of RNA.
k  chain positive plasma cells were the most 
predominant in all of the sections, and this difference 
was statistically significant (p < 0.01). Mean
percentages calculated from these data were 67.5 ± 9.5 % k
(53 - 82.8 %) and 32.5 % X (17.2 - 47 %) producing cells.
The ratio of k  to X chain positive cells ranged from 1.1
to 4.8 (mean = 2.4 ± 1.1 SD) . Table 16 indicates the
number of biopsies per patient and shows both mean site
and subject percentages of k  light chain positive plasma 
cells. Considering the subject as the analytical unit, 
the mean percentage of patient plasma cells with the k 
light chain is 70.4% (SD ±7.0%), and the range between 
patients is 60-79%.
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16. 
Patient 
details, 
site 
pocket 
depths 
and 
percentages 
of 
plasma 
cells 
which 
were 
positive 
for 
k 
light 
chains. 
Means 
and 
Standard 
Deviations 
(SD) 
are 
given 
for 
each 
subject.
3.2.2 Study of local production of IgG and IgA
Preliminary experiments verified the specificity of the 
IgG and IgA subclass-specific probes. In all gingival 
biopsy tissues, cytoplasmic staining was observed in 
plasma cells for IgG and IgA subclass probes in serial 
sections. The majority of immunoglobulin positive cells 
were observed in the lamina propria and some cells were 
identified subjacent to the epithelium. Specificity of 
the hybridization signals was confirmed by the control 
results. The negative control sections incubated with a 
hybridization solution without probe or sense probe, 
showed a complete absence of signal in plasma cells and 
lymphocytes, in all cases. Further results of the 
hybridization staining procedure following treatment with 
RNAse were negative, confirming that the method 
specifically indicates the presence of RNA (data not 
shown). In addition, the hybridization of the labelled 
probes was greatly reduced or abolished when the 
concentration of unlabelled probe against the same 
subclass was five- or ten-fold in excess. In contrast,
2 0 5
the hybridization of the labelled probes was unaffected 
when the concentration of unlabelled probe against the 
other subclass was five- or ten-fold in excess.
The major IgG subclass mRNA expressing cells was IgGl 
(mean 63%) followed by IgG2 (23%) of total IgG plasma 
cells and IgG3 and IgG4 were present to a much lesser 
extent (3% and 10% respectively). Similar proportions of 
IgG subclass proteins were detected in GCF as determined 
by ELISA (Table 17) . The relative proportions of IgG3 and 
IgG4 varied somewhat between GCF and biopsy plasma cells 
but these differences were not statistically significant.
Serum levels of IgG subclasses were not measured in this 
study.
IgAl mRNA-expressing cells were predominant (65.1%) 
than IgA2 mRNA-expressing cells and this difference was 
statistically significant (p < 0.0001) but evenly
distributed IgA2 mRNA-expressing cells (i.e. %IgA2 between 
45 and 50%) could be also seen in 5/24 cases. IgAl/IgA2 
ratio varied widely (median 1.67, range 1.03 - 10).
Gingival tissue sections used in this study gave the 
strongest hybridization signals with a proteinase K 
concentration of 30-50 mg/ml and showed good morphological 
detail at this concentration, while the proteinase K
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digestion at less than 10 mg/ml gave very weak or no 
signal. Counterstaining with 1% neutral red gave better 
contrast than haematoxylin (blue color) with the ISH 
staining, as the precipitation colour of NBT with BCIP is 
blue black.
IgAl (1024 ± 2558 mg/ml) and IgA2 (6536 ± 11105
mg/ml) proteins were detected in all GCF samples 
(IgAl<IgA2, p=0.009). The proportion of IgA subclass 
proteins in GCF samples is shown in Table 17 (IgAl = 21%; 
IgA2 = 79%) . IgAl Fab fragments (1989 ± 2781 mg/ml) were 
higher than intact IgAl but this was not statistically 
significantly (p = 0.09). However, when correction was
made for the molar ratio of Fab: intact IgA of 
approximately 3.3:1, then this became significant at 
p<0.05. There was no significant correlation in the 
amounts of IgAl and IgA2 proteins in GCF samples with the 
numbers of their respective IgA subclass mRNA-expressing 
cells taken from the same site (r = -0.1383, -0.0972; r =
Pearson's correlation coefficient), respectively. An 
example of double staining with IgG and IgA probes is 
shown in Figure 9. Figure 10 shows detection of IgGl 
and IgG2 . IgG3 and IgG4 are demonstrated in Figure 11.
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Figure 12 shows IgAl and IgA2. Negative controls for 
IgG and IgA are shown in Figure 13.
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periodontitis, 
s
a
m
pled 
at 
(i) 
baseline; 
(ii) 
after 
52 
weeks 
and; 
(iii) 
following 
antibiotic 
therapy 
at 
75 
weeks.
3.3 Studies of serum antibody avidity
3.3.1 Preliminary study of effects of periodontal 
treatment on antibody avidity and plaque microbiology
The isolation of A. act inomycetemcomi tans and P. 
gingivalis from each patient during this study at 
baseline, week 52 and after antibiotic therapy at week 
75 is given in Table 18. At baseline all patients 
harboured one or both of the putative periodontal 
pathogens under investigation. A. actinomycetemcomitans 
was isolated from five patients at baseline and all 
five were again positive at week 52. From three further 
patients at baseline colonies resembling A. 
actinomycetemcomitans were cultured but were found to
be catalase negative and were presumptively identified 
as Haemophilus aphrophilus. All three patients had lost 
this organism by week 52 but one became positive for A. 
act inomycetemcomi tans at that time. P. gingivalis was 
isolated from 9/10 patients at baseline. It was isolated 
from one additional patient by week 52 but five patients
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appeared to have lost P. gingivalis from all sites 
sampled after the hygiene and surgical phase of the
study. Following antibiotic therapy and re-sampling at 
week 75, P. gingivalis was not isolated from any site 
in any patient. Three subjects, however, from whom A. 
actinomycetemcomitans was isolated at week 52 yielded A. 
act inomycetemcomi tans again at week 75. Two of these
patients had the organism at baseline and from the
third, H. aphrophilus was isolated at baseline. The
degree of growth of A. actinomycetemcomitans declined, 
however, in all sites and the number of sites in these 
three patients from whom A. act inomycetemcomi tans was 
isolated declined from a total of 13/15 to 7/15.
Individual patient antibody titres, expressed as 
log-LQ ELISA units, at baseline and after treatment are
given for P. gingivalis in Table 19 and for A. 
actinomycetemcomitans in Table 20. There was a wide 
variation in antibody titres and for P. gingivalis 
(Table 19) there was no correlation between the change 
in titre and the loss of the organism on culture. Indeed 
for IgG and IgA, six subjects showed a rising titre by 
week 75 compared with baseline. Most subjects showed a 
decline in antibody titre to A. actinomycetemcomitans
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when the organism was lost on culture. Subject no. 4, 
that gained A. actinomycetemcomitans during the study 
showed a rise in specific antibody titre in each 
antibody class (Table 20).
Table 21 shows the differences in median titres of 
each class of antibody to P. gingivalis and A. 
actinomycetemcomitans and differences in median
avidities when comparing the baseline serum samples from 
the post-treatment samples obtained at week 75. The 
changes over the treatment period were rather small and 
never significant. The median avidities for each class 
of antibody to A. actinomycetemcomitans declined 
following treatment, almost reaching significance for 
IgM. Table 22 shows the differences in median antibody 
titres and avidities obtained when comparing the 
baseline sample from the 10 patients with the matched 
control samples and Table 23 shows the differences in 
median antibody titres and avidities obtained when 
comparing the post-treatment patient samples with the 
control samples. There was no significant fall in median 
antibody titre nor in median antibody avidity to either 
organism from baseline to week 75, following therapy and 
antibiotic administration. When compared with matched
2 1 1
controls at baseline (Table 22) and week 75 (Table 23) , 
however, significantly higher values were obtained for 
the patients than controls with respect to avidity to: 
(i) all classes of antibody directed against P. 
gingivalis and; (ii) for IgG against A .
actinomycetemcomitans. Median antibody titres to P. 
gingivalis IgA were also significantly higher in 
patients than in matched controls.
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3.3.2 Longitudinal study of clinical and immunological
effects of periodontal therapy
An analysis of the entire patient group before and after 
HPT is given in Table 24. This demonstrates a tendency 
towards an increase in avidity of IgG to P. gingivalis 
and significant increases in titre to A. 
actinomycetemcomitans after therapy. For comparison only, 
since this study did not attempt to relate diseased and 
healthy individuals, the corresponding healthy control 
data for IgG, IgA and IgM avidity (mean, interquartile 
range) and titre (median, interquartile range) 
respectively to these organisms were as follows:- 
Pg: IgG; 1.00 (0.69-1.12). 320 (118-587).
IgA; 1.18 (0.60-1.69). 13 (7-30).
IgM; 0.70 (0.56-0.86). 412 (188-1139).
Aa: IgG; 0.81 (0.60-1.00). 749 (171-3217).
IgA; 1.38 (0.75-2.02). 8 (4-153).
IgM; 0.64 (0.38-1.04). 152 (95-298).
Analyses were performed for the effect of treatment 
on avidity and titre of antibody to the two organisms
after dichotomisation of the treatment group into sub-
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Table 
26: 
Analysis 
of 
treatment 
effect 
on 
IgG, 
IgM 
and 
IgA 
antibody 
to 
A. 
actinomycetemcomitans 
in 
terms 
of 
s
u
b
­
groups 
which 
were 
seropositive 
or 
seronegative 
at 
baseline. 
p-value 
for 
paired 
comparison 
was 
derived 
from 
p
a
i
r
e
d
 
t-test 
(avidity) 
or 
Wilcoxon 
signed 
rank 
test 
(titre). 
Interquartile 
ranges 
given 
in 
parentheses. 
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28: 
Analysis 
of 
response 
to 
treatment 
according 
to 
initial 
serostatus 
in 
terms 
of 
IgG, 
IgM 
and 
IgA 
a
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t
i
b
o
d
y
 
gingivalis. 
The 
average 
percentage 
of 
sites 
(SD) 
with 
PD 
>
3.
5mm 
and 
BOP 
at 
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end 
of 
HPT 
and 
at 
the 
first 
nance 
visit 
are 
given. 
Comparisons 
between 
seropositive 
and 
seronegative 
subgroups 
were 
made 
using 
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29: 
Analysis 
of 
response 
to 
treatment 
according 
to 
initial 
serostatus 
in 
terms 
of 
IgG, 
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and 
IgA 
a
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(SD) 
with 
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>
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5mm 
and 
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at 
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end 
of 
HPT 
and 
at 
the 
first 
maintenance 
visit 
are 
given. 
Comparisons 
between 
seropositive 
and 
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were 
made 
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n
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two-sample 
t-tests.
groups based on serostatus at baseline. The data for the 
response to P. gingivalis (Table 25) , and A. 
actinomycetemcomitans (Table 26) are given. A large and 
statistically significant increase in avidity of IgG to P. 
gingivalis (0.69M, p=0.026) was detected only in the
seropositive sub-group. By contrast, IgG and IgA titres 
to this organism tended to increase in the seronegative 
sub-group. However, Table 26 shows that there were no 
significant increases in antibody avidity to A. 
actinomycetemcomitans, but titres in all three classes 
increased significantly only in the seronegative sub­
group .
An analysis of the differences between seropositive 
and seronegative patients at baseline in terms of clinical 
parameters was also performed (Table 27) . This showed a 
tendency towards higher mean pocket depth and higher 
percentage of BOP sites in seropositive subjects. Since 
the inclusion criteria demanded that all sites should be 
>4mm at baseline, 100% of sites had PD > 3.5mm at this 
stage when related to later time-points in Tables 28 and 
29. This table is presented to show that seropositive 
patients did not have better clinical presentation at
2 1 4
baseline which may have contributed to their better 
response to treatment.
The response to treatment was assessed after 
dichotomisation of the test group into subgroups according 
to serostatus at baseline. It should be noted that one 
patient dropped out of the study between post-HPT and the 
first maintenance visit. Table 28 presents the data 
according to serostatus for P. gingivalis and Table 29 for 
A. actinomycetemcomitans. Seropositive subjects for IgG 
against P. gingivalis demonstrated a significantly lower 
percentage of sites with PD > 3.5mm at the end of hygiene 
phase therapy. Similarly, seropositive subjects for IgA 
against P. gingivalis demonstrated a tendency towards 
lower % of sites with PD > 3.5mm at post-HPT and
significantly lower % of deep and bleeding sites at the 
first maintenance visit. No significant differences in 
the response to treatment were observed between 
seropositive and seronegative subjects in terms of 
antibodies to A. actinomycetemcomitans.
The PCR analysis showed 5/17 (29%) of the patients
being P. gingivalis-positive and 8/17 (47%) being A.
actinomycetemcomitans-positive in at least one site at 
baseline.
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Table 
30: 
Differences 
between 
patient 
groups 
in 
terms 
of 
avidity 
of 
antibody 
to 
P. 
gingivalis 
in 
terms 
of 
median 
avidity 
(M) 
and 
median 
titre 
(EU) 
with 
inter-quartile 
range 
(Q
1
-
Q
3
)
.
* 
denotes 
significant 
difference 
at 
p=0.003.^ 
denotes 
significant 
difference 
at 
p=0.008.
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Table 
31: 
Differences 
between 
patient 
groups 
in 
terms 
of 
avidity 
of 
antibody 
to 
P. 
gingivalis 
ARG-1 
in 
terms 
of 
median 
avidity 
(M) 
and 
median 
titre 
(EU) 
with 
inter-quartile 
range 
(
Q
1
-
Q
3
)
.
3.3.3 Avidity of antibody to Arq-1 protease of P. 
crinaivalis in relation to treatment effects
Forty three rapidly progressive periodontitis patients 
were used to carry out this study as a cross-sectional 
examination. The samples were divided into groups 
depending upon their treatment status i.e. untreated 
patients (Group 1), patients who were undergoing 
treatment but had shown no sign of improvement (Group 2- 
maintenance), and successfully treated patients (Group 
3). Tables 30 shows a significant difference between 
group 2 and group 3 patients in terms of antibody 
avidity to P. gingivalis whole cells. However, this was 
not found for antibody avidity to P. gingivalis ARG-1 
protease (Table 31).
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3,4 Immunological parameters with obstetric significance
3.4.1 IcrGl-4 in recurrent spontaneous abortion and 
successful pregnancy
The levels of IgG subclasses were measured by ELISA. 
Their levels in non-pregnant women are shown in Table 
32. IgGl was the predominant IgG subclass in non 
pregnant women. The serum concentrations of IgGl, IgG2, 
IgG3 and total IgG were significantly increased in the 
first trimester of a normal pregnancy. The rise in IgG2 
was particularly significant (5.7±3.7 vs 1.4±0.9mg/ml), 
and this became the predominant subclass at 56.7% of the 
total IgG. In the second and third trimesters of a 
normal pregnancy, the serum IgG subclasses decreased 
gradually. At no time in the pregnancy was there any 
significant change in IgG4 levels. By 6 weeks post 
partum all values were returning towards normal.
The distribution of IgG subclasses in Group 3 women is 
given in Table 33. The results showed there to be no 
significant difference in IgG subclass distribution
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Table 34: First trimester IgG subclass distribution in
patients from Groups 3,4 and 5.
IgG GROUP2 GROUP 3 GROUP4 GROUP5
SUBCLASS
IgGl 3.1±0.8 3.9±1.1 2.4±0.4 2.3±0.7***
* * *+ +
IgG2 5.7±3.7 5.4±0.5 3.2±0.9* 2.3±1.1*
IgG3 0.8±0.1 0.7±0.1 0.5±0.1** 0.7±0.4
IgG4 0.5±0.1 0.1±0.1 0.3±0.2 0.2±0.1
TotallO.4±4.2 10.6±0 . 5 6.8±4.2*+ 7.6±1.8*
IgG
All data is expressed as mean ± SD
* P < 0.0 4; * *P<0.004; ***P<0.002 compared to Group 2
+P < 0.05; ++P<0.001 compared to Group 3
between Groups 2 and 3. The effects of miscarriage 
(either spontaneous or recurrent) on IgG subclass 
distribution are given in Table 34. Women with a history 
of RM, whose pregnancy again ended in miscarriage later 
on in the first trimester, was associated with 
significant decreases in levels of IgGl, IgG2, IgG3 and 
total IgG. Spontaneous abortion was associated with 
significant decreases in the levels of IgGl, IgG2 and 
total IgG. There were no significant differences between 
Groups 4 and 5. Early in the first trimester before the 
outcome of the pregnancy was known there were 
differences in levels of IgGl between RA whose 
pregnancies continued and those whose pregnancies 
failed. In the small numbers studied an IgGl level of 
less than 2.5mg/ml appeared to indicate miscarriage.
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3.4.2 Thyroid auto-antibodv as a pregnancy outcome
marker
Table 35 shows the comparison between RMc patients, i.e. 
those who had previously suffered from recurrent 
abortion but on this occasion continued to term (group 
1), and RMa patients, i.e. recurrent abortion patients 
who again aborted during the first trimester (group 2), 
in terms of titre and avidity of auto-antibody to TPO. 
Median values are given with interquartile ranges and p- 
values for the comparisons between the two groups by 
Mann-Whitney test. Group 2 patients were found to have 
significantly higher titre and avidity of auto-antibody 
than group 1 patients.
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3.5 Can fragments of bacterial DNA be detected in the
host bloodstream?
No positive PCR reactions were detected for any of 
twelve sera tested.
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Chapter 4
Discussion
4. Discussion
4.1 Local antibody studies
4.1.1 Humoral immunity in sites with differing clinical 
indices within the same patient
Specific IgG levels to P. gingivalis in GCF were found to 
be lower in periodontitis sites than in gingivitis sites 
in the same patient. Moreover, when correction is made 
for the systemic contribution by expressing results as 
EU/30s sample/mg albumin, this distinction appears more 
significant suggesting that increased consumption of 
locally-produced antibody in periodontitis sites may be 
responsible for this difference. Alternatively, there 
may be a failure of local production, or adsorption by 
plaque bacteria, or a combination of these mechanisms. 
Lamster et al (334) reported a significant correlation 
between total IgG in gingival crevicular fluid and 
specific serum antibody to Bacteroides intermedius but not 
P. gingivalis. They conclude that the development of a 
serum immunoglobulin response to suspected periodonto- 
pathogens is consistent with a protective host response.
A corollary of this view is that a local deficiency of IgG
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to P. gingivalis may lead to local disease progression. 
Alternatively, Kilian (145) has demonstrated that P.
gingivalis can degrade human IgG and IgA, suggesting that 
low gingival crevicular fluid levels of IgG may be caused 
by degradation by P. gingivalis, or that locally available 
antibodies are adsorbed by the greater mass of subgingival 
plaque present.
Baranowska et al (331) found no difference between
levels of specific IgG to P. gingivalis in healthy and 
diseased sites within the same individual. However, fixed 
volume samples of 0.5(il were taken. This means that
strips from sites which did not yield 0.5M-1 were discarded 
and that samples were taken over variable time periods
resulting in variable rates of serum contamination (398) .
Since healthy sites tend to yield lower volumes than 
diseased sites, this method treats healthy and diseased 
sites in different ways. Therefore, these results are not 
strictly comparable with the present study. An earlier 
study by Schenck (335) showed an inverse relationship 
between the number of deep pockets (>4mm) and serum 
antibody level to P. gingivalis lipopolysaccharide in
chronic periodontitis patients. Mouton et al (336) 
demonstrated a dichotomy in serological responses to P.
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gingivalis among chronic periodontitis patients with one 
sub-group exhibiting high serum antibody levels and 
another having levels similar to those of healthy 
individuals. The patients with high serum antibody levels 
appeared to respond better to therapy as evidenced by 
reduction in the number of deep pockets within one month 
post-treatment. These findings are consistent with the 
data reported here that periodontitis sites have lower IgG 
levels to P. gingivalis than gingivitis sites in the same 
patient.
It has been shown that GCF IgG antibody can inhibit 
colonisation of the gingival root surface by mutans 
streptococci (399). Bacterial immunoglobulin cleavage 
activity in GCF has been shown to have a role in localised 
juvenile periodontitis (400).
It should also be noted, however, that a recent paper 
by Gemmell et al (274) has shown that adult periodontitis 
patients tend to produce serum antibodies to Porphyromonas 
gingivalis lipopolysaccharide (LPS) to a much greater 
extent, and to higher molecular weight antigens to a much 
lesser extent, than gingivitis subjects. Highlighting the 
indications that LPS does not induce a protective 
response, their results suggest that periodontitis
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pathology may be related to an inability to target high 
molecular weight antigens, e.g.. the 91.4kDa band. In the 
present study it may be that the whole cell preparation 
used in the assay allows detection of antibodies to high 
molecular weight antigens to a greater extent than 
antibodies to LPS, thus contributing to the observed 
difference between periodontitis and gingivitis sites.
The present findings confirm previous observations in 
this laboratory (338) and those of OuYang (339-340) . The 
indications of these studies are that a failure of local 
antibody production or reduced amounts due to e.g. 
degradation by bacterial proteases, may contribute to the 
switch from gingivitis to periodontitis pathology. The 
present study has corrected for systemic factors by 
performing paired analysis within the same patient and 
allowed for systemic input by the use of albumin assays. 
This permits the tendency of reduced IgG to Porphyromonas 
gingivalis in periodontitis sites to be more clearly seen.
Moreover, this appears to be the first report to indicate 
an immunological difference between gingivitis and 
periodontitis sites purely on the basis of clinically- 
assessed site disease status. However, a larger study 
comprising both a larger patient group and a greater
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number of sites sampled per patient is necessary to 
corroborate these findings.
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4.1.2 Effects of ageing on immune and inflammatory
responses during experimental gingivitis
The results of the present study suggest that there are 
differences between young and old periodontally-healthy 
individuals in terms of immune and inflammatory responses 
during the course of experimental gingivitis. In
particular, IgGl and IgG4 levels in GCF are lower in old 
subjects and IgG3 is higher than in young individuals. 
Analysis of levels as a ratio to albumin suggest greater 
local synthesis of IgG3 and lower synthesis of IgGl in 
older subjects. Moreover, LF levels were lower in older 
individuals suggesting reduced PMN infiltration, since it 
has previously been shown in this laboratory that the 
level of this protein is correlated with the number of 
crevicular PMNs (401). The ability of these acute-phase 
proteins in GCF to distinguish healthy, gingivitis and 
periodontitis sites has also been demonstrated in this 
laboratory (377).
Ebersole and Cappelli have demonstrated that >95% of 
sites with elevated IgG4 antibody to Actinobacillus 
act inomycetemcomi tans were colonised with the organism,
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whereas <50% of sites with elevated IgG2 demonstrated this 
microorganism (402). They conclude that the frequency and 
distribution of antibody in the GCF as related to 
colonisation with this microorganism were consistent with 
localised host-parasite interactions at the individual 
tooth sites, and suggest that the potential exists for 
this local antibody to play an important role in the 
gingival sulcus in relation to colonisation and clinical 
presentation. Moreover, it has also recently been 
demonstrated in this laboratory that strong correlations 
exist between IgG subclass levels in GCF and in serum and 
IgGl-4 mRNA expressing plasma cells in the gingiva (403).
It is generally accepted that there are changes in 
the humoral immune response with ageing. For example, a 
decreased response to vaccination and defective specific 
antibody synthesis have been demonstrated in ageing 
humans (212,213).
Interestingly, Hu et al found that old mice had an 
increased CD5+ B-cell response but decreased CD5- 
response. This is related to the increased ability of 
aged animals and humans to produce autoantibodies whilst 
having an impaired response to foreign antigens (404) . 
However, in terms of the specific antibody response to
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plaque antigens in experimental gingivitis, Lekic found 
that this was increased in adult rats as opposed to 
young rats (405). It should be borne in mind that this 
study was in a rat model and the distinction was between 
adult and juvenile rather than elderly and young 
individuals.
Additionally, Spector et al have demonstrated that 
psychological conditioning of the immune response may be 
an important factor in ageing (406). Bovbjerg et al 
report that dysregulation rather than exhaustion of the 
immune response is the most important factor with 
ageing, i.e. there is an increased autoantibody response 
despite a reduced response to foreign antigen (407).
It has been shown here that there are differences 
between the immune and inflammatory responses in young 
and old individuals during the course of experimental 
gingivitis. These age-related differences may have a 
bearing on the natural progression of periodontal 
disease with ageing in humans. However, further studies 
are required to establish whether these mechanisms are 
important during the normal course of periodontal 
disease.
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4.1.3 Humoral immune response at matched tooth and 
implant sites in the same patient
Osseointegrated implants represent a realistic 
alternative treatment for partial and total edentulism.
This long-term success has been established in 
longitudinal studies to be well over 90% after ten 
years. Once osseointegration has been achieved, such 
high success rates depend upon the establishment and 
maintenance over time of a host-parasite equilibrium in 
the peri-implant sulcus.
Recent studies have determined that peri-implant 
microbiota (408-411) and peri-implant anatomy and 
function (412) are generally comparable to those 
pertaining to periodontal tissues.
The dearth of studies dealing with the local 
humoral immune response in PISF prompted us to conduct 
the present study. Tables 9-12 show that specific 
antibody titres tended to be lower and measures of local 
production, i.e. RCE ratios, tended to higher in implant 
sites than in matched natural tooth sites. These 
differences were not statistically significant, but they
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may provide an indication that specific antibody levels 
are lower around implants and also that proportionately 
more of that antibody is locally produced.
This may suggest differences in T-cell traffic to 
the gingiva between the periodontal and peri-implant 
environment. Naive and memory T-lymphocytes demonstrate 
different traffic patterns (413). The effect of 
antigenic stimulation is clonal expansion and 
differentiation of lymphocytes from naive into effector 
or memory cells. Memory lymphocytes acquire the ability 
to migrate into tertiary lymphoid tissues. Once 
activated, lymphocytes are not relatively homogeneous 
like naive cells but show selectivity in homing 
behaviour (414,415). Some studies have indicated that 
memory or activated lymphocytes traffic preferentially 
back to the tissue where they were first activated. 
Selective homing of memory lymphocytes can be mediated 
by differential regulation of receptors, which are 
adhesion molecules needed to recognise and bind to 
endothelial cells within different tissue sites.
Those memory T-lymphocytes can selectively home to 
non-lymphoid (or tertiary lymphoid) tissues (416,417). 
Therefore, most T-cells found in tertiary lymphoid
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tissues (such as gingiva) are memory cells (418).
Binding to endothelium (419) seems to be the first step 
in the transmigration of lymphocytes into the tissues 
(420). This is regulated by the differential expression 
of surface molecules on the effector lymphocyte and also 
on the endothelium of the target tissue. Lymphocyte 
homing is therefore initiated by surface molecule 
expression.
Therefore, it may be that the observed differences 
between periodontal and peri-implant antibody levels 
reflect differences in lymphocyte traffic into these two 
environments. A larger study is required to establish 
whether or not this is the case.
Tables 13-15 demonstrate that the correlations 
between immunoglobulin class responses to specific 
organisms which pertain for natural teeth do not hold 
for matched implants, and also that rates of local 
antibody production of the IgG and IgM classes do not 
correlate for matched teeth and implants. These 
observations indicate that class switching (e.g. IgM- 
>IgG) in peri-implant tissue may also be interfered with 
by some mechanism involving changes in the micro­
environment .
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These findings suggest differences in the plasma 
cell infiltrate in natural teeth and implants. Further 
studies focusing on GCF and PISF antibody levels in 
conjunction with comparative studies of cellular events 
at matched teeth and implants are required to elucidate 
these findings.
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4.1.4 Checkerboard immunoblotting of GCF
The pilot study carried out here suggests that this 
technique has the potential to allow multiple 
assessments of antibody reactivities with antigen. 
However, since GCF samples had to be diluted 
hundredsfold before analysis, low antibody
concentrations may not be picked up. Moreover, the 
results yielded are qualitative, making it difficult to 
make definite statements about relative levels in 
different types of sites. Further studies would involve 
quantitation using laser densitometry provided that the 
membrane substrate can be rendered transparent.
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4.2 In situ hybridisation studies
4.2.1 Study of k /A, light chain producing plasma cells in 
gingival tissue
There is a complex involvement of the cellular and humoral 
immune responses in the pathogenesis of periodontal 
disease. It is generally accepted that B cells and plasma 
cells are abundant in gingival tissues affected with 
moderate and advanced periodontitis and these cells 
locally produce immunoglobulin G (IgG), IgA and few IgM 
positive cells as seen by immunohistochemical techniques 
(421-424) . The immunohistochemical staining for
immunoglobulin using antibodies are however often 
unreliable due to the high background staining that may be 
derived from non-specific binding of immunoglobulins in 
the tissues (425) and serum derived immunoglobulin (426).
In addition, the detection of immunoglobulin protein 
in vivo presents several technical difficulties because
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the protein can be degenerated by neutrophil elastase 
(427) and oxidant (428) in inflamed sites. Moreover, it 
has been reported that periodontal bacteria secret IgAl 
proteases which cause the cleavage in the hinge region 
resulting in Fab and Fc fragments (146). Wilton et al. 
have recently reported that IgG subclasses, except IgG4, in 
gingival crevicular fluid (GCF), are largely derived from 
plasma. They based this conclusion on the poor
correlation between the amounts of IgG subclass proteins 
in GCF detected by ELISA and the clinical indices (429). 
Controversies exist regarding the relative importance of 
local and systemic antibody synthesis in the periodontium.
Immunolocalisation of immunoglobulins at the protein 
level presents many technical difficulties and also 
difficulties in interpretation. In situ hybridisation is 
a molecular biological technique which permits the 
detection of specific messenger RNA (mRNA) expression even 
in small tissue samples. This technique avoids many of 
the problems alluded to above and offers the opportunity 
to detect, localise and quantify the cells producing 
immunoglobulins. It has been reported that the in situ 
hybridisation method for detection of immunoglobulin light 
chain mRNA positive cells may give different results to
those obtained by immunohistochemistry (425,430,431). 
Further, although the ratio of k to X light chain positive 
cells varies in different sites and diseases (432-434), 
no data exist for the expression of immunoglobulin light 
chain mRNA in inflamed gingival tissues from patients with 
periodontitis. This study therefore investigated the 
localisation and proportions of immunoglobulin light chain 
mRNA positive cells in inflamed gingiva using the in situ 
hybridisation (ISH) technique and considers their 
potential relevance to the local humoral immune response 
of the periodontium.
This study confirms that immunoglobulins are locally 
produced by plasma cells within the gingival tissues of 
patients with periodontitis and further indicates that the
predominant plasma cells are k  light chain producing cells. 
Although immunoglobulin in the GCF of patients with 
periodontitis may be derived from the systemic circulation 
(426,429), it is likely that the most relevant 
immunoglobulins are produced by local plasma cells at 
these sites. The build-up of these "periodontal disease 
relevant" plasma cells may arise via selective homing of 
specific lymphocytes and/or by the clonal proliferation of 
specific B cells in this region (368,435).
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Immunoglobulin light chain mRNA positive cells were 
clearly seen in all sections. The in situ hybridisation 
method performed in this study has particular advantage
over immunohistochemistry in studies where the gene 
products are rapidly exported from the cell into the
tissue and systemic circulating immunoglobulin may have
influence. Previous efforts at immunolocalisation of
immunoglobulin using monoclonal antibody techniques in 
this laboratory have been disappointing due to the 
excessive background staining thought to be due to the
systemic and local soluble immunoglobulin presence.
Further, it has been reported that the cytoplasmic 
immunoglobulin detected by immunohistochemical methods may 
not be a result of synthesis but of uptake by the cell
(425,431). In situ hybridisation methods for detection of 
immunoglobulin light chain mRNA positive cells may give
different results to those obtained by
immunohistochemistry (425,430,431) which would explain why 
the results presented here differ from the previous report 
employing immunohistochemistry (436) . In these
circumstances, the in situ hybridisation technique shows 
precise localisation of gene expression free from the
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problems associated with the detection of extracellular 
targets and their possible uptake by other cells.
This study demonstrates a predominance of k  light
chain positive cells (k : X = 2.4 : 1) among plasma cells
in the human inflamed gingival tissues. Low k/X ratios 
have been reported for other inflamed tissues such as 
duodenum, tonsil (432) and renal biopsy samples from 
patients with IgA nephropathy (433). Moreover, an 
increase in IgG-1 has been correlated with infectious 
status (434) although the precise reasons are unknown. 
These reports suggest that the ratio of the two
immunoglobulin light chains may vary due to the severity 
of the lesions such that there may be heterogeneous 
responses even in related inflammatory diseases. The k/X 
ratio of inflamed sites could be a useful method of
distinguishing the stage or activity of periodontitis 
lesions and may differ between different forms of
periodontitis.
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4.2.2 IgG and IgA subclass production bv plasma cells in
periodontal tissue
This is the first report demonstrating IgG and IgA 
subclass-specific mRNA-expressing plasma cells in inflamed 
gingival tissues affected with periodontitis. The results 
also suggest the possibility that class switching pathways 
are induced in periodontitis sites and these may provide a 
basis for understanding the mechanisms of B cell 
differentiation in these sites, although it cannot be 
ruled out that the switching occurs in local lymph nodes; 
committed B cells home to gingival tissues, and 
periodontally diseased tissue may have lymph node-like 
features.
This is also the first report of the use of 
oligonucleotide probes for IgG and IgA subclass expression 
studies, although an earlier study used RNA probes for IgA 
(437). Oligonucleotide probes, because of their size, are 
more able to penetrate permeabilised tissue sections; 
allow for less cross-reactivity than that seen with full- 
length cDNA probes, and hybridize in the presence of 
formamide with retention of good tissue morphology. In
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addition, oligonucleotide probes are much easier to work 
with than RNA probes, due to their greater stability. In 
this study digoxigenin labeled oligonucleotide probes were 
used allowing the completion of this in situ hybridization 
procedure within two days, obtaining very high contrast 
and optimal histological resolution. The disadvantage of 
this non-isotopic in situ hybridization technique may be 
lower sensitivity than the autographic method, but IgG and 
IgA subclass-specific mRNA could easily be detected in all 
gingival tissues tested. As a preliminary, the
hybridisable mRNAs in the tissue sections were examined by 
using poly d(T) oligonucleotide probes. Plasma cells and
epithelium, especially basal layers, were usually strongly 
stained. Furthermore, strong signals for Ig light chain 
mRNA in plasma cells were shown by non-isotopic in situ 
hybridization (438).
It is important to note that optimization of 
proteinase K digestion was the most important step in this 
work in terms of enhancing signal strength and a narrow 
optimum for proteinase K digestion exists for maximum 
hybridization without significant destruction of
cytological structure and solubilisation of the target 
sequences. The effects of varying the proteinase K
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concentration on the in situ hybridization signal has been 
previously demonstrated (430).
IgGl mRNA-expressing plasma cells were the major 
subclass of IgG mRNA bearing plasma cell detected, which 
is similar to previous literature (439), and levels 
reported for normal tissues (440) and synovium from 
patients with rheumatoid arthritis (441). In contrast, a 
relative increase in IgG4 plasma cells was shown in this 
study and it is similar to previous reports (439,429). 
The subclass distribution of IgG antibodies produced as a 
consequence of bacterial infection varies according to the 
nature of the eliciting antigens. Protein antigens induce 
mainly IgGl antibodies, with small amounts of IgG3 and 
IgG4 antibodies (442,443). In contrast, IgG antibodies 
reactive to carbohydrate antigens, including
lipopolysaccharide (LPS), are predominantly IgG2. Since 
certain antigens elicit an Ig response largely confined to 
one IgG subclass (444,445), the distribution of IgG and 
IgA subclasses in gingiva may provide clues to pathogenic 
mechanisms.
Protein antigens from periodontal bacteria or their 
products may induce one subset of B cells to switch 
subclasses that are clustered in the 5 1 region of the Ig
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heavy chain gene. Another switching pathway of Ig 
constant regions may occur in the 3' region (g2-g4-e-a2- 
3') which seem to be predominantly involved in LPS- 
specific responses. It has been reported that the protein 
and lipid carbohydrate antigens of P. gingivalis induce 
two distinct patterns of IgG and IgA subclass responses in 
inflamed gingiva (446) . Therefore it is possible that the 
change in IgG and IgA subclass obtained is due to the 
change of microbial antigens or possible other mitogens 
involved at various stages of periodontitis. The data 
presented here shows reduced local production of IgG2 
which suggests that the response to carbohydrate antigens 
may be less important at the local level than protein 
antigens.
This is supported by the observation that local IgG4 
production is much higher than systemic levels would 
indicate as normal. However, actual levels of IgG4 and 
IgG3 are much lower than indicated by their local 
production levels (specific plasma cell levels), but these 
findings must not be interpreted too strictly as much 
variation exists, particularly with these subclasses which 
are present in low percentages of total IgG. Several 
studies indicate that the average serum proportion of the
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IgG subclasses is as follows: IgGl 65%, IgG2 30%, IgG3 5% 
and IgG4 4% (378) . IgGl appears at constant levels in
terms of systemic and local concentration and local 
production. However, IgG2 local production is reduced 
relative to local and typical systemic levels, which could 
suggest, as IgG2 is linked with Ig responses to 
carbohydrate antigens, a reduced involvement of the local 
response to carbohydrate antigens in the periodontium. 
The local levels of IgG3 and IgG4 are substantially 
reduced relative to their serum concentration and levels 
of local production but these immunoglobulins are at low 
numbers which makes analysis and thereby inferences less 
reliable.
In terms of IgA, predominance of IgAl-producing cells 
(65.1%) was observed, however, IgAl-producing cells were 
detected in equal proportions to IgA2 in 5 out of 24 
sections (2 sites were from same subject and the others 
were from different subjects). The gingival tissues are 
exposed to a heavy bacterial load, and IgA2 is resistant 
to several bacterial proteases which can cleave IgAl 
(146) . Therefore, increased IgA2 production would appear 
to be advantageous in the periodontitis gingiva and should 
aid killing of bacteria in the GCF. However, these
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results are not in accordance with the previous reports on 
the percentage of IgAl-producing cells determined by 
immunofluorescence (447) or enzyme-linked immuno spot
(ELISPOT) assay (439) which have reported proportions of 
more than 90%, similar to those seen in serum (448) . 
Immunohistochemical studies for Ig in inflamed sites are 
often unreliable due to high background staining, as has 
been established in this laboratory. In an ELISPOT assay 
described by Ogawa et al. (439,446), gingival mononuclear 
cells were isolated and cultured for 3h before the assay, 
suggesting no effect of IgAl proteases for IgAl production 
in their in vitro system. Further, although the amount of
IgA subclass mRNA expression in each cell could not be 
quantified, the rate of IgAl subclass secretion may be 
higher than that of IgA2. Further investigation of these 
points would be worthwhile.
IgA antibodies specific for protein antigens are 
found predominantly in the IgAl subclass, while specific 
antibodies to LPS and lipoteichoic acids are predominantly 
of the IgA2 subclass (449,450). Therefore the
distribution of IgAl- and IgA2-producing cells in inflamed
gingiva may reflect a difference in the predominant type 
and nature of antigens involved in the induction of the
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local humoral immune response in periodontium. The 
observed preponderance of IgAl or IgA2 cells in gingival 
tissues may be due to differences in the original 
precursors of IgA plasma cells destined for population of 
gingival tissue, selective homing of specific B cells
and/or the local expansion of specific B cell clones by 
various antigens that induce preferential IgAl or IgA2 
responses (368,435).
B cell differentiation and the regulation of the 
switch to different Ig isotypes is cytokine driven (451,
452) . TGF-pl and/or IL-4 increase the level of a germ- 
line transcript, and then B cells are induced to switch 
from membrane-IgM+ to membrane-IgA+ (453) . TGF-ftl but not 
IL-4 mRNA was detected by the reverse transcription- 
polymerase chain reaction method in inflamed gingival
tissues (454) . Therefore TGF-pl could influence IgA
subclass switching in periodontitis gingiva, although TGF-
pl mRNA signals could not be detected by the in situ 
hybridization method described in this study. Recently it 
has been reported that germ-line transcripts are relevant 
to the Ig class and isotype switch recombination in the in 
vivo immune response in humans (455) . In addition to the
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influence of cytokines, direct cell to cell interaction 
may also be involved in isotype switching mechanisms. IgA 
subclass-specific mRNA bearing plasma cells were seen in 
sections as discrete cells, i.e. not clustered. IgA mRNA 
bearing plasma cells, however, were often noted in contact 
with IgG mRNA expressing plasma cells, as detected by 
double-target in situ hybridization.
IgG and IgA subclass proteins were also detected in 
the GCF. Because local cellular events in gingival tissue 
must always be related to the events in the GCF, i.e. the 
quantities and specificities of antibody proteins actually 
being released and deployed locally. There was no 
correlation between the amounts of IgA subclass protein in 
GCF and the numbers of IgA mRNA-positive cells of the same 
subclass at the same sites, although strong correlation 
between the amounts of IgG subclass protein in GCF and the 
numbers of IgG mRNA-positive cells. These results suggest 
that IgG in GCF is composed of serum derived and locally 
produced IgG subclasses, although determining the actual 
ratio of serum derived to locally produced will be 
technically complex and thus this ratio is presently 
unknown. It has been reported that Ig can pass from serum 
to the oral cavity via GCF (426) and that large
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proportions of the IgG in GCF is derived from plasma
(429) . A possibility is that serum IgA subclasses 
influence the GCF proportions. This is unlikely however, 
because serum IgAl is always approximately 90% of total 
IgA (448) , whereas the proportions of IgG in GCF were
similar to that of serum making this hypothesis unlikely.
Higher concentrations of IgAl Fab fragments than 
intact IgAl were detected. It has been reported that 
periodontal bacteria degrade IgAl (145). Several
explanations to this discrepancy are possible. First, the
monoclonal antibody used reacted strongly with Fab
fragments of IgAl produced by specific IgAl proteases from 
Prevotella and Capnocytophaga species and weakly with Fab 
fragments induced by specific IgAl proteases of other 
cleavage specificities. Therefore, a possible explanation 
for this lack of correlation between IgAl producing cells 
and IgAl concentration in GCF may be that IgAl was 
degraded by periodontal pathogen-derived IgAl proteases. 
Another possibility is that IgAl may bind to bacteria and 
migrated PMN in GCF both specifically and non-specifically 
rather than IgA2. Thirdly, IgA subclass-positive cells at 
the mRNA level were investigated, but further mechanisms 
are involved in the translation stage i.e. prior to Ig
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being released, and thus the possibility exists that 
although IgAl mRNA positive cells are abundantly present 
their protein products may not be as readily released as 
say IgA2.
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4.3 Antibody avidity studies
4.3.1 Preliminary study of treatment effects in 
refractory patients
This study presents findings from a small group of 
patients that appear to be resistant to periodontal 
treatment. The compliance of these patients with their 
respective treatment plan had been good and their oral 
hygiene was always within acceptable limits (386) . Apart 
from the presence of putative periodontal pathogens in 
the gingival crevice of all patients, perhaps the 
strongest common factor to the continuing disease 
progression in eight of these subjects was that they 
smoked. Cooperative patients that nevertheless fail to 
respond to periodontal treatment are recognised in most 
clinical periodontal practices (456-457) , although 
fortunately they form only a small proportion of 
patients.
The presence of putative periodontal pathogens in 
the test sites in these patients from baseline to week 
52 has been described elsewhere (386). Elimination of P.
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gingivalis was achieved more readily than for A. 
actinomycetemcomitans in most cases. The potent 
antibiotic combination chosen in this study has been 
shown to be effective in eliminating A. 
actinomycetemcomitans from the periodontium in patients 
with localised juvenile- and rapidly progressive 
periodontitis (458) . In the present study, however, this 
antibiotic combination failed to eliminate A.
actinomycetemcomitans in all of these subjects by the 
end of the study at week 75 although P. gingival is 
could not be isolated from any test site by then. The 
success of most antibiotics in eliminating even 
sensitive organisms is, to a greater or lesser degree, 
dependent on assistance from the patient's immune 
system. A failure of the immune system at the local 
level in these patients with resistant periodontitis may 
explain why the antibiotic was not able to eliminate the 
organism.
The present study confirms previous findings that 
antibody avidities to suspected periodontopathogens are 
higher in patients with periodontal disease than in 
age/sex matched control individuals (330) . 
Specifically, this investigation has shown that
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avidities of antibodies in all three immunoglobulin 
classes to P. gingivalis and IgG to A. 
actinomycetemcomitans are higher than in controls. Chen 
et al, (273) found that RPP patients had low avidities 
that subsequently rose after treatment. This was not 
found in the material of the present study perhaps 
because these patients had been on regular recall for 
hygiene therapy before the baseline measurements were 
made (386) . The longitudinal element of the study, 
however, failed to show any significant differences in 
antibody avidity during the course of treatment. 
Previously, it has been shown that adult periodontitis 
patients who were initially seropositive developed 
higher avidity antibodies to P. gingivalis during the 
course of therapy and had a better response to treatment 
(45 9). The present group of ten patients was not 
suitable for this type of analysis. For example, seven 
out of the ten patients were seropositive for P. 
gingivalis at baseline, making sub-grouping impossible.
More importantly, the present study was of patients who 
had proved to be resistant to treatment, and these may 
well be an immunologically distinct group.
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There have been a number of reports suggesting that 
there is a relationship between immunological
parameters and treatment response in adult periodontitis 
and early-onset periodontitis. A recent report by 
Ebersole et al, (460) quotes data showing that 60% of 
periodontitis patients exhibited increased titres to a 
battery of suspected periodontopathogens post-treatment, 
and that these patients had fewer episodes of active 
disease during the monitoring interval (two years) than 
those who did not demonstrate increased titres. Mouton 
et al, (336) demonstrated that initially seropositive 
patients responded better to therapy than those who were 
initially seronegative. Moreover, the tendency to 
develop further attachment loss in maintenance patients 
is related to antibody avidity to P. gingivalis (330) .
Gingival crevicular fluid (GCF) IgG titres to P. 
gingivalis have been found to be lower in deeper 
pockets and more inflamed sites in maintenance patients 
(338) . This suggested that failure of production of 
antibody at systemic and/or local level combined with 
failure of deployment at local level, perhaps caused by 
low binding strength (avidity) and/or degradation or 
inactivation of immunoglobulin by microorganisms (145-
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146) , may lead to further periodontal breakdown on a 
site-specific basis.
The clinical, microbiological and immunological 
findings in this small group of well-motivated patients 
suggest that continued disease progression in patients 
resistant to periodontal treatment may be related to a 
defect or deficiency in their immune system. With the 
exception of IgA titres to P. gingivalis antibody 
titres were not significantly higher in these patients 
than controls. Avidities were significantly higher for 
each class of antibody to P. gingivalis but only for 
IgA to A. actinomycetemcomitans. Clearly these patients 
mount an immune response to these putative periodontal 
pathogens but it does not seem to be adequate to stop 
disease progression. The underlying immune defect, if 
such exists, presumably is at a very local level. 
Further studies of this type of subject may help to 
elucidate the balance between host factors and putative 
pathogens in adult periodontal disease. A larger study 
group is required but, as this type of patient is not 
common, a multi-centre collaborative investigation seems 
worthwhile.
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4.3.2 Longitudinal study of immunological parameters in 
relation to treatment outcome
The results presented here suggest that the further 
development of the humoral immune response to suspected 
periodontopathogens is predicated on serostatus before 
treatment commences. For example, Table 25 demonstrates a 
large and statistically significant increase in IgG 
avidity to P. gingivalis for initially seropositive 
patients, whereas seronegative patients showed no change 
in avidity but a tendency towards increased titres 
(+474EU, p=0.08) which failed to reach statistical
significance. Initial serostatus is dependent on a number 
of factors including timing and extent of previous 
exposure to the subgingival microflora, the nature of the 
latter and host susceptibility.
The effect of treatment on antibody responsiveness 
may result from an inoculation effect during scaling and 
root planing, or from the reduction in antigen load 
resulting from these procedures and improved oral hygiene, 
or from a combination of these two mechanisms. Reduction 
in antigen load is known to result in selection of B-cell
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clones producing higher avidity antibodies (182). 
Treatment may also permit the development of a normal 
maturation of the immune response, perhaps mediated by an 
inoculation effect, leading to antibodies of increasingly 
higher avidity.
Patient sub-grouping was performed by Chen at al 
(273) in their investigation of treatment effects on 
rapidly progressive periodontitis patients. They found 
that avidities of IgG antibody to P. gingivalis increased 
in their seropositive sub-group after therapy, whereas 
titres decreased. Therefore, the present study tends to 
confirm this effect in adult periodontitis patients. It 
should also be noted that antibody avidities to 
periodontopathogens are generally low in humans compared 
with those to other commonly occurring antigens, and also 
when compared with avidities observed in animals immunised 
with periodontopathogens (273,190,325).
The present study, being concerned with the systemic 
immune response, did not set out to relate site 
microbiology to site or systemic immune response. 
However, plaque samples were analysed by PCR in order to 
provide some data on this point. Mombelli et al (461) 
showed that, when whole-mouth analysis for P. gingivalis
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was carried out in periodontal disease patients, 3 0% of 
patients were organism-negative in all sites. Moreover, a 
further 30% of patients had this organism in only 1-10% of 
sites. This suggests that, at any particular time, a 
maximum of 40% of patients with periodontal disease would 
be classified as P. gingivalis-positive by a 
representative sample of 8 sites. Our PCR analysis showed 
29% of patients being P. gingivalis-positive and 47% being 
A. actinomycetemconii tans-positive. This compares well 
with another recent study in our laboratory showing 12/43 
(28%) patients being P. gingivalis-positive and 40% being 
A. actinomycetemcomitans-positive based upon
representative site sampling (462).
Little data exists on the relevance of differences in 
immune response to periodontopathogens to clinical 
improvement. However, Mouton et al (336) demonstrated that 
initially seropositive patients responded better to 
therapy than those who were initially seronegative. 
Moreover, a recent study by our group suggested that the 
tendency to develop further attachment loss in maintenance 
patients is related to antibody avidity to P. gingivalis 
(330) . In an earlier report from this laboratory, it was 
demonstrated that gingival crevicular fluid (GCF) IgG
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titres to P. gingivalis were lower in deeper pockets and 
more inflamed sites in maintenance patients (338) . This 
suggested that failure of production of antibody at 
systemic and/or local level combined with failure of 
deployment at local level, perhaps caused by low binding 
strength (avidity) and/or degradation or inactivation of 
immunoglobulin by microorganisms (146,396), may lead to 
further periodontal breakdown on a site-specific basis.
A recent experimental gingivitis study by Danielsen 
et al (463) showed that reductions in serum IgG titres to 
P. gingivalis during the experiment were predominantly 
attributable to subjects who had high initial titres and 
who went on to develop marked gingival inflammation during 
plaque accumulation. They suggested that the development 
of more extensive gingival inflammation in these subjects, 
perhaps equivalent to seropositive or previously 
sensitised individuals, could be a prerequisite for 
successful reduction or elimination of the organism 
through protective immune and inflammatory mechanisms.
Moreover, Ranney et al (464) and Gunsolley et al 
(345) demonstrated less disease in patients with higher 
antibody titres than in those with lower titres. However, 
a contradictory finding by Chen et al (273) was the
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observation that there was a statistically significant, 
albeit weak, negative correlation between IgG antibody 
avidity to P. gingivalis whole cell sonicate and both 
severity of bone loss and pocket depth. This latter 
study, however, investigated RPP rather than adult 
periodontitis subjects and the negative correlation did 
not apply for P. gingivalis LPS or protein. The 
significance of this study is, therefore, difficult to 
assess.
The present study indicates that the characteristics 
of the humoral immune responses to P. gingivalis and A. 
actinomycetemcomitans serotype a may be quite different. 
Avidities to P. gingivalis tended to increase after 
therapy in seropositive patients, whereas titres to A. 
actinomycetemcomitans tended to increase in seronegative 
patients.
Table 24 demonstrates that the increase in IgG 
avidity to P. gingivalis during the course of therapy in 
the entire patient group is, when considered with Table 
25, attributable to the influence of the seropositive sub­
group. Our data suggest that seropositive subjects, in 
terms of IgG and IgA against P. gingivalis, demonstrate a 
tendency toward a higher chance of clinical improvement
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after conventional periodontal therapy (Tables 28 and 29) .
This is despite the finding that seropositive subjects 
tended to have deeper mean pocket depths at baseline 
(Table 4) . Although the significance of our findings is 
weak, our data agree with the observation of Mouton et al 
(336) who demonstrated that initially seropositive 
patients responded better to therapy than those who were 
initially seronegative. This observation would also 
concur with those of Ebersole et al (465) and Danielsen et 
al (463) . The suggestion is that the prior development of 
a protective (although in an attenuated fashion) humoral 
immune response has a positive contribution to disease 
resolution during and after therapy. A recent study by 
Sjostrom et al has also indicated that scaling and root 
planing induces a humoral immune response which has a role 
in the beneficial effects of periodontal treatment (466).
There are indications that the humoral immune 
response to periodontopathogens may be unique in 
character. There have also been indications from previous 
studies and the present study that previous exposure and 
host susceptibility have a bearing both on the development 
of periodontal disease and response to treatment. 
However, further work on the effects of periodontal
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treatment on the humoral immune response is required to 
elucidate this phenomenon.
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4.3.3 Avidity of antibody to ARG-1 protease of P.
ainaivalis
The results presented in Tables 30-31 suggest that, 
although these outcome groups could be distinguished in 
terms of antibody avidity to P. gingivalis whole cells, 
this was not found for reactivity to the ARG-1 protease 
of this organism. This may suggest that other proteins 
are more important as virulence factors in RPP.
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4.4 Significance of immunological parameters in
pregnancy
As was touched upon in the Introduction (section 1.4.4.), 
Lopatin et al (190) have speculated that in utero exposure 
to periodontal antigens may occur because of pregnancy 
gingivitis, which is often severe leading to bacteraemia 
(214-216) , followed by placental transfer. Clearly, if 
this occurs early during immune maturation, there is the 
real possibility that these antigens will be recognised as 
auto- rather than allo-antigens. Similarly, Collins et al 
have shown recently that P. gingivalis has deleterious 
effects on pregnancy outcome in hamsters (467-468). 
Significantly, this effect can also be detected with heat- 
killed cells and also LPS from this organism. These latter 
two studies suggest that bacterial antigens do cross the 
placenta.
Moreover, Nelson et al have demonstrated that a 
disparity in HLA class II alloantigens is associated with 
the remission of rheumatoid arthritis which has previously 
been described in pregnancy (469). A mechanism has been 
postulated involving maternal tolerance to foetal
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antigens. This prompted a preliminary study of IgG 
subclass responses during pregnancy, since previous 
studies have linked the absence of an IgG blocking factor 
with foetal rejection (239-242). It was not possible 
within the present project to determine whether or not 
bacterial antigens penetrate into the maternal/foetal 
circulation or reactivity of the subclasses with specific 
bacteria, but this would appear a promising area for 
further research.
4.4.1 The relationship between serum levels of IgG 
subclasses and pregnancy outcome
Miscarriage is the most common complication affecting 
human gestation. It has been suggested that the rate of 
women who miscarry three consecutive pregnancies is 0.4% 
of all clinically recognised pregnancies (470-471) .
This pilot study is the first to detect the distribution 
and changes in IgG subclasses during the course of a 
normal pregnancy and those suffering recurrent 
miscarriage (RM). The data from this study has shown an 
association between levels of IgG subclasses and normal
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pregnancy or pregnancy loss. It was found that the 
concentrations of serum IgGl, IgG2 and IgG3 were 
significantly increased in the first trimester of a 
normal pregnancy compared to non pregnant women. While 
IgGl, at 65% of total IgG, is the dominant IgG subclass 
in non pregnant women, IgG2 increased markedly and 
became the dominant IgG subclass in the first trimester 
of a normal pregnancy. During pregnancy, serum levels of 
IgGl, 2 and 3 decreased gradually, but returned towards 
non pregnant levels during the six weeks following 
delivery.
Previous studies have shown that IgG and IgM 
production was significantly raised in the first 
trimester of a normal pregnancy (244-245). It has been 
proposed that an increase in B cell numbers or B cell 
activity may account for the increased production, 
although from the studies carried out to date it is not 
clear which is responsible. There have been reports in 
the literature of increased numbers of B cells occurring 
in normal pregnancy (472).
An investigation was also conducted into why some 
women with a history of recurrent miscarriage should 
have a pregnancy that continued to term whilst others
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miscarried again later on in the first trimester. 
Comparison of the IgG subclasses showed the levels of 
IgGl, IgG2 and IgG3 to be significantly lower in RM who 
again miscarried. Similar results were found in women 
admitted suffering spontaneous abortion. Why and how IgG 
production should be blocked in these women is not 
clear. In this small pilot study levels of IgGl appeared 
to act as a marker for miscarriage in these women.
It is well known that the foetus inherits antigens 
from the father that are foreign to the mother. The 
mechanism by which the foetus evades immunological 
rejection is unknown. Early in the 1970's Rocklin and 
his co workers found that maternal lymphocytes can 
produce an immigration inhibitory factor in normal 
pregnancy (239) . Their studies on the nature of the 
blocking factor indicated that this factor was an IgG 
antibody and it was directed against paternal antigens. 
Moreover, women who abort lack this antibody in their 
sera (240-242). The mechanism by which IgG exerts its 
influence is not yet completely understood. It has 
become clear that IgG has immunosuppressive properties 
(473). Several recent studies have suggested that during 
pregnancy IgG may block antibody binding to Fc receptors
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of target cells, thus prohibiting local antibody 
effects. Feedback inhibition of antibody synthesis by 
the high serum concentration of IgG, thus enhancing 
suppressor T cell function (474-475), may explain the 
IgG subclass decrease during normal pregnancy. Serum IgG 
subclass in women with a history of recurrent 
miscarriage but whose pregnancies continued showed 
patterns similar to those in normal pregnant women.
From the results obtained in this study it is 
possible to hypothesise that the inhibition of immune 
activity is associated with high levels of serum 
immunoglobulin. In the first trimester of normal 
pregnancy, the increased IgG inhibits the immune 
activity which contributes to the maintenance of a 
normal pregnancy. In those with recurrent miscarriage 
whose pregnancy again failed the serum levels of IgG, 
though increased, were not high enough to interfere with 
the regulation of the immune responses itself. The 
interactions between the feedback inhibition and the 
exact IgG subclass level in serum requires further 
study. It is also possible that higher levels of IgG are 
protective in that they reduce an antigenic challenge
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which could trigger abortion.
4.4.2 Effect of TPO auto-antibodv status on pregnancy 
outcome
Patients who again aborted were found to have 
significantly higher titre and avidity of auto-antibody 
than those who had a successful pregnancy outcome. This 
suggests that the production of auto-antibodies may be 
relevant to pregnancy outcome.
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4.5 Penetration of bacterial fragments into the host
circulation
The preliminary experiments conducted here indicate that 
bacterial DNA cannot be detected in host serum.
However, other studies are required using a wider range 
of probes in a wider patient group (e.g. pregnant women 
with severe gingivitis) to verify this conclusion. 
Moreover, inhibitory effects of host DNA or proteins on 
the PCR reaction require to be excluded.
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4.6 Overall Conclusions
The general aim of this project has been to investigate 
the relevance of systemic and local humoral immunity to 
the aetiology and progression of periodontal disease; 
and to place these findings in the wider context of 
immune-inflammatory processes.
A correlation has been confirmed between local 
levels of antibody to P. gingivalis and site disease 
status. Moreover, levels of immunoglobulins and 
inflammatory mediators have been shown to be different 
in healthy sites in younger and older individuals, 
suggesting that these changes may be relevant in the 
development of periodontal disease as a disorder of 
ageing. Possible differences between local humoral 
immune responses at matched oral implant and natural 
tooth sites have also been highlighted.
The in situ hybridisation studies of the gingival
plasma cell infiltrate have demonstrated that K-light 
chain producing plasma cells predominate in 
periodontitis lesions and this could be a useful method 
of distinguishing the stage or activity of periodontitis
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lesions, and may differ between different forms of 
periodontitis.
Levels of IgGl-4 in the GCF have been shown to 
correlate well with plasma cell proportions in the 
gingiva, but GCF levels of IgA2 were much higher than 
IgA2-producing plasma cell counts would indicate. 
Moreover, high levels of IgAl Fab fragments in the GCF 
suggest preferential IgAl digestion by bacterial 
proteases.
The antibody avidity studies have demonstrated a 
correlation between serostatus to P. gingivalis and the 
development of antibody avidity and treatment outcome. 
This may have a major impact on the management of 
periodontal therapy.
The studies of obstetric immunology, similarly, 
have shown correlations between serum levels of IgGl-4 
and TPO auto-antibody and pregnancy outcome. This puts 
the studies in periodontal disease into a wider context, 
indicating that differences in systemic humoral immunity 
may be important in the differential diagnosis and 
management of patients with a range of immune- 
inflammatory conditions.
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This project has illuminated a number of areas 
which would merit further study. The relevance of 
antibody avidity and serostatus to P. gingivalis 
requires particular attention in studies with larger 
patient groups followed prospectively over longer 
longitudinal monitoring periods.
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